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Preface
In the early 1980s, the Belgian Health Authorities decided to provide an 
understandable insert with written drug information, to be enclosed with 
every package of every medicine dispensed in the country. In doing so, the 
Belgian government anticipated upcoming European regulations.
In 1985, Prof. Marc Bogaert, Professor of Clinical Pharmacology at Ghent 
University and member of the Belgian Drug Registration Committee, invited 
me to join a small group of experts, called upon to give sound 
recommendations for the editing of patient package inserts. I was then a 
practicing physician in the city of Ghent, with 7 years of practice experience, 
and a member of the Research Organisation of the Flemish Scientific 
Association of General Practitioners. While working on the committee, I 
realised what an tremendous task it was for the more than 200 pharmaceutical 
companies to revise the data sheets and to edit a patient package insert (PPI) 
for the more than 5,000 drugs in Belgium.
When all was well under way, a scientific evaluation programme of the 
introduction of PPIs in Belgium was started. In 1988, the kick-off for the 
programme was given with an international scientific symposium at the 
University of Ghent[1], where world experts gathered to discuss the framework 
and the objectives of the evaluation programme. I served as a part time 
coordinator of this programme, with Chris Van haecht as a full time 
researcher. In 1992, he defended his doctoral thesis on this subject[2].
Later on, I continued the work on written drug information at the Heymans 
Institute, with several new studies, while remaining a practicing family 
physician till today. This thesis is an overview of the research carried out over 
a period of 18 years.v

Summary
This thesis discusses the patient package insert (PPI), a folded sheet of paper in 
the drug package with a text which is supposed to be comprehensible for the 
general public. The PPI contains information on how the drug must be taken, 
on the risks of taking the drug, and a limited amount of information on what 
the drug is for.
Belgium was the first country in Europe, together with Switzerland, to 
introduce PPIs. PPIs were first introduced in 1988 and the process was 
completed in 1992.
In Europe, health authorities decided in 1992 that all medicinal product 
packages should contain a comprehensible insert. This decision is slowly but 
surely being implemented in all European countries. Similar developments did 
not take place in the US and other parts of the world, where medicines are 
distributed in bulk and dispensed without much information, even when 
dealing with powerful prescription drugs. 
During the introduction of PPIs in Belgium, a research programme was 
conducted to evaluate this change in the way drug information was provided 
in the drug distribution system. This thesis provides an overview of the studies 
carried out during that period. In addition, a number of other descriptive 
studies of the flow of drug information in specific patients groups is provided. 
Finally, a number of experimental studies is presented, which evaluate the 
impact of written drug information on patients’ benefit/risk perception.
The acceptance of a drug distribution system with mandatory PPIs in all drug 
packages will be evaluated on the basis of Belgium’s relatively long and well-
documented experience with PPIs. We address the following questions:  what 
is the percentage of patients who read, accept and appreciate PPIs; what 
happens when a country changes from technical inserts with difficult jargon to 
comprehensible PPIs; what do we know about the impact of PPIs on patients 
knowledge and feelings about their drugs?
In this thesis, an attempt is made to understand the mental processing of drug 
information which precedes patients' decisions and coping strategies, 
necessary for successful drug treatment. The question here is whether the PPI 
is capable of influencing the benefit/risk perception of patients. A further step 
is to study the impact of the PPI on behaviour. Here, other questions are at 
stake. Does the PPI have an impact on patients' reporting of health problems 
and side-effects, on their ability to carry out a treatment correctly and safely, 
on their adherence to therapy at the beginning of treatment, and on their 
motivation to continue crucial therapy? These questions are addressed only to 
a limited extent in this work, as we have focused on the preceding cognitive 
process of benefit/risk perception.vii
SUMMARYThis thesis is composed of 4 parts: an introductory section, two sections with 
results from the various studies, and a closing section with a discussion, 
recommendations and final conclusions. In annex 1, we add six facsimiles, one 
for each of the six publications which make up the formal basis of this thesis. 
However, these core publications are also reported in a slightly simplified and 
condensed way in the two middle sections, but this time placed within the 
wider context of the thesis and in a style similar to the other studies reported 
here.
In the introductory section, the aims of this collection of studies are described.
First, we review the literature on patients’ objective and subjective needs for 
drug information. We define the notion of the patient package insert, along 
with its characteristics and functions. We review what is known about the 
impact of the PPI on patients level of knowledge about medicines.  The history 
and current status of insert programmes in Europe, the US and other parts of 
the world are given. Afterwards, we focus on the introduction of the PPI in 
Belgium between 1988 and 1992, as this was the background setting for this 
thesis. 
The introduction ends with a short overview of the theoretical models used to 
design the studies presented here and an outline of the structure of this thesis.
In Part II, descriptive studies are presented, which were carried out before, 
during and shortly after the introduction of PPIs in Belgium.
In Chapter 1 of Part II, we present the 1988 population survey in Belgium, 
among adults from 18 to 64 years old, with door-to-door interviews. This 
study was carried out just before PPIs were introduced, at the end of a period 
of 25 years of drug distribution with more or less incomprehensible technical 
inserts (TIs). Results showed that a high percentage of patients (around 90%) 
claimed to read the TI, and to find it useful. There were some complaints 
about readability.  The specific role of the insert was acknowlegded, in 
addition to the role of the physician and the pharmacist.
In Chapter 2 of Part II, a report is given of a mail questionnaire study among 
Belgian physicians. Most physicians apparently underestimated the percentage 
of patients reading the insert.
Three types of physicians were discovered in a cluster analysis: somewhat 
older physicians, overtly negative towards the PPI, but engaging frequently in 
personal verbal instructions on drug use; somewhat younger physicians, 
welcoming the PPI as a relief from providing routine information; and 
physicians with mixed feelings towards the PPI, because they observed their 
patients more thoroughly and observed positive as well as negative effects of 
the insert.
In Chapter 3 of Part II, we present a study in nursing homes with an 
observation of a sample of residents and an interview with their attending 
nurses. In these nursing homes, drug utilisation was high. The insert was not  viii
SUMMARYdistributed to residents. Even cognitively fit residents had lost their autonomy 
over the use of their drugs. The nurses made only limited use of the insert as a 
source of drug information.
Chapter 4 of Part II starts with a description of the linguistic tools developed 
in the Belgian PPI Programme (writing style guides, multilingual glossary of 
technical and popular medical terms and a computerised readability test for 
the French and the Dutch language). In addition, an overview is given of 
eleven supplementary studies: a mail questionnaire study among regulatory 
affair managers, a repeat of the 1988 population study in 1991, two 
consecutive clinical registration studies among hypertensive patients in general 
practice, five studies among specific population groups, two studies on drug 
distribution in nursing homes and hospitals, and finally a quality evaluation of 
a sample of Belgian inserts in 2000.
The regulatory affairs managers are the authors of PPIs within the 
pharmaceutical industry. The survey demonstrated that they underestimated 
(as did the physicians) the percentage of patients reading the insert. Their 
opinion on the usefulness of this source of information was generally positive 
with some reservations.
The repeat of the population survey in 1991 confirmed the high percentage of 
readers. In addition, it was clear that the introduction of PPIs was well 
underway (39% penetration), and was proceeding smoothly and unnoticed.
In the two consecutive clinical registration studies among hypertensive patients 
on chronic therapy, somewhat lower reading percentages were found, 
although they were still high. There was little difference in (high) satisfaction 
according to the type of insert (TI or PPI). However, we observed a somewhat 
higher level of spontaneous reporting of health problems and side-effects 
among the PPI readers. 
In the descriptive studies among the elderly, a paradox was observed of higher 
drug consumption and lower subjective need for drug information. Among 
socially active elderly people, a wide range of information sources was 
observed, with the PPI still playing a prominent role.  Frail elderly people 
living at home and no longer able to leave their houses were found to have lost 
contact with the pharmacist, while paramedical caregivers took over as 
information providers. Among the elderly in acute geriatric wards, the role of 
the PPI disappeared, in a setting with  poor drug information. Among healthy 
adolescents, the PPI played a prominent role, in the relatively rare instances 
when a medicinal drug was taken.
The analysis of a small sample of Belgian inserts from the year 2000 indicates 
that some linguistic improvements have been made (shorter sentences, less 
jargon) but the length, content, and quality of the Belgian PPIs remains 
variable, eight years after their introduction.ix
SUMMARYIn Part III we present the experimental studies, focusing on how patients 
perceive the benefits and risks of their medicines.
In Chapter 1 of Part III (published as the chapter of a book), the relation 
between drug information, benefit/risk perception and patient compliance is 
explored, in the light of a new, precise method for measuring patient 
compliance (electronic monitoring).
In Chapter 2 of Part III, we report on a study where this new measurement 
technique was applied in a randomised clinical trial, comparing atenolol with 
lisinopril in the treatment of hypertension. Both treatment groups were further 
divided into two subgroups: one subgroup without an insert, and one 
subgroup with a hybrid PPI (in which typical side effects of the two drugs were 
mixed). This study was originally designed and monitored by a 
pharmaceutical company, but we added the element of testing the impact of 
written drug information. There were deficiencies in the blinding of allocation 
of patients to treatment in this study. Some general practitioners broke the 
randomisation as they preferred not to give beta-blockers to elderly patients. 
Hence there were no conclusive results. However, the methodological lessons 
from this study are discussed, and some hypotheses for further research are 
suggested.
In Chapter 3 of Part III, we report on an experimental psychology study in 
healthy volunteers, predominantly women. A PPI with a benefit section (a 
short paragraph of approximately 80 words on the benefit of the drug) was 
tested against a normal PPI (as customary, without a benefit section) and 
against no PPI. For this study, three scenarios were tested (cisapride for acute, 
benign digestion problems; itroconazol for fungal toenail infections; risperidon 
in the chronic treatment of psychosis). In each scenario, approximately 90 
patients were divided into three experimental groups and given no insert, a 
normal PPI or a PPI with a benefit message. Subjects who did not receive an 
insert rated the benefit of the medicine higher than its risks, but scored low on 
the knowledge test. Subjects who received a normal PPI knew more about the 
medicine, but rated lower on the benefit/risk. Subjects who received a PPI with 
a benefit message knew more about their medicine, and consistently rated the 
benefits higher than the risks. These findings were  consistent in the three 
scenarios.
In Chapter 4 of Part III, we report on a randomised clinical trial with an anti-
inflammatory drug among patients with acute pain from a benign trauma. 
Half of the patients received their drug with the existing technical insert 
(basically incomprehensible), and the other half received their drug with a PPI 
(same content, same lay-out, but shorter sentences and less jargon). In both 
groups the insert was read by a similar high percentage of patients. The 
satisfaction with the insert was high in both groups, but patients reading a PPI  
rated lower on the benefit/risk ratio, and had more spontaneous reports of 
health problems and side effects. Finally, we discuss the design of a study x
SUMMARYwhere we tried to combine a number of the elements described above. This 
study was halted, however, because of recruitment problems, probably caused 
by a design that may have been overly ambitious to conduct the study.
In Part IV, the closing section, the relevant results of the properly conducted 
studies are discussed in relation to other findings in the literature. In addition, 
hypotheses for further research are formulated. A number of 
recommendations are made concerning the liability issue and the production 
and testing of better PPIs. We make a plea to embed PPIs in the new 
information media, in the context of more general health policy and patient 
education efforts.
The following final conclusions were drawn. 
Patient package inserts are an essential part of modern drug distribution 
systems and a tool for patient education and health policy. Routinely provided 
inserts are read by the vast majority of patients and have a positive impact on 
patient satisfaction, regardless of their quality. 
A drug distribution system with patient package inserts has been accepted and 
welcomed by the population.
High quality patient package inserts have a positive impact on knowledge 
about drugs in those patients who read the insert. This has been proven in 
research by others and confirmed in our studies.
The effects on readership, satisfaction, and on knowledge alone may warrant 
their automatic provision, each time a medicinal product is dispensed, with or 
without prescription, in spite of the slightly higher distribution costs. These 
are strong arguments for the universal application of the European system of 
mandatory and comprehensible patient package inserts. Additional claims of 
positive behavioural effects of PPIs on patient compliance have barely been 
demonstrated. There is little evidence to ascertain that current PPIs reduce 
medication errors and off-label use, increase the observance of  precautions, 
and stimulate adequate reactions when side-effects occur.
Benefit/risk perception is an important cognitive concept for understanding 
patients mental processing of written drug information in patient package 
inserts. Direct measurement of benefit/risk perception with more validated 
tools is necessary to comprehend the relation between benefit/risk perception 
and behaviour. This may be crucial to design (and retest) better patient 
package inserts, to help patients make informed and shared decisions about 
adherence to drug treatment, and to assist them in the proper and safe 
continuation of treatment. One instrumental aspect of writing better PPIs may 
be the introduction of an elaborate benefit section. By combining benefit 
messages and risk messages in the patient package insert, improved transfer of 
information and a more balanced benefit/risk perception may be achieved.xi

Samenvatting in het Nederlands
Dit werk gaat over de bijsluiter ingesloten in de verpakking van 
geneesmiddelen, met een tekst die bedoeld is om voor het grote publiek 
verstaanbaar te zijn. De patiëntenbijsluiter bevat informatie over hoe het 
geneesmiddel moet worden genomen, wat de risico's zijn van het gebruik, en 
tot op zekere hoogte waarvoor het geneesmiddel dient. 
België speelde in 1988 een pioniersrol in Europa door samen met Zwitserland 
als eerste patiëntenbijsluiters in te voeren. Die omschakeling liep tussen 1988 
en 1992. 
In Europa werd in 1992 besloten dat alle geneesmiddelenverpakkingen zo'n 
verstaanbare bijsluiter moesten bevatten en geleidelijk aan werd dit ook overal 
in Europa gerealiseerd. Amerika en andere delen van de wereld kenden deze 
evolutie niet. Daar worden geneesmiddelen nog veel in bulk verpakt en 
dikwijls zonder veel informatie verdeeld, ook als het gaat om krachtige 
geneesmiddelen op voorschrift. 
Tijdens de introductie van de patiëntenbijsluiter werd in België een 
evaluatieprogramma opgezet om de omschakeling op de voet te volgen. Dit 
werk bevat een overzicht van alle studies die toen werden opgezet. Ook een 
aantal andere beschrijvende studies worden hierin verwerkt, omdat ze een licht 
werpen op hoe specifieke groepen patiënten zich informeren over hun 
geneesmiddelen. Tot slot worden ook een aantal experimentele studies 
besproken, die dieper peilen naar de invloed van geneesmiddeleninformatie op 
de manier waarop patiënten zich een voorstelling maken van het voordeel en 
het risico van hun geneesmiddel (voordeel/risico perceptie). 
Vanuit de ervaring in België wordt gepoogd een uitspraak te doen over de 
aanvaardbaarheid van de verplichte aanwezigheid van een patiëntenbijsluiter 
in alle geneesmiddelenverpakkingen. Daarbij stellen we ons een aantal vragen. 
Hoeveel patiënten lezen, aanvaarden en waarderen de bijsluiter? Wat gebeurt 
er als een land omschakelt van moeilijke naar verstaanbare bijsluiters? Is die 
omschakeling in België gelukt? Wat weten we over de invloed van de 
patiëntenbijsluiter op de kennis, emoties en percepties van patiënten over hun 
geneesmiddelen?
In dit werk is gepoogd om een beter begrip te krijgen van de invloed van de 
bijsluiter op de mentale processen die voorafgaan aan de beslissingen en 
handelingen van patiënten wanneer ze geneesmiddelen gebruiken. De vraag is 
hier of de patiëntenbijsluiter de perceptie van patiënten over het voordeel en 
het risico van geneesmiddelen kan beïnvloeden. Een verdere stap is uit te 
maken hoe de bijsluiter inwerkt op gedrag. Dat kan gaan over het melden van 
gezondheidsproblemen en bijwerkingen, over het vermogen om de 
behandeling juist en veilig uit te voeren, over de aanvaarding van het 
geneesmiddel bij de start van een behandeling en over de motivatie om een xiii
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enkele aanzetten gegeven, omdat we ons toegespitst hebben op de studie van 
de cognitieve processen van voordeel/risico beleving die voorafgaan aan 
beslissingen van patiënten.
De thesis bevat vier delen: een inleidend deel, twee delen met de resultaten van 
de verschillende studies en een afsluitend deel met bespreking, aanbevelingen 
en conclusies. Achteraan zijn in annex de copies toegevoegd van de zes 
publicaties waarop deze thesis formeel is gebaseerd. In het boek zelf wordt de 
verslaggeving van deze 6 publicaties ook gegeven, maar dan wel geplaatst in de 
context en met een eenheid van stijl, die ook is toegepast voor de andere 
studies in dit werk vermeld. 
Het inleidende deel omschrijft eerst het doel van de onderzoeken die hier 
worden voorgesteld. Daarna worden de literatuurgegevens over de objectieve 
en subjectieve nood aan geneesmiddeleninformatie bij patiënten besproken. 
Dan worden de kenmerken en de functies van de bijsluiter besproken, samen 
met wat er reeds lang is geweten over de invloed van de bijsluiter op feitelijke 
kennis over het geneesmiddel. De geschiedenis en de huidige stand van zaken 
rond bijsluiterprogramma’s in Europa, Amerika en enkele andere landen 
wordt toegelicht. Daarna gaan we dieper in op de introductie van de bijsluiter 
in België, tussen 1988 en 1992, omdat dit toch de achtergrond was voor dit 
werk. Om de inleiding af te ronden, worden kort de theoretische modellen 
geschetst die werden gehanteerd bij het uittekenen van de studies. Tenslotte 
wordt ingegaan op de structuur van dit werk.
In het tweede deel worden de beschrijvende studies voorgesteld, die werden 
uitgevoerd vóór, tijdens en kort na de introductie van de bijsluiter in België.
In Hoofdstuk 1 van Deel II wordt een bevolkingsonderzoek van 1988 in België 
voorgesteld, bij volwassenen van 18 tot 64 jaar, met huis-aan-huis interview. 
Dit onderzoek werd uitgevoerd net voor de introductie van 
patiëntenbijsluiters, na 25 jaar geneesmiddelendistributie met nagenoeg 
onbegrijpelijke technische bijsluiters. Uit de resultaten bleek dat deze 
technische bijsluiter door de grote meerderheid van de patiënten (87%) 
gelezen werd. De bijsluiter werd ook gewaardeerd als nuttig, met beperkte 
klachten over leesbaarheid, en met een aparte rol, naast deze van arts en 
apotheker.
In Hoofdstuk 2 van Deel II wordt gerapporteerd over een bevraging via de 
post bij Belgische artsen. Hieruit bleek dat artsen onderschatten hoeveel 
patiënten de bijsluiter lezen. Via een clusteranalyse werden drie types artsen 
beschreven: wat oudere artsen die ronduit negatief stonden tegenover de 
bijsluiter, maar die zelf de moeite doen om veel mondelinge instructies te 
geven; wat jongere artsen die de bijsluiter als een verlichting van hun 
informatietaak zien; tenslotte artsen die gemengde gevoelens hebben tegenover 
de bijsluiter, omdat ze scherp op de reacties van patiënten letten, en dus zowel 
positieve als negatieve gevolgen zien. xiv
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werden naar Vlaamse rusthuizen om een staalkaart te maken van het 
geneesmiddelengebruik onder de bejaarde bewoners. In het rusthuis was het 
verbruik hoog, en bleek de bijsluiter te verdwijnen uit de distributie. 
Zelfs cognitief fitte bewoners verloren hun autonomie over het 
geneesmiddelgebruik. Alleen de behandelende verpleegkundigen hanteerden de 
bijsluiter nog enigszins als bron van informatie.
In Hoofdstuk 4 van Deel II belichten we eerst de taalkundige hulpmiddelen die 
in het kader van het Belgische bijsluiterprogramma werden ontwikkeld 
(schrijfadviezen, meertalige woordenboeken van moeilijke en makkelijke 
medische termen en een leesbaarheidstest voor bijsluiters in het Nederlands en 
het Frans). Daarna volgt een kort overzicht van elf bijkomende beschrijvende 
onderzoeken. 
Het gaat om een bevraging via de post van de schrijvers van de bijsluiter 
(regulatory affairs managers), een herhaling in 1991 van de bevolkingsenquête 
van 1988, twee opeenvolgende registratiestudies in huisartsenpeilpraktijken 
van huisartsen in 1989 en 1990, vijf studies in specifieke bevolkingsgroepen 
(sociaal-actieve bejaarden, kwetsbare bejaarden in de thuiszorg; bejaarden op 
geriatrische ziekenhuisafdelingen, en gezonde adolescenten), twee studies over 
geneesmiddelendistributie in bejaardentehuizen en in ziekenhuizen, en 
tenslotte een beoordeling van de kenmerken van de Belgische bijsluiters in 
2000. We lichten de kerngegevens van elk van deze onderzoeken hier telkens 
toe.
De schrijvers van de bijsluiter binnen de farmaceutische industrie bleken al 
evenzeer als de artsen te onderschatten hoeveel patiënten de bijsluiter lezen. 
Hun oordeel over het nut van dit informatiemedium was evenwel genuanceerd 
positief.
In het herhaald bevolkingsonderzoek werden de hoge leespercentages 
bevestigd. Ook was duidelijk dat de introductie van de patiëntenbijsluiter goed 
opschoot (39% penetratie) en probleemloos en onopgemerkt verliep. 
In twee opeenvolgende klinische registratiestudies bij hypertensiepatiënten 
werden iets lagere, maar toch nog hoge leespercentages gemeten. Er was 
weinig verschil in (hoge) tevredenheid naargelang van het type bijsluiter, maar 
wel een hogere graad van spontane melding van gezondheidsproblemen en 
bijwerkingen bij de lezers van de patiëntenbijsluiter. 
In de studies bij bejaarden werd de paradox aangetoond tussen hoger 
geneesmiddelenverbruik en dalende behoefte aan geneesmiddeleninformatie 
bij deze groep. Terwijl bij sociaal-actieve bejaarden nog een ruime waaier aan 
informatiekanalen bestond met nog steeds een prominente rol voor de 
bijsluiter, vernauwde dat bij kwetsbare bejaarden in de thuiszorg, die niet meer 
het huis uit konden; ze verloren contact met de apotheker en de paramedische 
zorgverleners namen over. Bij bejaarden in acute geriatrische afdelingen xv
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gezonde adolescenten bleek de bijsluiter een prominente rol te spelen, naast 
ouders, arts en apotheker, in de uitzonderlijke gevallen waar toch een 
geneesmiddel werd genomen.
Uit de analyse van een kleine staalkaart bijsluiters uit het jaar 2000 blijkt 
duidelijk dat doorgaans wel enkele taalkundige ingrepen zijn gebeurd (kortere 
en minder ingewikkelde zinnen, minder jargon), maar dat de lengte, de inhoud 
en de kwaliteit van de Belgische patiëntenbijsluiters erg variabel blijft, ook 
acht jaar na hun introductie. 
In deel III worden de experimentele onderzoeken besproken die zich toespitsen 
op de manier waarop patiënten het voordeel en het risico van geneesmiddelen 
beleven.
In Hoofdstuk 1 van Deel III wordt een overzichtsartikel (gepubliceerd als 
hoofdstuk in een boek) besproken over de relatie tussen 
geneesmiddeleninformatie, voordeel/risico beleving, en therapietrouw, en dit in 
het licht van een nieuwe, precieze techniek voor de meting van therapietrouw 
(electronische monitoring).
In Hoofdstuk 2 van Deel III wordt die techniek toegepast in een 
gerandomiseerd klinisch onderzoek waar atenolol wordt vergeleken met 
lisinopril bij de behandeling van hypertensie. Beide behandelingsgroepen 
werden nog eens onderverdeeld in twee groepen: een subgroep zonder 
bijsluiter en een subgroep met een hybride bijsluiter (waarin typische 
bijwerkingen van beide geneesmiddelen in één tekst verenigd werden). Deze 
studie werd uitgevoerd door een farmaceutisch bedrijf en het luik over de 
bijsluiter werd er aan toegevoegd. Bij het toevallig blind toewijzen van de 
patiënten tot één van beide groepen liep iets mis. Sommige artsen doorbraken 
de randomisatie omdat ze liever geen beta-blokker gaven aan oudere 
patiënten. Daarom waren er uit deze studie geen echte conclusies te trekken. 
Wel wordt de opgedane methodologische ervaring belicht en worden enkele 
hypotheses voor verder onderzoek geformuleerd. 
In Hoofdstuk 3 van Deel III wordt een experimentele psychologische studie 
besproken met gezonde vrijwilligers (overwegend vrouwen). Een bijsluiter met 
een voordeelboodschap (een paragraaf van ongeveer 80 woorden) werd getest 
tegenover geen bijsluiter en tegenover de gewone bijsluiter (zonder 
noemenswaardige voordeelboodschap). Dit onderzoek werd uitgevoerd met 
drie scenarios (cisapride bij acute, banale spijsverteringsklachten; itroconazol 
bij schimmelbesmetting van teennagels; risperidon bij chronische behandeling 
van psychosen), telkens met ongeveer 90 proefpersonen verdeeld over drie 
experimentele groepen (geen bijsluiter; normale patiëntenbijsluiter; 
patiëntenbijsluiter met voordeelinformatie). Proefpersonen die geen bijsluiter 
kregen bleken het voordeel van het geneesmiddel hoog in te schatten, maar 
scoorden laag op de kennistest. Proefpersonen die een gewone bijsluiter kregen 
wisten meer over het geneesmiddel, maar scoorden de voordeel/risico xvi
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voordeelinformatie wisten meer over het geneesmiddel en bleven de voordelen 
hoger inschatten dan de nadelen. Deze bevindingen waren consistent in de drie 
scenario’s. 
In Hoofdstuk 4 van Deel III wordt een gerandomiseerde klinische studie 
gerapporteerd met een ontstekingsremmer bij patiënten met acute pijn door 
een banale kwetsuur. De helft van de patiënten kreeg het geneesmiddel met de 
bestaande technische bijsluiter (in principe moeilijk verstaanbaar), de andere 
helft kreeg de patiëntenbijsluiter (zelfde inhoud, zelfde lay-out, maar 
eenvoudiger geschreven). Uit de resultaten bleek dat in beide groepen de 
bijsluiter evenveel gelezen werd, dat de tevredenheid over de bijsluiter even 
hoog was, maar dat bij de patiënten met een patiëntenbijsluiter de voordeel/
risico beleving toch negatiever was. In dezelfde groep werden er meer 
gezondheidsklachten spontaan gerapporteerd en werd er meer een verband 
gelegd met het geneesmiddel. Ter afronding werd in Deel III nog het ontwerp 
besproken van een studie waarin gepoogd werd veel van de bovenstaande 
elementen te verenigen. Deze studie lukte evenwel niet, wellicht door de 
ambitieuze opzet.
In het afsluitend deel IV sommen we de relevante resultaten van de goed 
uitgevoerde beschrijvende en experimentele studies nog eens op en bespreken 
deze in relatie met literatuurgegevens. Ook suggereren we hypotheses voor 
verder onderzoek. We formuleren een aantal aanbevelingen met betrekking tot 
de problematiek van aansprakelijkheid en de productie en het testen van 
betere bijsluiters. We bepleiten de inbedding van bijsluiters in de nieuwe 
media, in een context van gezondheidspolitiek en patiëntenopvoeding.
De conclusies luiden als volgt. 
Patiëntenbijsluiters zijn een essentieel onderdeel van moderne systemen voor 
de distributie van geneesmiddelen, maar ook een instrument voor 
patiëntenopvoeding en gezondheidspolitiek. Bijsluiters die routinematig bij de 
aankoop van een geneesmiddel ter beschikking worden gesteld, worden 
gelezen door de patiënt en beïnvloeden de tevredenheid van de patiënt positief, 
ongeacht hun kwaliteit. Het lezen van een patiëntenbijsluiter van hoge 
kwaliteit heeft een bewezen positieve invloed op het kennisniveau over het 
geneesmiddel. De effecten op leesgedrag, tevredenheid en kennis zijn op 
zichzelf al een voldoende argument om een patiëntenbijsluiter te verstrekken, 
telkens er een geneesmiddel wordt afgeleverd, of dit geneesmiddel nu op 
voorschrift is of niet, en ondanks de ietwat hogere distributiekosten. Dit zijn 
sterke argumenten om het Europese systeem met verplichte verdeling van 
verstaanbare bijsluiters te veralgemenen. Beweringen dat patiëntenbijsluiters 
bijkomende positieve effecten zouden hebben op therapietrouw zijn niet echt 
onderbouwd. Ook is de evidentie schaars voor de stelling dat de huidige 
bijsluiters medicatiefouten en het oneigenlijk gebruik van geneesmiddelen xvii
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bewerkstelligen, of meer adequate reacties op bijwerkingen zouden stimuleren.
De voordeel/risico perceptie van het geneesmiddel door de patiënt is een 
belangrijke schakel in de verwerking van de geneesmiddeleninformatie in 
bijsluiters. Voordeel/risico perceptie kan direct gemeten worden. Voor die 
meting dienen gevalideerde meetechnieken ontwikkeld te worden. 
Dat is nodig om de relatie tussen kennis, begrip en gedrag bij het gebruik van 
geneesmiddelen te doorgronden en om betere bijsluiters te ontwerpen en te 
testen. Betere bijsluiters kunnen patiënten helpen samen met de arts gedeelde 
beslissingen te nemen (op basis van voldoende informatie) rond het opstarten 
van een behandeling. Ze kunnen patiënten ook kunnen helpen bij het juist en 
veilig verderzetten van de behandeling. Een belangrijk aspect bij het schrijven 
van betere bijsluiters is de invoering van een korte paragraaf met 
voordeelinformatie. Door informatie over voordeel en risico te integreren in 
een verstaanbare bijsluiter, zou een verbeterde overdracht van informatie 
kunnen gecombineerd worden met een meer gebalanceerde beleving van het 
voordeel en het risico van het geneesmiddel door de patiënt.xviii
Part I
Introduction
L’homme a inventé la parole pour cacher ses idées.
Prince De Talleyrand
1 Aim of the present thesis
Every year, billions of boxes of prescription medication are dispensed in the 
Western industrialised world. In Europe, each of these boxes contains an 
extensive folded sheet of paper, the patient package insert (PPI). This official 
drug labelling document lists in understandable terms the indications, 
contraindications, side-effects of the medication and other benefit and risk 
messages, to be read by the patient or his proxy, before the start of therapy or 
later while taking the medication. In this system of distributing drugs, the 
pharmaceutical companies assemble branded cardboard packages of fixed 
pack size, including the medication in fixed strength (in blisters or bottles) and 
the patient package insert. These branded packages are then distributed to the 
pharmacies, to be dispensed to patients. This drug distribution system for 
ambulatory care is called unit-of-use distribution or original pack dispensing. 
The efforts of writing, submitting, printing and distributing patient 
packages insert slightly add to the cost of distribution, as dispensing 
pharmaceuticals in bulk to pharmacies may be somewhat cheaper. The 
question is what the rationale is for consuming so much paper and ink and for 
spending the incremental cost of the distribution of a patient package insert in 
every box of medication.
This thesis aims to assess the impact of distribution of written drug 
information in original pack dispensing on:
• the acceptance of the patient package insert by the patient
• the benefit/risk perception of the patient.
Acceptance of drug information and benefit/risk perception are cognitive  
processes, preceding behaviors such as noncompliance, medication errors 
made by patients, inadequate reactions of patients to side-effects.  These 
behaviors may have a more direct impact on clinical outcome of the patients, 
but are not the main focus of this study. We considered that a better 
understanding of preceding cognitive  processes was necessary to understand 
behavioral responses and to design more effective interventions.   1
PART IWe decided to focus in this thesis on two cognitive processes: acceptance of 
written drug information (or patient satisfaction with information) and 
benefit/risk perception. 
For the focus on acceptance of patient package inserts by the public, two 
motives were predominant. Firstly, acceptance is  a key factor in evaluating the 
usefulness of a drug distributing system based on prepacked medicines with 
inserts versus a drug distribution system based on bulk medicines without 
information. Patient satisfaction (with drug information in general and with 
insert in particular) may be considered as a goal on its own, as it is an 
instrument to enhance patient compliance.  
Secondly,  opinion leaders among physicians and in the pharmaceutical 
sector are still making unsubstantiated statements about low percentage of 
patients reading the insert and high percentages of dissatisfaction and that it 
was time to replace "experience-based statements" with empirical evidence. 
Our focus on benefit/risk perception was motivated by the possibility to 
further upgrade the quality of the communication in patient package inserts 
and to design intervention studies on the impact of written drug information 
on patient behavior , using inserts with a proper balance between risk and 
benefit information. 
This thesis is based on 6 peer-reviewed first author publications, and a 
report of other relevant studies in which the author was involved. These 
studies were conducted between 1988 and 1997 and published between 1991 
and 2002. Most of the research was related to the introduction on a national 
scale of patient package inserts in Belgium between 1989 and 1992. 
In this thesis we focus on communication about prescribed allopathic 
medicines, formulated from active substances, synthesised by chemical 
reactions, or extracted in sufficient quantities from natural medicinal sources.
We have limited ourselves primarily to communication to patients on 
prescription medication in ambulatory care. 
The following topics will be addressed in the introduction:
• Drug information needs of patients
• Information on patient package inserts
• The introduction of the patient package insert in Belgium
• Theoretical models about the impact of written drug information
• The structure of this thesis.
2 Drug information needs of patients
2.1 Objective need for (written) drug information?
It is well known that the level of knowledge about drug therapy in general and 
about medicines which patients are currently taking in particular is poor 2
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elderly,[3][4][5][6][7][8][9][10][11][12] but by no means exclusively among the elderly.[13] 
In the years prior to the shaping of the European legislation on patient 
packages inserts, minimal requirements of what a patient needs to know to use 
a medicine correctly were formulated for over-the-counter medicines[14] and 
for prescription medicines.[15]
These minimal requirements constitute an extensive body of knowledge on 
indications, side-effects, dosage regimen, precautions, warnings, 
contraindications and storage instructions, to be conveyed to the patient.
In contrast to the field of written drug information, formal minimal 
requirements for drug information to be delivered to the patient by physicians 
or pharmacists have not been established yet, except for general 
recommendations concerning the professional role of health care providers 
with regard to patient education,[16] and the duty to inform patients about 
proposed therapy.[17] 
It is clear that these official requirements for drug information set a high 
standard to the amount of information to be transferred, especially with 
regard to risk information. They establish an extensive and rather complex 
collection of information items that should be transferred to fulfil the need for 
drug information. 
Evidence in the literature clearly indicates that the traditional sources of 
oral drug information, the physician and the pharmacist, do not suffice to 
ensure the adequate transfer of minimal drug information to patients, 
especially with regard to risk information. 
Observations of discourse between physicians and patients have revealed 
that the time devoted to information transfer regarding drug therapy is short 
in routine consultations.[18] In general practice, consultations tend to be short 
(between 6 and 20 minutes),[19] during which the patients must expose the 
reason for encounter, the physician must ask questions, examine the patient, 
and come to a diagnosis and a therapy plan. This must be discussed, agreed 
upon and explained. A recent study estimated that the time spent to 
medications is about one fifth of the consultation time.[18]
The short interaction between the physician and the patient is a potentially 
stressfull event for the patient, where the senses have to process extensive 
information in a highly emotional context, under time constraints and where 
drug therapy information is but one of the points of focus. Patients may forget 
the information,[21] and strong emotions (fear, anxiety, relief, dissatisfaction, 
satisfaction) may reduce the receptivity of the patient to information.[22] While 
the doctor explains about how to take the drug, the patient may be wondering 
about the consequences of the diagnosis, how it will affect his/her life and 
work: in such conditions the patient may completely miss the message. 
Physicians and pharmacists who engage in information giving must 
overcome a number of hurdles. They often received no or ineffective training 
in communication skills.[23] There is an educational, cultural and linguistic gap 
between the physician and the patient.[24][25][26][27][28][29] Finally, the scientific 3
PART Iconcepts of the doctor and the layman’s framework of ideas differ 
substantially.[30] 
The low prevalence, the low quality, and the low effectiveness of 
information giving activities does not facilitate communication about 
medication between the patient and the health care provider.
Moreover, there is little communication between physicians and 
pharmacists in routine medical practice, and hence a risk of conflicts in 
information from two trusted sources, as the pharmacist is unaware of the 
contents of the discussion during consultation.[31][32] 
On these theoretical grounds, it may be argued that there is an objective 
need for a trustworthy source of drug information in the drug distribution 
process. 
2.2 Subjective need for (written) drug information?
Judging from studies that have directly measured patients’ preferences about 
health information, the answer to the question “do patients want drug 
information” is a clear and definite “yes”.[33][34][35][36][37][38][39][40][41][42][43][44] The 
majority want (more) drug information, with a special interest in risk 
information, even concerning infrequent risks,[45][46][47][48] contrary to what the 
physicians think about this matter. 
Discussion about and reporting of side-effects are prominent subjects on 
the voiced or unvoiced agenda of patients to be discussed during 
consultation.[49] 
The source of drug information which patients undoubtedly prefer is the 
physician.[37][44][50][51][52] In most of the studies cited above, the pharmacist is 
mentioned as the second preferred source, at some distance behind. 
This desire for drug information from the physician pertains as much to 
procedural information (how to take the drug) as to the effectiveness (how 
does the drug work) and the safety of therapy (what are the risks of treatment 
and what to do in case of side-effects). The biggest “information gap” is 
perceived in the two latter areas.[33] There is also a desire for information on 
treatment alternatives.[34][53]
The third preferred source of drug information is the patient package 
insert, at least in countries where it is available. In countries where it is not 
available, people would welcome its provision.[42][44][54]
Additional sources of drug information are relatives and friends and the 
media. In quantitative surveys, the role of the social network around the 
patient is minimised. In qualitative research, personal contacts seem to be 
somewhat more important.[30][55] The information provided by the media 
about benefits and risks of medications has been described as inadequate, 
incomplete and biased by industry sources,[56] or as alarmist in times of crises. 
In sharp contrast with the data on the subjective desire for information, a 
number of studies have indicated the passivity of patients when information 
needs were not fulfilled, both in asking questions or requesting written 4
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consultation, especially with regard to risk information, the information need 
most often unfulfilled.[57] 
A number of possible reasons have been listed for this passivity:[57]
• Patients do not want “to bother” the physician
• Low level of information search, even for high involvement items, is a 
general feature of consumer behaviour
• Patients perceive barriers, based on the physicians’ behaviour
• The cost of getting information elsewhere is perceived as too high
• The ability to find information elsewhere is perceived as too low.
It is beyond the scope of this thesis to comment in greater detail on 
segmentation analyses. We will quote Morris, author of two of such analyses 
presented here: “Segmenting patients according to risk information seeking 
patterns helps us understand how risk information is differently sought by 
various groups of patients. When this segmentational analysis is done, 
however, we see an overwhelming passivity of patients, when obtaining 
therapeutic advice.” However, we will demonstrate in the next paragraphs 
that patients display an overwhelming tendency to read written drug 
information, provided it is readily available.[58][59]
There is overwhelming evidence that: 
• most patients express a subjective need for written drug information, 
especially for risk information
• most patients are interested in receiving patient package inserts
• the majority of patients read patient package inserts, whenever these 
are offered, even if the quality of the document is substandard.
In our view, the intensity, focus and motivation of reading reflects a genuine 
interest in seeking risk information as a coping strategy to deal with 
threatening illness and its therapy. 
In original pack dispensing distribution systems, the small minority of non-
readers is composed of at least three groups:
• risk avoiders
• healthy individuals with little experience of illness, who are not (yet) 
interested in medicine(s)
• elderly people who have emotionally adapted to chronic therapy and 
are no longer interested in drug information, even when (they know 
that) their level of knowledge is insufficient.
Each of these groups will require suitable attendance by other means, beyond 
the scope of the PPI.
Among the patients who read PPIs there are two predominant groups: 
• passive patients, longing for information, but not actively asking the 
health care provider for information or for a share in the decision 
making, nor seeking information when (unvoiced) questions remain 
unanswered5
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making, who would have departed on an information hunt for other 
sources, if no PPI was provided.
3 The patient package insert (PPI)
3.1 Definition of the PPI
The medium we have selected is the patient package insert, a sheet of paper 
folded inside a prepacked medicinal product package, in the framework of the 
unit-of-use drug distribution model. In this model, medicines are distributed in 
packages with a fixed number of units of a fixed strength, under a brand 
name, under the responsibility of a marketing authorisation holder, and with 
an outer container, intrinsically linking a package insert to the medicine.
The patient package insert is information from an authoritative source, as 
its content is approved by the regulatory authorities, sometimes after long 
discussions between the health authorities, experts from the scientific medical 
community and the pharmaceutical company.
The patient package insert is clearly an instrument of mass 
communication, controlled by registration authorities and pharmaceutical 
companies. However, the patient who receives and reads the insert has been 
targeted to receive this specific piece of information by prescription from a 
physician and/or delivery from a pharmacist.
Patient package inserts have a word count varying from 500 to 2000 
words. They are longer than the label on the outside of a medication box, 
which is limited to major instructions or warnings. PPIs are usually shorter 
than brochures or pamphlets with extensive information. 
The patient package insert is derived from the scientific data sheet or the 
Summary of Product Characteristics. This official labelling document is kept 
with the regulatory authorities, as a reference document for the different forms 
of drug information, derived from it for communication with professionals or 
patients or the general public. In the past in some countries, the text of the 
scientific data sheet was transcribed (sometimes in a slightly abbreviated 
version) into a technical insert (TI). This was the case in Belgium between 
1964 and 1988. The text of the TI is usually somewhat longer than the text of 
the PPI, as technical information for the professional or sometimes vital 
information is left out in the PPI. 
The content of the PPI is fixed for the average patient (or groups of 
patients). Adaptation of its content to the gender, age, literacy level, and 
cultural background of the recipient is not possible. Its target is the patient 
with a disease (or risk profile), for whom the need exists to take a medicine 
with preventive, symptom-relieving or healing properties. It is not a do-it-
yourself manual, but shares many of the characteristics of instructional user 6
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applications, or for assembly of construction kits. It is not its purpose to 
promote non-medicinal therapeutic interventions, but rather to support the 
relationship of the patient with the prescribing physician and/or the dispensing 
pharmacist. Its tone, however, differs substantially from the oral persuasive 
communication often practiced by physicians and pharmacists, in order to 
convince patients of the need to take the medicine as directed. It is a unique, 
and supposedly balanced mixture of tips for patients on the proper use of the 
medicine (procedural instructions), of warnings (risk information), and of 
information on the potentially beneficial effects (benefit information). It is 
unique, because in no other industrial branch are products released with such 
a full and readily available account of the potential risks of the product (longer 
and more explicit than the warning labels for tobacco products, alcoholic 
beverages, and dangerous chemical substances).
In short, the concept of the patient package insert brings together four 
important notions: 
1. the notion of linking the chemical substance (the medicine) and the 
information that goes with it (the insert) into one branded product 
(the package) in the course of retail distribution
2. the notion of authoritative medication information, approved by 
health regulatory agencies, after consensus with pharmaceutical 
companies and medical experts
3. the notion of balance between risk and benefit information
4. the notion of intentional, and legally enforced readability.
3.2 The context in which the PPI is used by patients
Other information channels around the patient
In the information network surrounding the individual patient, there are many 
oral information sources, each playing its role. Health professionals, i.e. 
physicians and pharmacists, are the information sources preferred by the 
patients.[60][51] Field studies, however, have demonstrated that information 
from these sources is limited, especially with regard to risk 
communication.[61][62] Traditionally, there has been very little cooperation 
between physicians and pharmacists in bringing information about 
medications to the patient.[63][64] 
A social network of relatives, neighbours, and friends surrounds the 
patients. Patients consult this network when in trouble, e.g. when deciding 
whether to seek professional help, or to start (or to continue) taking 
medicines. The media influence the patient directly and indirectly through the 
social network. Some of the information provided by these sources is 
repetitive, some is conflicting, some diverges from accepted knowledge. 
Patients can actively seek information in books, magazines, and on the Word 
Wide Web. 7
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It is instructive to plot the encounters of the patient with information sources 
on a time axis. First, the patient decides to go and see the doctor. During this 
encounter he/she will receive some information from the doctor, and a 
prescription. Then the patient goes to the pharmacy, again with the possibility 
to obtain information. An important moment comes when the patient returns 
home with the dispensed medication and has to decide whether or not to take 
the medicine. At that moment the patient might read the insert. The insert may 
also be important at a later point on the time axis. The time of onset of side-
effects is often unpredictable. However, an appropriate and swift reaction of 
the patient is often crucial, to limit the harm caused by side-effects. With some 
side-effects, e.g. allergic reactions, the patient should stop the medication and 
consult the physician promptly. With other side-effects, the patient should 
continue the medication, because abrupt halting might be hazardous. For 
some side-effects, the physician should be informed as soon as possible, for 
others only at the next scheduled checkup. 
note Some argue that the patient should have access to all the necessary 
information before buying the medicine from the pharmacist. It is 
possible that modern techniques of information providing will – or do 
already – alter the normal flow of events described here.
It is obvious that some important decisions in the therapeutic process are left 
to the patient. At such moments of doubt, it might be convenient for the 
patient to consult the patient package insert, provided the box and its content 
have not been thrown away. This is one of the reasons for having an insert in 
every box, even for chronic therapy, despite the environmental strain this 
potential waste of paper might cause, and despite the small but significant 
incremental cost of the distribution system. 
3.3 The quality of the scientific data sheet and 
the quality of the patient package insert
The scientific data sheet is the official summary of the huge amount of 
information that is available when the medication is registered, and it should 
reflect the accumulating evidence of its benefits and risks, as more and more 
patients are exposed to the drug, in the years after the release of the drug onto 
the market. 
The quality of the scientific data sheet is determined by: 
• the art and science of clinical pharmacology, pharmacovigilance, 
pharmaco-epidemiology, pharmaco-economics and outcomes research, 
all fairly new disciplines, called upon to produce a balanced account of 
the risks and benefits of medicines
• the quality of the interaction between the regulatory authorities, 
pharmaceutical companies, and medical experts.8
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• the quality of the scientific data sheet 
• the communication skills of the medical communication officer (or 
regulatory affairs manager or medical director) within the 
pharmaceutical company (or his/her ability to seek and find the right 
consultants)
• the company policy and the national regulatory policies, determined by 
the local balance between the legal, regulatory and educational 
function of the PPI.
3.4 The functions of the PPI
3.4.1 The legal function of the patient package insert
Liability currently has the most profound impact on the content and style of 
the PPI. The document is seen as a protection against liability claims, and as 
such, will always be reviewed by the company’s lawyer. It is the primary 
reason why the pharmaceutical industry claims the responsibility of 
authorship of the document, while the regulatory authorities restrict 
themselves to reviewing the document and approving its content, after seeking 
expert advice from the medical community. 
In Europe, liability issues are governed by the EEC Product Liability 
Directive (85/374/EEC), which states in Article 6 that: “A product is 
considered to be defective when it does not provide the safety which a person 
is entitled to expect, taking all circumstances into account, including: the 
presentation of the product ...”.
“Presentation of the product” means the full disclosure of instructions for 
use, necessary to reduce the risk of the product, and of all possible side-effects. 
The Directive introduces the principle of strict liability within the European 
Union, which means liability of the producers for damage caused by their 
products without their fault or negligence, if labelling or instructions for use 
do not correspond to knowledge available in medical science.[65] Very few cases 
of liability, solely based on poor labelling, ever went (successfully) to court in 
Europe. Nevertheless, the reaction of the European pharmaceutical industry, 
and the lawyers advising them, has been to overload the inserts of their 
products with detailed information about side-effects. It is not certain that this 
policy will really protect companies from claims regarding new and 
unexpected side-effects. These long enumerations include the obligatory list of 
frequently occurring minor side-effects (even those not occurring more often 
than with placebo), to every adverse event ever reported anecdotally (even if it 
occurred only once, and causality was never properly assessed). Under those 
circumstances, it is difficult to translate the side-effect section of the scientific 
data sheet into an understandable, meaningful and not too frightening 
message that is helpful to the patient. 9
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The patient package insert has become more than a passive conveyor of the 
current state of available information. It has also become an instrument of 
regulatory policy. When facing a safety crisis caused by the emergence of a 
signal of a potential serious adverse reaction to a marketed drug, the 
regulatory authorities traditionally have three options. They can play it safe 
and withdraw the product from the market, thereby protecting future patients 
from harm. Or they can take a risk and leave the product on the market, so as 
not to endanger the important investments. However, there is a third option, 
often a way out of impossible dilemmas. The regulatory authority can 
officially request a change in the scientific data sheet. This can then be 
communicated to the health professionals by “Dear Doctor” letters and other 
means. In cases where patient package inserts are available in the distribution 
system, direct communication with the patients taking the drug can be 
achieved by a mandated change in the document, whether or not enforced by 
some method of emphasis. This is an example of the use of information as an 
instrument of regulatory policy.[66] In a number of instances this approach has 
permitted the regulators to prevent or successfully cope with media crises. It 
explains why the regulators tend to exert thorough control over the structure 
and content of this official document. 
The European Directive 92/27/EEC goes to great lengths to define the 
number of sections, the content of the sections and the order of sections in 
what is officially called the “User Leaflet”. Moreover, this legislation is a clear 
choice for the full information patient package insert, with little or no loss of 
information, as compared with the scientific data sheet. This is especially true 
for the section on side-effects, warnings, and contraindications. These sections 
are the main targets for regulatory control, to check whether there are no 
important omissions. In addition, regulatory authorities check whether the 
enumeration and formulation of official indications is correct. In practice, in 
Europe, regulatory authorities have not allowed long sections on the benefit of 
the medication, probably in fear of the administrative workload for checking 
and debating this section. 
3.4.3 The educational function of the patient package insert
The patient package insert is an instrument to fulfill the patients’ right to 
know, a right claimed by consumer organisations in Western Europe and to a 
lesser extent in the USA. 
In an early review of 8 studies looking into the impact of PPIs without any 
additional intervention, knowledge was improved in 7 studies, especially with 
regard to less commonly known information such as precautions, side-effects, 
or special warnings.[67]10
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interventions) only one study was found where there was no knowledge gain 
comparing subjects receiving a PPI to those who did not receive one.[68] 
A review of this issue in 1998[38] focused on studies in the UK,[7][8][69][70] and 
more specifically on the Southampton studies, published between 1987 and 
1990.[71][72][73] These studies confirmed that patients who had received a leaflet 
(a PPI) were again more knowledgeable (and more satisfied).[74] This series of 
studies, partially sponsored by the King’s Fund, had a strong impact on the 
Association of the British Pharmaceutical Industry and on Britain’s position 
during the passing of the European Directive on patient information in 1992.
The studies described above were non-randomised intervention studies, 
mostly testing intervention versus no intervention. 
The impact of leaflets on knowledge was also confirmed in a number of 
studies in pre-post design.[74][75][76][77] 
For a thorough discussion of the differential impact on knowledge of 
different aspects (background information, instructions, side-effects) we refer 
to the thesis of van der Waarde.[78]
Few comparative evaluations of the differential impact of technical inserts 
(TIs) versus patient package inserts (PPIs) have been conducted. First attempts 
were made in Switzerland in the study by Rupf.[79] A recent large scale 
randomised double blind comparison (N=1560) of TI versus PPI was 
conducted in Spain, with knowledge assessment by a questionnaire distributed 
to patients, to be filled in at home (possibly with the insert at hand). The 
questionnaire focused on procedural items. The mean proportion of correct 
answers was 45.7% in the TI group and 75.5% in the PPI group. The odds 
ratio of answering more than 70% of the questions correctly was 13.5 (CI95 
10.5-17.5).[80]
The complicated relationship between verbal and written information has 
been discussed elsewhere,[67][81][82][83][38] strongly suggesting that verbal 
information reinforces the effect of written information on knowledge, but 
that physicians and pharmacists tend to engage in persuasional efforts and 
procedural information rather than in risk communication. 
3.5 The history of the PPI
3.5.1 Historical developments in Europe
A start of drug registration
In the early 1960s Western Europe was the theatre for a crisis with the drug 
thalidomide (a drug for nausea in pregnancy), causing the birth of thousands 
of children with malformations primarily of the arms (focomelia).[84] In the 
following years most countries in Western Europe installed a formal procedure 
to have drugs registered and evaluated by a Drug Registration Authority.[85] 
The European Union (EU) issued a Directive in 1965, which fixed the outline 
of a scientific data sheet, also called Summary of Product Characteristics 11
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for registration.[86] 
Southern European countries regulated that this scientific data sheet 
should be put into the branded boxes of medicines (the dominating way of 
dispensing medicines in these countries). In the Northern European countries, 
where medicines were distributed in bulk dispensing (taken from big 
containers and dispensed in small white paper bags or caps ), this obligation 
was not enforced. In 1975 the concept of the patient package insert was 
introduced in European legislation, but without immediate practical 
consequences. Meanwhile, the quality but also the sophistication of the 
scientific data sheet grew with the growing regulatory impact on the drug 
development process. By 1985, all drugs, including those registered before the 
thalidomide crisis, needed to have a scientific data sheet and have this sheet 
revised every five years. In those countries where the scientific data sheet was 
contained in the medication package, there was strong pressure of the 
consumer movement for a more understandable patient package insert. 
The European pharmaceutical industry did not oppose the concept 
because the British industry considered the insert an essential part of original 
drug dispensing (dispensing of medicines in branded fixed boxes). That was 
the reason why the British government for once did not say no to a proposal 
for European regulation, and backed the crucial decision of the Council of 
Health Ministers, under the Belgian Presidency in 1988.[85] In 1992, the 
Directive 92/27/EEC was passed introducing mandatory patient package 
inserts in all countries of the European Union (EU). 
The legal road to patient package inserts in Europe
We will limit ourself to the enumeration of and brief comment on the different 
Directives, relevant to this subject: 
• Directive 65/65/EEC (O.J. 22 of 9.2.1965), which decreed that an 
application for marketing authorisation should contain a Summary of 
Product Characteristics (SmPC), and, in addition, a draft of a package 
leaflet, in countries where one is to be enclosed, similar to the SmPC. 
• Directive 75/319/EEC (O.J. L 147 of 9.7.1975), which introduced the 
concept of a patient package insert, without making it mandatory, but 
specifying minimum information required when enclosed.
• Directive 83/570/EEC (O.J. L 332 of 28.11.1983), which further 
specified the content of the SmPC for new marketing authorisations 
from 1986 on and, in addition requiring a similar SmPC for all existing 
drugs (even those registered before 1964) before the end of 1990. 
• Directive 92/27/EEC (O.J. L 113 of 30.4.92), which made the 
provision of a patient package leaflet (in accordance with the SmPC), 
mandatory in all member states in all dispensed medicine boxes. 12
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In the United Kingdom, in the Netherlands, and in most of the Scandinavian 
countries the concept of written drug information was unknown to the 
population (except for some voluntary initiatives). In Denmark, the inclusion 
of written information in the drug packages was even explicitly forbidden. In 
Belgium, as in Germany and in the Southern European countries, at the end of 
the 1980’s, patients were familiar with (technical) inserts in the drug 
distribution process. Germany passed a decree to create two types of inserts 
(PPI and TI) in 1986, but was not able to solve the problem of an excessively 
long side-effect section due to liability issues.[65] France had a similar provision 
since 1985, but the PPI was rather short and devoid of useful information (e.g. 
a side-effect section could be limited to: “in case of problems, consult your 
physician”). 
Joossens (1990) presents an overview of the status of written drug 
information in the 12 member states for the European Union of Consumer 
Associations.[87] The conclusions are:
• the European Union was still far away from achieving complete, 
standardised, up-to-date, available, legible and readable information 
for patients
• there were three types of countries: countries with no inserts, countries 
with technical, unintelligible inserts (TIs), and countries with 
(unsatisfactory) patient package inserts (PPIs) 
• information in the inserts from products with the same active 
ingredients differed substantially across Europe, as far as side-effects, 
contra-indications and dosages were concerned.
Joossens also points out that research had shown that technical inserts were 
basically unintelligible to patients. Despite this fact, research in Belgium, 
Switzerland and Italy has shown that these technical inserts are both read by 
the majority of citizens, and judged useful. This paradox was considered 
indicative of the great need for information about medicines among patients, a 
need unmet by the then current drug information practices in Europe. This 
influential report undoubtedly had a great impact on the developments in 
Belgium and in Europe.
3.5.2 Historical developments in the US
The USA escaped from the thalidomide crisis because the Food and Drug 
Administration (FDA) had not yet registered thalidomide when the epidemic 
of malformations became obvious elsewhere in the world. The USA had no 
tradition of written drug information inside packages, and drugs were 
predominantly dispensed in bulk with some limited labelling instruction on the 
white paper bag (e.g. “to be taken twice a day”). During the late 1960’s, the 
FDA introduced patient package inserts for isoprotorenol (an inhalation drug 13
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1970’s for oral contraceptives.[88] In 1984, the Patient Labelling Project was 
initiated to conduct research and evaluation studies and to design a full scale 
implementation plan. During the final weeks of the Carter Administration, the 
FDA issued final regulations for a 3-year PPI pilot programme covering 10 
drug classes. However, once the Reagan Administration took office, the PPI 
pilot programme was immediately put on hold, with preference given to the 
development of voluntary private sector initiatives. 
The rationale of the FDA to propose a mandatory PPI was based on 
economic assumptions. The FDA referred to the costs of hospitalisations 
caused by inappropriate use of prescription medications, estimated at 78.6 
billion USD annually for the USA, an amount almost equal to the actual drug 
budget itself.[89][90] However, the evidence that drug related hospital 
hospitalisations or medication errors are (even partly) caused by the lack of 
written drug information is not substantial. 
One of the reasons for opposition to PPIs in the US was the liability issue. 
There are fundamental differences between the legal systems of the USA and 
Western Europe. The USA has a Common Law system, where legal doctrine is 
created from actual rulings of the court, while most European countries have a 
Napoleontic System, where the Law is a result of parliamentary activity, 
interpreted by the judges. Plaintiffs who have experienced harm from the use 
of pharmaceutical products are more likely to go to court in the USA, maybe 
because of the higher probability of winning cases and higher ensuing 
compensation. The lawyers of the pharmaceutical companies in the USA have 
built a specific defence against liability claims. They argue that physicians and 
pharmacists are the first information sources of the patients (the learned 
intermediaries), who have the responsibility to inform the patient of the 
inherent risks of the pharmaceutical product. The companies have the duty to 
inform the health professionals but should not intervene between patients and 
their caregivers. This peculiar legal doctrine continues to dominate the 
approach in USA courts. However, the basis of this doctrine (the doctor and 
the pharmacist will provide the patient with the necessary risk information) is 
refuted by the results of studies, which have clearly shown that health 
professionals engage only very seldom and very superficially in risk 
communication during routine practice.[61][62][91]
Nevertheless, this legal doctrine is probably a major reason why in the 
American drug distribution system information from the scientific data sheet 
has not found its way into the drug packages in the form of patient package 
inserts. As the scientific data sheet was never intended to be inserted into the 
medication boxes, it grew longer and longer. This reflects the legal interest of 
debates on the exact wording of indications, because the document was more 
used as a reference document in conflicts over off-label use and inappropriate 
benefit claims in pharmaceutical promotion to prescribers and direct-to-
consumer advertising.[92] Pharmaceutical advertising paradoxically is far more 
frequent in the US media, compared to Western Europe.14
INTRODUCTION3.6 Current status of PPI programmes in the world
3.6.1 The regulatory situation in Europe
After the 1992 legislation on patient information, the European Commission 
invited a Consumer Association expert (Luc Joossens, the same expert who 
conducted the comparative study of leaflet quality in 12 European countries in 
1990[93]) to provide recommendations for the legibility of labels and leaflets of 
medicinal products. In this document, a rather small type size was proposed (8 
pica points for monolingual leaflets and 7 pica points for multilingual leaflets, 
each with one pica point leading).[94] This document was later followed by a 
formal guideline on readability, adopted in 1998.[95]
The European Agency for the Evaluation of Medicinal Products (EMEA) 
created an internal working group, called the Quality Review of Documents 
group (QRD). This group issued templates, reference documents and guidance 
on user testing for centrally authorised products, as well as guidance on 
various other aspects of terminology and style, the provision of general health 
information in PPIS, and guidance to address the paediatric or incapacitated 
patient. The positive aspect of this process was that a dialogue developed 
between EMEA and the industry about the aim and methods of user testing. 
However, a rather superficial method of testing was proposed.[96] Nevertheless, 
this resulted in an unprecedented level of user testing of product information, 
and a certain build-up of expertise. Moreover, the industry and the EMEA 
successfully discussed the linguistic review of product information within the 
timetable of a marketing authorisation application. Indeed, because of the 
tight schedule of a marketing application and because of the translation 
problems with the nine official languages of the European Union, it proved 
difficult for companies to allocate sufficient attention to the linguistic quality 
of patient package inserts in the early stages of the marketing authorization. 
Fortunately, EMEA decided to simplify the reviewing process and to 
implement a new process for the linguistic review of product information of 
products submitted to the European (centralised) registration procedure. The 
assessment of the content is based only on the English language version of the 
Summary of Product Characteristics and package leaflets. As soon as an 
official opinion is made (normally on day 210 of the application), a linguistic 
review process of translations starts (maximum 40 days), with input from the 
member states.[97] 
A development worth mentioning was the initiative of the Dutch 
regulatory authorities to allow pharmaceutical companies to adopt “house-
styles” for the development of PPIs of all their products. This house style can 
diverge from the European templates, provided it is underpinned by user 
testing.[98] 
A joint EMEA/industry group started the PIM project (Product 
Information for Medicines), a first attempt to bring the production, review, 
and publication process of formal patient information into the technical realm 15
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Language XML, a standard for content management and Internet 
applications.
Another EMEA project, called Medication Information Network for 
Europe (MINE) aimed to provide European citizens with a database of all the 
medicinal products on the European market, including the text of the PPI, but 
unfortunately this project failed, as did all of its predecessors.[99] 
Although no new formal reevaluation of the current situation regarding 
patient information in the different European countries has been made (except 
for small studies in a limited number of countries[100]), it seems that progress 
has been made in the availability of PPIS in countries where they did not 
previously exist.[101] In these countries and in countries with a long tradition of 
PPIS, the quality and congruity of drug information for patients has not 
increased.[102][103][104][105][106][107][108] For companies producing PPIs for the 
member states, differences in national regulations may have increased rather 
than decreased over the past decade.[109] 
After the Treaty of Maastricht in 1992, the development of a public health 
approach became possible in the European institutions. A thorough review of 
European pharmaceutical legislation was undertaken by the European 
Commission, setting in motion a long constitutional approval process in the 
European Union, to be finished by 2004. As part of this process, three 
developments deserve to be mentioned.
• a concerted effort between the regulatory authority and patient 
advocate groups
• the G10 High Level Medicines group
• the tense debate in the European parliament on direct-to-consumer 
advertising.
The EMEA and its commission for drug approval, the Committee for 
Proprietary Medicinal Products (CPMP), has started a concerted action with 
patient advocate groups and consumer associations about communication 
with patients on issues of drug approval and drug safety. In a series of 
meetings between 2002 and 2004, a plan of action is to be established 
regarding pro-active pharmacovigilance, product information, transparency 
and dissemination of information.[110] 
On the political front, the European Commission engaged in a wide 
consultation in the G10 High Level Medicines Group on innovation and 
provision of medicines, created in 2000 to explore ways of improving the 
competitiveness of the European pharmaceutical industry, while encouraging 
high levels of health protection. A formal meeting was organised in 
Luxembourg (December 2001), by the Directorate General of Health and 
Consumer Protection with patient advocate groups and different stake-
holders, to discuss the issue of patient information. In the final report of May 
2002 with recommendations for action, a chapter is devoted to patients, with 
a recommendation concerning the distinction between information and 16
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groups, optimal pharmacovigilance, and, finally, review of the legislation 
regarding patient information leaflets (Recommendation 11). 
All of this was the prelude to an intense political debate about the possible 
introduction of direct to consumer advertising in Europe, against the 
background of a thorough revision of European regulations regarding 
medicines.[112] In April 2002, in an unusual coordination effort, European 
consumer groups, patient advocate organisations, an international federation 
of mutualities (semi-public health insurers), and the International Society of 
Drug Bulletins formed a “Medicines for Europe Forum” to promote a 
responsible public-health-oriented policy towards medicines in general and 
support for independent drug information to professionals and patients in 
particular. 
In October 2002, the European Parliament voted on legislation, forming 
the legal framework for human medicines throughout the European Union in 
years to come.
There was also an amendment by the Commission to allow the industry to 
advertise medicines for HIV/AIDS, asthma and diabetes. This amendment was 
rejected by a vote of 494 to 42, as it was felt that the proposal would weaken 
the EU’s ban on advertising prescription-only medicines to the public. The 
Parliamentary Committee on Environment, Public Health and Consumer 
Policy called on the Commission to outline a comprehensive consumer/patient 
information strategy, ensuring good quality, non-promotional and reliable 
information about medicines and other treatments. In 2003, the dialogue with 
consumer organisations and the EMEA was resumed.[110]
It remains to be seen whether the issue of high quality, independent, 
transparent and easily accessible product information (including PPIs) will 
remain high on the agenda of both regulatory health authorities and patient 
advocate groups. The arrival of 10 new member states may absorb a lot of 
energy of all the constituencies, now that the number of official languages is to 
rise from 11 to 19 languages in 25 member states. The Council Meeting on 
Employment, Social Policy, Health and Consumer Affairs in Brussels, in 
December 2003, adopted a forceful and detailed Council Resolution on 
“Pharmaceuticals and public health challenges - Focusing on the patients” 
which may set the agenda for progress in this area at the European level for 
the coming years.[112]
3.6.2 The regulatory situation in the United States of America
In 1995, a new confrontation between the voluntary and mandatory approach 
originated, when the FDA announced the MEDGuide project, reinforcing as 
its target that by 2000 75% of the patients to whom drugs are dispensed 
should receive written drug information.[113] In February 1996, the FDA held a 
workshop on prescription drug information, to confirm its intention to move 
forward in this area. In December 1996, an action plan for the provision of 17
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E. Shallala of the Department of Health and Human Services. This action plan 
stimulated both private and governmental initiatives and provided a new plan 
for strict evaluation of the private sector approaches.[114]
The MedGuide programme was finally adopted in 1998[115] and the FDA 
remained active in revising drug labelling and patient information for several 
drug groups, including antibiotics[116] and oral oestrogens.[117][118]
In 2000, research surveys should have provided conclusions about the 
success of voluntary programmes of drug information distribution, as 
announced in health care targets, e.g. for menopausal women taking 
oestrogens. At this point, the Clinton Administration was moving to its end. 
Al Gore (a well known advocate of readability issues in communication 
between state, companies and the citizen) was campaigning against George 
Bush. Since the Bush Jr. Administration took over, the fate of governmental 
drug information initiatives looks bleak for some time to come.[119] 
Surprisingly, much research on this issue has been carried out in the US, 
but so little action was undertaken at the regulatory level. On the other hand, 
Europe undertook a major regulatory change in drug distribution on a rather 
scant evidence base. Maybe reluctance to regulatory change is greater in the 
USA, because the constituencies know that once decided, rules get 
implemented. In Europe, laws and directives are voted with elegant ease and 
little preparation, but few seem to mind that implementation stalls and differs 
from what was envisioned. 
3.6.3 The regulatory situation in other parts of the world
Although Japan has a long history of packaging inserts,[120] current medical 
practice still seems to be dominated by a paternalistic approach to patients by 
dispensing physicians. The development of the role of the pharmacist in drug 
information is ongoing.[121] Cultural factors among patients and health care 
providers with regard to drug information might be different.[122][123][124] The 
pharmaceutical industry has Drug Information Centres which give direct 
response to consumer inquiries.[125] In 1997, the law obliged manufacturers 
and drug distributors to provide information. Voluntary drug information 
activities are coordinated by the RAD-AR Council, a consortium of scientists 
and the pharmaceutical industry. 
In 1992, the Australian Federal Government adopted legislation to ensure 
that Consumer Medicines Information (the Australian version of the PPI) 
would be available for all new and existing drugs by 2004. This goal has been 
met by intense collaboration between the parties involved, some of them 
initially reluctant.[126][127] In an early phase, information design experts were 
consulted, resulting in excellent recommendations, frameworks, vocabularies 
and testing procedures.[128][129][130] Peculiar to the Australian approach is that 
the policies to provide consumers with high quality information are part of a 18
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remain about the level of effective distribution of the (excellent) inserts, despite 
subsidizing of pharmacies to install specially designed laser-printers at the 
point of dispensing. 
In Canada, patient package inserts have been made mandatory as part of 
the marketing authorisation for a large number of drugs, all inhalers and 
patches and self-administered biologicals. An excellent guide for producing 
well designed PPIs was published by the Canadian Public Health Association 
in 2002.[132] 
In Israel, patient oriented package inserts became legally mandatory in 
1979, in 3 languages (Hebrew, Arabic and English), with several revisions 
since.
For the sake of completeness, we list some reports from South America 
and Asia on the subject.[133][134][135]
3.6.4 Recent research meetings on PPIs
On the scientific front, interest in the subject has been kept alive, with experts 
meeting in two Drug Information Association (DIA) symposia, held in London 
in 2000 and in Bruges in 2002; the 2nd international Shared Decision Making 
conference in Swansea, UK (2003); a workshop from the health information 
design network in 2003 in Coventry, UK; and symposia at the 2002 and 2003 
meetings of the International Federation of Pharmacy FIP in Nice, France, and 
Sydney, Australia.
4 The introduction of PPIs in Belgium 
and its evaluation
4.1 Some background information about Belgium 
For a good understanding of the research presented here, it is important to be 
familiar with some key characteristics and peculiarities of Belgium, a country 
with a complex governemental structure, and of its patient package inserts. 
Belgium is a small but densely populated country, situated at the crossroads of 
Europe, with 10 million inhabitants and 3 official national languages. These 
languages are:
• Dutch, the language of the Dutch-speaking part of Belgium (6 million 
inhabitants) 
• French, the language of the French-speaking part (4 million 
inhabitants)
• German, the language of a small number of villages (40.000 
inhabitants) near the eastern border19
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but has been occupied at different times in history by the armies and 
administrations of every dominant nation in Europe, and hence it has been 
subjected to a variety of cultural influences. In no other country have the 
French and Anglo-saxon medical traditions interacted with such intensity. 
4.2 Characteristics of the Belgian drug distribution system
Technical inserts were gradually introduced in Belgium from 1964 on, when a 
Drug Registration Committee was installed, after the thalidomide crisis. These 
inserts were in fact the scientific data sheets (sometimes in a somewhat 
shortened version), inserted inside the boxes distributed to the patients. Over 
90% of the medication dispensed in the pharmacies (which hold a monopoly 
to dispense medication) is dispensed as branded boxes with a fixed pack size 
and a fixed strength of content (the remaining 10% being ready-made 
formulations by the pharmacist, a tradition which is almost extinct). 
Unfortunately, for legal reasons, it was decided that technical package inserts, 
regardless of their place of distribution in the country, needed to be printed in 
the 3 official languages. This decision is indicative of the priority given to the 
language problem by the regulators. This had a number of consequences. In 
order to keep the sheet of paper inside the medication packages down to a 
reasonable size, the text was printed in small print size, on the thin paper used 
for Bibles, and with a dense and dull layout, with a sometimes cluttered aspect 
in the order of the three language versions. The Belgian technical inserts did 
not have a side-effect section as long as the one in the German inserts. They 
were longer and more informative than the French inserts, which basically did 
little more than refer patients to the physician in case of problems.
4.3 The legal road to PPIs in Belgium
The wheels of the process were set in motion in Belgium by a law (amending 
the basic medicines Act of 1964) passed in 1983 (Act of 21.06.1983), followed 
by two royal decrees in 1984 (R.D of 23.7.1984; R.D. of 9.7.1984). The 
health administration prepared for a huge operation of revision of all the 
technical data sheets for all drugs (including drugs on the market prior to 
1964), to begin in 1986, as requested by Europe (see above). In addition, the 
administration knew that new legislation was on its way regarding the 
provision of understandable information to patients. An expert committee was 
set up to investigate whether and how the revision operation could coincide 
with the introduction of patient package inserts. Finally, in 1986 the new 
Minister of Health decided to go ahead with the operation. A Royal Decree 
was made on January 27, 1986, fixing the time schedule over one year for the 
introduction of drafts of PPIs. Belgium was by then the first country in Europe 20
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process with the validation of the drug information on older products and the 
first wave of a 5-year revision cycle for all products. A few back-and-forward 
changes were made to the official wordings of the headers of the patient 
package inserts, and finally the Belgian legislation incorporated European 
Directive 92/27/EEC with the Royal Decree of 31.12.1992, as the first 
European country to legally and practically enact this piece of legislation. In 
the mean time, a new Belgian government had been formed, and the political 
interest in this project had vanished. 
4.4 The characteristics of PPIs in Belgium
To understand the transition to patient package inserts which started in 1988, 
we must bear in mind two crucial features. Firstly, as stated above, it was a 
transition from an original drug dispensing system with technical inserts to an 
original drug dispensing system with patient package inserts. Secondly, the 
main difference between the patient package insert and the old technical insert 
was merely of a linguistic nature. Both texts have a similar overall look (in 
fact, rather dull) and are of similar length. Only when the text is read do the 
differences become apparent, essentially a reduction of jargon, and a reduction 
of the length and complexity of the sentences. Unfortunately, the requirement 
to have the insert in three official language was maintained, hence the type size 
of the Belgian inserts has remained small, sometimes less than 9 pica points, 
which is probably too small. 
The following elements should be added: 
• a clear choice for a full information insert
• structured in 16 items, expressed in simple, uniform titles, to provide 
the reader with a grid to scan the content
• a fixed order of items, with the order chosen to reflect the mental 
process of an individual reading the insert before the intake of the first 
dose
• omission of the section of the scientific data sheet on pharmacological 
properties
• a standardised reference to the pharmaceutical group to which the 
drug belongs, with some efforts to coordinate with the wording in the 
section on interactions
• no information on how the drug works or how drug action can be 
perceived (benefit information)
• long and unstructured lists of possible side-effects
• an informative, moderate tone, without any promotional messages.
The following additional characteristics are also important: 
• the final responsibility and authorship of the insert lies with the 
pharmaceutical company21
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adult with a formal education to the age of 16 years
• the insert is explicitly positioned as an instrument in the patient-
pharmacist-patient relation, and not a stand-alone, do-it-yourself guide
• the content of the insert is related to a specific drug, rather than to a 
drug class. 
4.5 Characteristics of the Belgian implementation efforts
From 1984 till 1987, there was active involvement by scientific associations, 
consumer associations, and the pharmaceutical industry in the preparation 
phase of the Belgian transition to patient package inserts, with intense debate, 
particularly on the issue of final authorship (firmly claimed by the industry), 
and the inclusion or omission of a benefit message (claimed by the consumer 
organisations, but in practice declined by the regulatory agencies). Policy was 
finally firmly established in 1986, after a compromise was reached, with 
which none of the constituencies were fully happy, especially not the 
consumers.[136] Once decided, a rather technocratic process evolved, run by the 
Pharmaceutical Inspection and the Medical Information officers of the 
companies, in cycles of draft deposition, revision and final acceptance of more 
than 2,000 inserts. A description of the implementation efforts was presented 
at the 25th Annual Meeting of the Drug Information Association in Boston, 
USA in 1989, and published in the DIA journal in the same year.[137] 
The goals of the PPI implementation were stated in the official motivation 
of the legislative process: 
• to fulfil the right to know
• to enhance patient compliance
• to enhance patient participation in the health care process and to 
improve the rationality of the process of drug utilisation
Part of the implementation process was to provide help, assistance and 
tools to the writers of the patient package inserts. The medical information 
officers inside the companies were academically trained physicians and 
pharmacists, heavily using medical jargon. They had great difficulty writing in 
a simple style. Training courses for communication in plain language were 
organised, and a booklet on the subject was commissioned from a linguistic 
expert, focusing on drug information.[138][139] In addition, a trilingual glossary 
of technical and popular terms was edited.[140][141] First, a selection was made 
of some 1.400 medical jargon terms, which often turn up in scientific data 
sheets. A Dutch/French/German list of these technical terms was then made, 
and finally, for each of the technical terms, an appropriate popular term (or a 
short description) was sought in each language. The list had no normative 
character, but was intended to avoid a “Babel-like” multiplication of 
“popular” terms. 22
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a two-step procedure. Firstly, there was a congruence check with the data sheet 
by the medical experts of the Pharmaceutical Inspection. Secondly, the 
readability of the text was evaluated. It was agreed that as the law said that 
inserts had to be understandable by the citizen, and so there was a need for a 
formal evaluation procedure to enforce this legal obligation. However, it was 
soon clear that the pharmaceutical industry would not accept refusals of drafts 
by civil servants, who themselves did not have a track record of clear and 
understandable communication. At that time, the only available example of a 
solution for this difficult situation was the USA Department of Defence 
Regulation DOD 3984X203, stating that manuals for guns, commissioned by 
the Navy, needed to be understandable by the average American private 
soldier, confirmed by a readability test.[142] After reviewing the literature on the 
pros and cons of existing readability tests, a research programme was 
commissioned to produce a context-specific computerised readability test (see 
chapter 4 of Part II). The readability of individual drafts was then screened by 
a medical doctor with linguistic training in medical communication. The 
computerised readability test was only used to confirm the identification of 
substandard inserts with low readability, and to document rejection decisions. 
A scanning system with Optical Character Recognition technology processed 
the drafts (with titles and technical sections obscured by markup) and was able 
to print a written result with an overall readability score, and with 
identification of technical terms and complex sentences. The very fact that the 
system was in place sent a signal to the medical departments of the 
pharmaceutical companies, indicating that the operation had to be taken 
seriously from a linguistic point of view.
The review process was organised in a time frame, taking one major 
therapeutic class after another. However, the control was performed on 
individual drafts for brands of different companies. There was no Document 
Management System available to compare e.g. the side-effect sections of 
different medicinal products, containing e.g. aspirin. Inevitably, inconsistencies 
crept in, weakening the fair enforcement of a minimum level of quality. 
The first validated patient package inserts appeared in packages in 1987, 
and the transition process gradually evolved in the ensuing years, to be 
completed by 1993. 
4.6 Evaluation of the introduction of PPIs in Belgium
In 1987, while we were involved in the implementation process, we proposed 
initiating an evaluation programme, and were able to convince the health 
authorities to fund the project. 
Lilja lists a number of criteria which can be used to measure impact (here 
presented in a slightly adapted form):[143]
• reception rate
• receivers’ satisfaction with the information provided23
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• changes in attitude 
• behavioural changes (compliance, different reporting of adverse drug 
reactions, more adequate reactions to adverse drug reactions) 
• health effects (including reduction in adverse reactions) 
• satisfactory balance between health information cost and benefits 
We chose reception rate and satisfaction as two primary criteria, as we 
were fairly confident that the results would be positive. We skipped changes in 
knowledge as a criterion for our programme, as we considered that the impact 
on these aspects had already been clearly demonstrated in other research 
projects. It was considered too difficult to demonstrate impact on health 
outcome. We were always reluctant to add the impact on patient compliance 
to the list, as we knew how poor measurement validity was and how 
contradictory the literature results were in that respect. In contrast, we were 
genuinely interested in the impact on attitude and on behavioural changes 
with regard to adverse reactions (be they negative or positive). Hence, the 
longer list was shortened to 4 criteria: 
1. reception rate
2. receivers’ satisfaction with the information provided
3. changes in attitude 
4. behavioural changes (reactions to adverse drug reactions).
5 Theoretical background to this thesis
5.1 A model for assessing acceptance of PPIs 
Lilja lists a typology of evaluation studies suitable for this kind of research:[143]
• evaluations which concentrate on determining whether or not the 
programme was properly implemented
• evaluations which concentrate on determining whether the 
assumptions about the influential features of the information 
programme were correct or not
• evaluations which aim at determining the impact and suitability of the 
programme.
For designing descriptive studies of the acceptance of patient package inserts 
in the drug distribution system of Belgium (presented in Part II), we combined 
elements of each of these types of evaluation studies.
In the beginning, we tried to exploit as much as possible the circumstances 
of this natural experiment (a massive change in drug distribution on a national 
scale). We concentrated on descriptive studies, prior to the implementation of 
the programme and repeated during the programme. By the time we obtained 
our first results from these studies (reported in Part II), interest in the 24
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on, we redirected our research to experimental studies (reported in Part III.) 
5.2 Theoretical models for assessing impact of PPIs on benefit/
risk perception 
In the fields of medical sociology, communication science, clinical psychology 
and health promotion a number of theoretical frameworks or models have 
been developed for explaining variations in health-related behaviours. These 
models can and have been applied to the field of patient compliance.[144] They 
can be grouped in two broad categories:
• Social Cognition Models for health behaviour based on beliefs and 
attitudes 
• Clinical Psychology Models.
These models are briefly described in the following subsections. 
5.2.1 Social Cognition Models
The most general theory, developed for the study of behaviour in general, but 
widely applied in health care is the Theory of Reasoned Action by Ajzen and 
Fishbein.[145] This model was further developed into the Theory of Planned 
Behaviour[146] by incorporating a new element, “perceived control”, in fact 
“perceived behavioural control and barriers” (e.g. do I have sufficient skills to 
carry out the behaviour and will I be able to overcome the barriers I see to 
fulfil my intention to display the behaviour). This concept is rooted in 
Bandura’s concept of self-efficacy[147] and also tries to incorporate the 
somewhat ill-fated notion of (health) locus of control.[148] 
The problem is that this theory ends up looking like a loose container of 
intellectually different approaches, ranging from social determinism to 
cognitive expectancy-value models (used more successfully in the analysis of 
the drug choice process by physicians),[149] to attitude and motivation research 
and clinical psychology concepts. Its application in the health care sector has 
been focused rather on preventive measure for health status maintenance (such 
as exercise, diets, smoking, and using condoms); the application to patient 
compliance was less convincing.[144] 
For historical reasons, what should also be mentioned is the Health Belief 
Model, originally directed at the desire of the individual to avoid a specific 
disease threat.[144][150][151] Many more revisions and the addition of modifying 
factors, combined with differences in operationalisation across the different 
studies make it difficult to draw conclusions about the viability of the 
model.[144][152]25
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social cognition models into the realm of health promotion and public health. 
The Health Action Model[153] incorporates political and ideological concepts 
of patient empowerment and the influence of mass-media. The PRECEDE/
PROCEED model[154] is oriented towards the planning and evaluation of 
health promotion. These last two theories introduce the notion of enabling 
and reinforcing factors and mainly take the perspective of the macro-level of 
society.
5.2.2 Clinical Psychology Models
5.2.2.1 Stages of Change Models. In these models, it is acknowledged that 
interaction between cognition and behaviour is dynamic, rather than static, 
that adoption of a new behaviour follows a temporal pattern, with a 
succession of stages in an orderly process, and that different cognitions are 
important at different stages.[144] 
The most prominent model is the Transtheoretical Model,[155] in which 5 
progressive stages (precontemplation, contemplation, preparation, action and 
maintenance) are discerned. 
Patient compliance with prescription medication can be also be seen as a 
consecutive process of different decisions.[156] First, the decision to go and see 
the doctor,[157][158][159] then the decision to start taking the medicine, and finally 
the decision to continue the treatment. These decisions are yes or no decisions 
and can be seen as a chain of Markov models, each with two probabilities (to 
take or not to take the action).[160] Whichever decision making theory is used, 
here are three consecutive, but different decisions to be looked at, probably 
each with their own stages and their own cognition processes. 
5.2.2.2 Ley's studies on Cognition, Memory and Emotion. Philippe Ley was 
an psychologist who conducted a number of pivotal studies on doctor-patient 
communication and compliance and the role of verbal and written 
information to patients in the late seventies and early eighties. Although he 
never proclaimed any formal theory carrying his name, his research has greatly 
influenced many aspects (and more specifically the important aspects) of the 
theories described above. What follows is an attempt to summarise important 
notions of his work. 
He was one of the first to acknowledge that following doctor’s orders is 
not always the wisest decision for the patient, that many physicians prescribe 
inappropriately, and that physicians are reluctant to give vital information on 
risks of medicines and indeed fail to do so.[144]
He stressed the basic communication principle that verbal messages (if 
they are given at all) need to be understood and recalled. He provided evidence 
that failure to recall information from a physician-patient encounter is high, 
even immediately after the consultation. An important reason is that during 26
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hampered by emotion. Emotion can arise from fear or severe anxiety 
(concerning the diagnosis and the future), from dissatisfaction with the 
physician-patient interaction, because the patient’s reason for encounter was 
not properly sought out or addressed, because information needs were not 
explored or addressed, or because the interactional style of the patient and the 
physician simply did not match. The basic message here was that negative 
emotion interferes with cognition and memory, leading to failure to recall 
information and inability to comply in a proper way, even if one wants to 
comply, which is unlikely if the preceding consultation was characterised by 
negative emotions.
On the other hand, patients leaving the surgery in a satisfied mood 
(pleased with the physician-patient encounter), would be more willing to 
comply with the prescribed medication, even if they have not received or do 
not recall enough information to be able to comply properly.
5.2.2.3 Leventhal's Self-Regulatory Model of Illness. This theory is about 
how people react to illness or health threats. Our account of the model is 
based on the original studies by Leventhal[161][162][163][164][165][166] and on other 
attempts at synthesis.[2][167] The fundamental premise is a view of the patient as 
an active problem solver, constantly monitoring internal and environmental 
signals, and attempting to close the perceived gap between current health 
status and a future goal state. Threatening internal and external signals will 
trigger two fundamental processes, viz. a cognitive response (a mental 
representation of the problem) and an emotional experience. These processes 
may interact but may also develop independently. Both the cognitive response 
and the emotional experience will lead to a sequence of first, an action plan for 
coping, and second, an appraisal of the outcome of this action plan. The 
results of carrying out the coping action may alter the representation of the 
illness, the emotional response and the appraisal process. 
The internal stimuli may be physical sensations of symptoms of disease or 
bodily (mal)functions. External stimuli may be comments from relevant others 
about one’s condition, health messages from the media, a result from screening 
programmes, a lab result or a diagnosis from a doctor. 
The cognitive representation of the illness problem is a complex notion 
(still under development). Patients can make immediate interpretations of 
what the meaning of the experienced stimuli might be, based on past 
experiences, common knowledge, dominant cultural explanations for specific 
symptoms and lay disease theories. Patients responding cognitively to stimuli 
retrieve schemata of structured knowledge from memory, characterised by the 
identity (the key collection of symptoms of an illness and its label), cause 
(what the illness can be attributed to), consequences (interference with daily 
life, and time-line (expectation about the duration of illness). In addition, the 
characteristics of the treatments known for the illness can be retrieved.[165] 27
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long term memory into the working memory of known schemata, or where 
stimuli generate multiple schemata (with a worst and a best hypothesis) may 
arouse strong emotions.[164] When the illness episode is over, recent experience 
is integrated in the schemata, disappearing from the working memory but 
stored as past experience. 
The theory of Leventhal (et al.) has been used several times in 
interventional research to change patient compliance[161][168][161169][170] and in the 
development of new measurement methods for the study of the cognitive 
representation of illness and medication.[163][171][164][172][165][173]
5.2.3 Relevance of these theoretical models to this thesis
These models were instrumental to our research in several ways, as they 
helped us to: 
• focus on prescription-only medicines (Rx), rather than on over-the-
counter medication (OTC)
• consider the consecutive decision processes for prescription medication 
taking
• see compliance as a process with a beginning, a middle and an end
• focus on benefit/risk perception of the treatment in the contemplation 
stage.
6 Structure of this thesis
After the introductory Part I, the results of our studies are described in the two 
middle parts of this thesis. In Parts II and III, a narrative report of the first 
author studies is given. Each of these parts consists of 4 chapters. The first 
three chapters of each part contain a vernacular description of first author 
articles (the facsimiles of the original publications of the six first author 
articles are enclosed in Annex 1), the fourth chapter contains a brief 
description of additional research in which the author of this thesis was 
involved but not as a first author.
In Part II, the focus is on the acceptance of patient package inserts during 
their introduction in Belgium, with descriptive studies, making use of the 
timeline of the Belgian PPI programme. 
In Part III, the focus is on benefit/risk perception, reporting on 
interventional studies. 
In Part IV, the general discussion, recommendations and final conclusions 
are given.28
Part II
Descriptive studies in the Belgian 
Patient Package Insert Evaluation 
Programme 
Everything put together, sooner or later falls apart.
Paul Simon
Part II provides a narrative account of the descriptive studies performed in the 
Belgian PPI Evaluation Programme from 1988 till 1998. The first chapter 
reports on a survey of the attitude of the Belgian population to (technical) 
inserts, just prior to the change in 1989. In the second chapter, we report on a 
1991 survey of physicians, to explore their attitude toward patient package 
inserts, at that time an innovation. The third chapter describes a survey of 
drug utilisation and drug information flow in nursing homes, to see to what 
extent this part of the population is reached by written drug information. In 
the fourth chapter, the other studies of the Belgian PPI Programme (in which 
the author of this thesis participated but was not the first author) will be 
described. 
We will discuss to what extent the explicit objectives of the Belgian PPI 
Programme were reached in the general conclusion in Part IV. 29

Chapter 1
Attitude of the public toward technical 
package inserts for medication information 
in Belgium
Originally published as: Vander Stichele RH, Van haecht CH, Braem MD, Bogaert MG. 
Attitude of the public toward technical package inserts for medication information in 
Belgium. DICP 1991;25:1002-106 (see facsimile 1 in Annex 1)
That must be wonderful. I don’t understand it at all.
Moliere
Motives for this study
In our first formal study in the research programme on the impact of the 
introduction of patient package inserts (PPIs), we wanted to measure the 
attitude toward written drug information among the Belgian population, just 
prior to a major change in the drug distribution system on a national scale. 
The study was conducted a few months before the first PPIs began to appear in 
the medication packages on the Belgian market, to make a zero measurement 
of the situation at that time. This would later enable us to demonstrate the 
(beneficial) impact of that change, by repeating the measurement after the 
change. 
Setting
Belgium is a Western European country, where the level of illiteracy is limited 
to less than 5% of the population. Patients in Belgium have become used to 
finding inserts in their medication packages since 1963. Drug distribution in 
Belgium occurs almost exclusively as original drug dispensing with a branded 
package, containing an insert. Between 1963 and 1988, that insert was always 
a technical insert (TI). This document, on thin paper used for bibles and folded 
into the package, was the scientific data sheet, written for the health care 
professional, heavily laden with medical jargon, basically unintelligible for the 
layman, but distributed in the medication package, and hence available to the 
patient, each time he or she bought a medication package. 
Objective of the study
Our primary aim in conducting this study was to know whether Belgian 
patients read the technical insert (TI) and whether they were satisfied with it. 
Time frame
June 1988, just prior to the change from TI to PPI.31
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A descriptive, exploratory, cross-sectional population survey.
Participants
We wanted to select a representative sample of the Belgian population aged 18 
years and older, stratified for Dutch speaking and French speaking citizens.
Method
We designed a questionnaire with closed questions, intended to be taken from 
citizens by trained interviewers, familiar with population surveys. The 
questionnaire was 84 items long, and took 30 minutes to answer. Patients’ 
perceptions of the TI were explored with 5 point Likert statements (five 
possibilities to answer between “strongly agree” and “strongly disagree”). 
Patients were asked to chose one or more items from a closed list of 
motivations to read the insert (4 items) and topics of interest in the insert (9 
items). Respondents were questioned for their preference for the future patient 
insert as to length and completeness in two separate questions.
We selected a random sample of 2 × 200 possible participants from the 
election registers of two major Belgian cities and their rural surroundings 
(each with a catchment area of approx. 950,000 inhabitants). We selected one 
Dutch speaking city in the northern part and one French speaking city in the 
southern part of Belgium. The trained interviewers visited the selected 
addresses and interviewed the adult person at home, willing to participate. In 
case of refusal or absence, the case was replaced with a new selection matching 
for sex and age, till the quota sample was complete.
The characteristics of the respondents were compared to the population 
characteristics and the results were weighted for those variables that showed a 
statistical difference (population percentage outside the confidence interval of 
the sample result). 
Short overview of the results in the original publication
We recruited 398 participants, 200 Dutch speaking and 198 French speaking, 
with a slight underrepresentation of the elderly (60+) and the less well 
educated (schooling age no higher than 14 years). Seventeen % of the sample 
stated that they had not taken any medication in the past year.
The weighted percentage of citizens stating that they read the insert (TI) 
when purchasing and using a medicine was 87%. Nine % did not read the 
insert, neither did another person. Four % did not read it, but a relative did. 
This relative was either the wife for the husband, or the mother for the 
younger adults. Women read the TI more often than men did (93% vs 75%). 
Among the readers, 78% stated that they always read the insert, regardless of 
the severity of their illness or whether the medicine was on prescription or 
over the counter. 32
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the readers was focused predominantly on risk information; viz. the side-effect 
section (read by 88%), contraindications (82%), indication – to check whether 
this matched the diagnosis – (79%), medication shelf life (76%). Another 
focus of attention was procedural information; how to take the medicine 
(85%), how much to take (85%), how long to take the medicine (57%). There 
was less interest in background information; how the medicine works (56%), 
composition of the medicine (39%). 
The motive to read the TI was to be able to execute treatment properly 
(83%) to be reassured (57%), to know more about the medicine (50%), to 
decide whether or not to take the medicine (31%). Thirty-five % had more 
than two motives (always including the first motive). 
The information contained in the insert was perceived by the readers as 
useful (86%) and complete (71%); 75% found it reassuring that a TI could 
always be consulted. Dissatisfaction was reported as difficulty to understand 
(57%), remember (52%), and read (45%). The insert was considered 
graphically dull by 69%. Induction of fear to take the medicine by reading the 
insert was reported by 31%, and 25% considered that confidence in the 
physician might be reduced by reading the TI . 
With regard to medicines on prescription, 55% would ask the physician, 
19% would stop taking the drug and 18% would continue to use the drug, if 
the insert mentioned a threatening side-effect; if the insert contained 
information that was not understood, 36% would turn to the physician, 33% 
to the pharmacist, and 15% would not look for further information. With 
regard to (over-the-counter) medicines, 26% would ask the physician, 43% 
would stop taking the drug, 16% would ask the pharmacist, if the insert 
mentioned a threatening side-effect; if the insert contained information that 
was not understood, 19% would ask the physician, 54% the pharmacist, and 
13% would not look for further information. 
If the content of the insert conflicted with the physicians’ advice, 41% 
would contact the physician, 37% would follow the physicians’ advice, 10% 
would ask the pharmacist. 
Sixty-seven% of the patients preferred the insert to be short and 88% 
wanted the insert to be exhaustive.
Twenty % knew that new, more readable inserts would soon be 
introduced. Their source of information was the media, not the physician or 
the pharmacist. 
Short overview of the discussion and conclusions in the original publication
There was a limited but obvious distortion of the representativity of the 
sample, caused by the quota sampling technique. This was corrected by a 
weighing technique, resulting in only a slight shift in the results. Because of the 
crude sampling technique and the limited sample size, this study is merely a 
temptative exploration of the attitude of the Belgian adult general public. 33
PART II • CHAPTER 1Several more specific descriptive studies were set up in elderly populations and 
in adolescents (see Chapter 4 of Part II). 
The data on the reading level of the insert reflected people’s intention and 
did not stem from observed behaviour. High levels of readership do not 
necessarily result in benefit in terms of increased knowledge or modified 
behaviour. 
The level of readership observed was higher than we expected. The gender 
differences observed might indicate that women are interested in medication 
not only for themselves but also as gatekeepers for medical information for the 
family.
Equally surprising was the high level of satisfaction with the technical 
insert (TI), notwithstanding criticism about graphical quality, readability and 
legibility. Negative emotional impact was reported by less than one third of the 
readers. Disturbing reactions to conflicts between information sources seemed 
to be limited. 
People react differently to information in inserts of prescribed medicines 
than to inserts of over-the-counter medicines. 
A phenomenon such as the popularity of the Physicians’ Desk Reference (a 
book on medicines for physicians) among American patients is virtually non-
existent in Belgium. 
The public wants an impossible compromise between concise and 
complete inserts.
It is difficult to understand how basically unintelligible medical jargon 
obtains such high levels of readership and satisfaction. Maybe, the very fact of 
providing written information is more important than the quality of the 
written information. Medical jargon may have a “magical” ring that satisfies 
patients, even if information transfer has not been achieved. 
Improvement of readership levels and satisfaction levels by changing to 
patient package inserts (PPIs) was hardly to be expected in Belgium, given the 
initial high levels. Some gain could be attained in reducing complaints on poor 
readability. 
Additional results from this study
We performed an analysis of differences in responses between Dutch and 
French speaking respondents. Only two items showed a statistically significant 
difference. We hesitated to stress these results, as an analysis of many variables 
may yield some positive results by mere chance, and because at that time we 
had no explanation for the findings. What we observed was that complaints 
about the vagueness of the text (as a proxy for understandability) were more 
frequent among the Dutch (55%) than among the French respondents (45%). 
On the other hand, the French speaking respondents reported complaints 
about legibility (47%) more frequently than the Dutch (33%).
An additional exploratory principal component factor analysis was 
performed to analyse the link between the different motivations to read the 
insert (4 items) and the topics of interest while reading the insert (9 items). 34
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the insert: 
• Risk information
• Procedural information
• Background information.
Interestingly, some topics of interest scored high on more than one factor. 
The item “indication” scored high on both risk information (is this the right 
medicine for me?) and high on background information (what is this medicine 
used for and how does it work?). The item “package shelf life” scored high on 
procedural information (how long can I keep this drug) and high on risk 
information (am I not taking an out-of-date medicine?). The item “dosage” 
scored high on procedural information (what is the right dosage to take?) and 
on risk information (am I not poisoning myself by taking too much of the 
medicine?). 
Further discussion in the context of this thesis
The results of our first study indicated that there was little hope for substantial 
beneficial change by the introduction of the patient package insert. 
Apparently, the level of readership was already so high that little incremental 
gain was to be hoped for. On the other hand, it was reassuring that providing 
written information resulted in high penetration, even with a low readability 
level. We felt that the result was so important that it needed confirmation in a 
subsequent study. 
It became clear to us that if change was to be documented and gain to be 
demonstrated, one had to look into reduction of complaints about readability. 
That meant that we needed a tool for the objective assessment of readability. 
We either had to look for an existing readability test or develop one ourselves, 
which we eventually did (see Chapter 4.1.2 of Part II). 
We realised that could be a tricky measure of satisfaction with written 
information. Provision of written information in itself seemed to bring about 
satisfaction, despite the presence of medical jargon and despite the 
predominance of risk information. It was not impossible that enhancing the 
level of readability, by using simple words and shorter sentences, would 
heighten the emotional impact of the insert, and hence reduce satisfaction, 
instead of augmenting it. Our decision was to repeat the population survey, 
two years after the first survey (see Chapter 4.4.1 of Part II), but without the 
satisfaction measurement. We did however include satisfaction measurement 
in the coinciding intervention study (see Chapter 4.1 of Part III) conducted at 
the same time. 
Another possible outcome parameter was the impact of a change from TI 
to PPI on patients’ knowledge of the medicine. We decided not to focus on this 
issue, as it has already been addressed adequately in other research 
programmes in Europe and in the US. It seemed clear to us that more 35
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there was no need for a replication of this finding in our studies. 
There was a striking gender difference in the first population survey, and 
concluded that women are a legitimate target for research and information 
campaigns, regarding medication information. In future research, we would 
not hesitate to sometimes recruit exclusively female populations (see Chapter 3 
of Part III). 
The differences in appreciation of the TI between the French and Dutch 
speaking respondents puzzled us for a long time. Basically, these results 
suggested that Dutch speaking people complained more often that they did not 
understand the content of the insert, and that French speaking people 
complained more often that they could not read the insert. Eventually, we 
formulated the following hypothesis as an explanation for the findings. The 
Dutch language is a Germanic language. Medical words in Dutch are 
fundamentally different from the medical jargon, which has its etymological 
roots in Latin and Greek. Therefore, Dutch speaking people have a problem 
with many of the difficult terms in the technical insert, and are less likely to 
understand its content. The French speaking people on the other hand, have a 
lexicon that is much closer to medical jargon, but they are confronted with 
another problem. The French language is written in an alphabet with 
numerous diacritical signs. These are accents above or under some letters of 
the alphabet, changing the pronunciation of the letter and the meaning of the 
word to which the letter belongs. Examples are é, è, ê, à, ç and ô. A text edited 
in a diacritical language will become much less legible when printed in a 
smaller size. A Dutch speaking person with slightly impaired eyesight might 
still be able to read a Dutch text set in 9 pica points type size, while under the 
same conditions, a French speaking person would no longer be able to read 
the same text in French. Note that the German language has both problems: 
lexical distance from the medical jargon and many diacritical signs (ü, ö). We 
concluded that readability and legibility problems are language specific. 
Hence, if a readability test was to be developed, one had to be developed for 
Dutch inserts and one for French inserts, and that it would be an aberration to 
apply to Dutch and French texts simple readability tests developed for the 
English language (like the Flesch test), based on word and sentence length. 
There were two consequences for our further research from our findings 
on the categorisation of information in the insert in risk information, 
procedural information and background information, based on an exploratory 
factor analysis. Firstly, our interest in aspects of balance between the positive 
and negative information (risk information and background (or benefit) 
information) was awakened (see Chapter 3 of Part III). Secondly, we used the 
insight in our own design of patient package inserts for intervention studies 
(see Chapters 2 and 3 of Part III). We used three rules of thumb while editing 
our inserts: 
• combine procedural information with risk information 
• combine background information with procedural information36
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information.
In the first population survey, there were few signs of problematic 
interaction between information sources, more specifically between the 
information in the insert and the information of the prescribing physician. We 
anticipated that this might change as PPIs would soon turn up in packages. It 
seemed important to know the attitude of health professionals, more 
specifically physicians, as we focused our research on prescribed medicines. 
Therefore, we undertook a survey of the attitude of physicians, in the spring of 
1990 (see Chapter 2 of Part II). 
Finally, we had some doubts about the representativity of our population 
survey for the Belgian population. Children and adolescents up to the age of 
17 were not represented. The number of people of 65 and older was too small 
to extrapolate on the attitude of the elderly, which are after all, the big 
consumers of medicines, with special drug information needs.[58] 37

Chapter 2
Attitudes of physicians toward patient 
package inserts for medication information 
in Belgium
Originally published as: Vander Stichele RH, De Potter B, Vyncke P, Bogaert MG. Atti-
tude of physicians toward patient package inserts for medication information in Belgium. 
Pat Educ Counsel 1995;28:5-13. (see facsimile 2 in Annex 1)
Grebles’ contradiction:
Eighty percent of people think of themselves
as above average automobile drivers.
Motives for this study
The prescribing physicians are the preferred information source for most of 
the patients.[51][174][175] Hence, we thought it would be helpful to know the 
attitude of Belgian physicians on the brink of the introduction of a renewed 
source of written information, in a major alteration of the drug distribution 
system. We considered to conduct a campaign towards the physicians, to ask 
their support for the introduction of the patient package insert (PPI). 
Setting
Belgium has 35,000 physicians, with some 10,000 active general practitioners 
(GPS), for 10 million inhabitants. In the hospitals there is quite some 
outpatient activity, and many specialists (gynaecologists, paediatricians) have a 
private practice outside the hospital. Most patients regularly attend one 
general practitioner (often shared with the rest of the family) but there is no 
formal registration of the population with GPs. Direct access to specialist care 
is possible and often sought, especially for paediatric and gynaecological 
problems. 
Objective of the study
Our primary aim was to explore possible differences in attitude to written 
medication information amongst physicians.
Time frame
Spring 1990, when one third of the medication packages on the market 
contained a PPI. 
Design
A descriptive, exploratory, cross-sectional survey of practicing physicians.39
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We selected a sample of the Belgian practicing physicians, stratified for general 
practitioners and specialists. 
Method
Together with a clinical psychologist and a communication scientist, we 
designed a questionnaire, within the theoretical framework of symbolic 
interactionism[176] (see part 2, introduction for explanation) along 
4 dimensions:
• Observations of patient behaviour by the physicians
• Reported actual use of written information by the physician
• Physicians’ perception of patient information behaviour
• Physicians’ perception of the impact of the PPI.
The first two dimensions were observations that could be made directly by the 
physician, either on their own behaviour (5 items), or on the behaviour of 
patients (5 items). We asked for frequencies of observations on a five-point 
scale (daily, weekly, monthly, yearly, never). The last two dimensions were on 
subjective perceptions of patient behaviour that could not be directly observed 
by physicians. Here we asked for estimated percentages of patients, presumed 
to exhibit the behaviour (5 items), and for agreement or disagreement 
(strongly or moderately) with statements about possible patient behaviour 
(19 items).
The questionnaire was pretested by 10 physicians and took 20 to 
25 minutes to complete.
The questionnaire was sent to 1,500 Dutch and French speaking general 
practitioners (an 8.2% random sample) and to 500 specialist in internal 
medicine (a 22.6% random sample), to enable for comparison between GPs 
and specialists. 
One written reminder was sent to non-responders after 4 weeks.
We performed a cluster analysis to identify relevant subgroups among the 
respondents. In this mathematical procedure, the respondents are divided into 
groups (clusters) with similar answers to the questions. The characteristics of 
these newly formed groups are then analysed and an appropriate label is 
sought for each of the groups. 
Short overview of the results in the original publication
The questionnaire was returned by 38.0% of the specialists and 23.5% of the 
GPs (overall response rate 27.5%, N=543)). The sample was representative for 
gender, age, language and workload. As no significant differences were found 
between GPs and specialists in internal medicine, their answers were 
concatenated in the subsequent analysis. 
The large majority (88%) had heard of the existence of patient package 
inserts, mostly trough their medical journals and the media, occasionally from 40
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but only one third had read a patient package insert. Motives to read an insert 
were: 
• to check whether a particular side-effect was listed (69%)
• to check what a patient had said about the content of the insert (52%)
• to know the precise formulation of the message in the insert (40%)
• to check for possible interactions (36%)
• to check the indication of the medication (32%)
• to know the composition of the medication (31%)
• other reasons (10%).
More than two thirds of the physicians had had at least one patient in the 
past month with whom she/he had discussed side-effects, with explicit 
reference to the insert, or a patient who had returned and asked for 
explanation of information from the insert. Half of the physicians reported a 
failure to start a prescribed medicine after reading the insert or request for 
another therapy. 
In comparison with the situation 1 year earlier, 75% of the physicians did 
not see any difference, 1% perceived a decrease, and 24% an increase in the 
events described above. Of the physicians perceiving an increase, two thirds 
thought there was a causal relationship with the shift to PPIs. 
Less then half of the physicians reported having advised a patient to read 
the insert, and one in five had read the insert together with a patient in the past 
month. 
Only one third of the physicians thought that more than half of their 
patients read the insert. Very few physicians thought that more than half of 
their patients would understand the technical insert. When asked what in their 
opinion the majority of their patients would do in the case of a contradiction 
between their oral information and the information in the insert, the answer 
was: 
• contact the physician to get further information (43%)
• do what the doctor told them (41%)
• contact the pharmacist to get further information (10%)
• look for clarification and stop therapy (8%)
• look for information elsewhere (family, friends, books) (5%)
• follow the instructions of the insert (2%).
The cluster segmentation resulted in a stable separation (segmentation) 
into three clusters, which were assigned the following names, after analysis:
• moderately positive physicians (CL1 20%)
• ambiguous to neutral physicians (CL2 44%)
• overtly negative physicians (CL3 36%).
The moderately positive physicians show little activity in writing personal 
notes with instruction on medication usage to the patient, and make only 41
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is seen as a valuable information tool that reduces the need for oral 
information, brings about better patient compliance and more adequate 
reactions to side-effects. 
The ambiguous to neutral physicians report substantial activity in writing 
personal notes and in discussing the PPI with the patient; 44% are younger 
than 40; the PPI is again seen as a valuable information tool, but it is too long 
and contains too much risk information, having a definite impact on patients’ 
emotions, which are to be dealt with. 
The overtly negative physicians regularly attempt to block access to PPIs, 
but, on the other hand, engage in writing personal notes. The PPI is seen as 
having negative impact (suggestion of side-effects, non-compliance) and is 
thought to make it more difficult to prescribe medicines with a high incidence 
of side-effects. 
The widest differences among clusters were found in the perception of the 
impact of the patient package insert. We present the statements and two 
extremes of percentages per cluster of physicians agreeing with the statement: 
• a patient will experience the side-effect read in the insert (CL1 62%; 
CL3 93%)
• the insert will help the patient to react more adequately in the case of 
unforeseen events (CL1 84%; CL3 33%)
• reading the patient package insert will enhance patient compliance 
(CL1 78%; CL3 25%)
• the patient package insert will reassure the patient (CL1 63%; CL3 
15%)
• the patient package insert is superfluous, because I give the 
information orally (CL1 8%; CL3 70%).
Short overview of the discussion and conclusions in the original publication
There was a low response rate in this survey, possibly caused by the length of 
the questionnaire and “survey fatigue” among Belgian physicians. However, 
there was no bias for gender, language, age or workload. Nevertheless, we 
learned from this study that more effort is needed to assure better response in 
postal mail surveys to physicians by sending multiple mail and/or telephonic 
reminders.  Because of the low response we refrained from extrapolating the 
frequencies of the clusters to the population of Belgian physicians. 
We observed that 70% of the physicians estimate that less than half of the 
patients reads the insert. This is a clear underestimation by the physician of 
patients’ readership of the written medication information (see Chapter 4 of 
Part II for further confirmation). 
Diverging attitudes among physicians should be taken into account in the 
design of public information campaigns and in medical education 
programmes for communication skills training. In our first cluster, we found 
young physicians, who disturbingly seem to consider written drug 
information a substitute for oral information. In the third cluster, the 42
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of extensive personalised efforts to communicate instructional messages. In 
our second cluster, we find physicians more receptive to the behavioural 
signals of their patients, with consequently a clearer view of the emotions of 
patients while dealing with oral and written information. Our segmentation 
into three clusters goes beyond the classical dichotomy between physician 
paternalism and patient autonomy. 
Physicians and pharmacists should explore ways to integrate the patient 
package insert into their communication strategies in routine practice. 
Further discussion in the context of this thesis
The absence of significant differences between general practitioners and 
specialists in internal medicine with regard to attitude toward written 
medication information was unexpected. As 80% of the prescriptions in 
ambulatory care are issued by GPs, an information campaign aimed at 
physicians could concentrate on GPs, and a separate or different campaign for 
specialists would not be necessary. 
Relatively few incidents were reported, although the penetration of the 
PPIs had already reached 30% at the time of the study. 
Most physicians apparently considered the technical insert a fairly useless, 
poorly used information source. They were unaware of the high percentages 
of patients reading the insert. However, their attitudes towards the patient 
package insert were strikingly different. The first cluster seemed to predict a 
positive (although somewhat disturbing) impact as a substitute for oral 
information, relieving the physician of some of the burden of providing 
complex information on medicines. The third cluster considered the shift 
from TI to PPI as a mere aggravation of the existing situation, causing 
unnecessary additional effort by the physician to put the patient back on 
track, after having been thoroughly and purposelessly disturbed by the insert. 
The second cluster seemed to welcome the arrival of the PPI, as a sensible 
improvement of an existing information channel, but expressed doubts about 
the quality of the document, and estimated that the emotional impact of 
understandable information on patients would be greater. This was not 
necessarily considered a negative development, but patients would require 
more counselling. 
At the time we reached our conclusions from this study, we considered the 
situation among the most important group (the prescribing physicians) 
complex and difficult to predict. There were many misunderstandings of 
reality, and diverging attitudes, all belonging to the realm of speculation. One 
thing was clear: that it was not going to be easy to involve the entire 
community of physicians in a programme for the implementation of patient 
package inserts. Moreover, the rate of penetration of the PPI was rather low 
(30% at the time of the study). It was impossible to predict at that time 
whether the Belgian PPIs would evolve into high quality communication 
tools, which one could recommend wholeheartedly to physicians. We 43
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attracting attention to the PPI and inviting patients to read and discuss the 
insert with the physician. But we abandoned the idea, once it became clear 
that the Belgian effort in the PPI implementation programme would not be 
continued in the nineties. Meanwhile, a new minister with other priorities had 
taken over, after an election, which maintained the previous coalition of 
political parties, but reshuffled the departments. 44
Chapter 3
Medication utilisation and drug information 
in homes for aged persons
Originally published as: Vander Stichele RH, Mestdagh J, Van haecht CH, De Potter B, 
Bogaert MG. Medication utilization and drug information in homes for the aged. Eur J 
Clin Pharmacol 1992;43:319-321. (see facsimile 3 in Annex 1)
Motives for this study
We wanted to assess information sources and information needs of the elderly, 
residing in nursing homes, the population the least likely to be reached by 
patient package inserts. 
Setting
Flanders, the Dutch-speaking part of Belgium, where the elderly of 65 and 
more years old comprise 17% of the population. Five % of these elderly reside 
in community nursing homes, most often in the vicinity of their previous 
residence. In these homes, elderly people with satisfactory functional and 
mental status live together with frail elderly, either demented or incapacitated 
by disease. Most institutionalised elderly are treated by general practitioners, 
often their own GP, who treated them before they entered the home. 
Objective of the study
The aim of the study was to quantify the utilisation and knowledge of 
medicines among residents of nursing homes in Flanders, and to describe 
medication distribution and information activities inside the nursing home. 
Time frame
February 1990. 
Design
A observational, descriptive, exploratory, cross-sectional survey of nursing 
home residents.
Participants
Residents of Flemish homes for the aged. 
Method
We worked with 23 experienced nurses, each working in a different nursing 
home, but meeting regularly for postgraduate training. Hence we constituted a 45
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each of the nursing homes, we made a random sample of 10 residents.
The 23 nurses were trained first to interview the nurse responsible for the 
selected resident, and then to assess the Activities of Daily Living Score and the 
functional and mental status of each resident. They reviewed the medication 
charts and identified how the medication was dispensed to each resident. 
Finally, residents were also interviewed directly, if possible and if permitted. 
For the assessment of the mental state no formal scales such as the NOSGER 
(Nurses' observation Scale for Geriatric Patients) Scale or Mini Mental Scale 
(both at that time in development) were used. However, the interviewers firstly 
assessed with a structured questionnaire the subjective appreciation of the 
nurse, responsible for daily care of the resident and secondly, the information 
from the medical chart as to mental orientation in time, place and person. The 
protocol was accepted by the Ethical Review Committee of Ghent University.
Short overview of the results in the original publication
Two directors refused to participate and one of the trained nurses fell ill. Two 
selected residents were lost to follow up. 198 patients were included in the 
study, with an interview of the nurse directly responsible for their care. Finally, 
128 residents were interviewed directly, as communication with the other 70 
residents was impossible because of dementia (55 patients) or communication 
problems such as aphasia and deafness (15 patients).
The characteristics of the 20 nursing homes selected were similar to those 
of nursing homes in general, although somewhat bigger institutions than 
average were selected (a mean of 81 residents per nursing home in our sample 
versus a mean of 61 in Flanders). Annual mortality was 30%. On average, 
there were 14 full time nurses per nursing home, 19 different GPs attending 
patients in the nursing home. Half of the nursing homes had a coordinating 
GP. 
Among the 198 selected residents, 76% were female, and the mean age 
was 83 years (range 62-103, SD 7), with a distribution very similar to the 
general population of nursing home residents.
The distribution of the Activities of Daily Living score was (N=198):
• Score 3: fully independent for hygiene, feeding and moving around 
(49%)
• Score 4-5: minor deficiencies for one or two items (22%)
• Score 6-10: major deficiencies, requiring considerable resources of care 
(29%).
According to the judgement of the nurses who took care of the selected 
elderly, 28% were deeply demented, 13% slightly demented, and 59% were 
judged cognitively fit.
The nursed judged 42% of the residents as functionally and cognitively fit. 
Twenty-three % of the residents were incontinent for urine, and 19% were 
also incontinent for faeces. 46
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hypochondriac, 3% euphoric, and 2% psychotic. Seven % had disruptive 
behaviour (aggression, regression, agitation). 
Hearing problems were present in 27% of the residents (4% functionally 
deaf), and serious problems with reading in 33% (9% functionally blind). 
The family regularly visited 57% of the residents. Eleven % received a 
regular visit from former neighbours and 7% from friends. The GPs visited 
82% at least monthly (22% weekly). 
The residents had a mean of 4.5 different medicines (range 0-12) on their 
medication chart. Only 4% did not take medicines (half of them because of 
therapeutic abstinence in terminal care); 47% had 5 or more medicines 
(polypharmacy). The number of medicines increased with age between 60 and 
79 years (from 3.7 to 4.8), but stabilised from 80 years on at 4.3 medicines per 
resident. 
Medication was ordered from community pharmacies in original drug 
dispensing packages, kept in ward rooms, and dispensed by the nurses. Nurses 
read the inserts of the medicines of 98% of the residents and kept the inserts of 
77% of the residents in the nursing office. 
Type of dispensing was as follows: 
• medication mixed in food (16%)
• dispensed dose per dose with observation of swallowing (34%)
• dispensed dose per dose with retrospective control (35%)
• dispensed in the room per package, with autonomy of the patient over 
medication intake (11%)
• no medication (4%). 
Thirty-two % of the residents were judged both cognitively and 
functionally fit, but lost autonomy over their medication. 
The 128 residents who were able to respond to the interviewer were able 
to name (either by name, color or indication) 3.3 of the 4.7 medications on 
their list. We identified the following elements in the knowledge of their 
medication (N=128):
• knowledge of dosage regimen (81% of the residents)
• rough idea of indications (71%)
• notion of potential side-effects of their medication (4%).
The two most important information sources about their medicines were 
the family physician and the nurse. Four % or less mentioned relatives and 
friends or the pharmacist. 
Short overview of the discussion and conclusions in the original publication
The small bias towards selection of somewhat larger institutions was probably 
caused by underrepresentation of small private nursing homes of less then 10 
residents in our quota sample. 47
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accordance with data from similar studies in the literature. 
There is a contrast between the 42% of the residents judged cognitively 
and functionally fit by the nurses, on the one hand, and the 11% of the 
residents, who were allowed to order medication independently, keep the 
medication packages in their room, without intake control, and, hence, to 
remain autonomous about their medication intake. In a nursing home, there 
are good reasons to subject a number of patients with cognitive and functional 
deficits to a tightly organised distribution system, in which the provision and 
the intake of medicines is controlled by the nurses. However, this military 
distribution system seems to be applied indiscriminately to all residents, even 
those who are functionally and cognitively fit. This loss of autonomy might 
lead to a loss of interest in the medication and the end of the role of the patient 
as a partner in monitoring effects and side-effects of the medication. However, 
we have no further data on patients' preference for more autonomy neither on 
what the risks and costs would be of a more flexible medication management 
approach for those cognitive elderly, who aspire for greater autonomy in the 
handling of their medication.
Only the general practitioner and the nurse provide a limited and probably 
inadequate amount of medication information. As a result, the elderly know 
very little about the risks of taking drugs.
It is not easy to inform the institutionalised elderly about medicines. The 
educational background of the current generation of elderly is low; mental 
deficits, hearing problems, visual impairment and problems of verbal 
communication may hinder human interaction and information transfer. 
When elderly people lose responsibility over their own drugs, interest may 
subside. It is unlikely that a piece of flimsy paper with a small type size will 
contribute much to solutions in this context. To help the receptive elderly to 
deepen their knowledge of their own medication and to preserve or restore 
autonomy, an individual approach with oral messages is needed.[58] 
The nurse in the nursing home is a suitable candidate to provide this 
tailored individual approach. The finding that these nurses intensively use the 
package insert as a personal source of medication information was 
unexpected. 
Further discussion in the context of this thesis
In the outpost of health care, the nursing home, we came across both the limits 
of written medication information and its unexpected role as a source of 
medication information for the care taking nursing staff. 48
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Other descriptive research
In addition to the descriptive research reported in Chapters 1 to 3, a number 
of other studies were conducted within the framework of the Belgian PPI 
programme. This fourth Chapter of Part II outlines the remaining descriptive 
studies and application research. 
4.1 Development of linguistic tools in the Belgian 
PPI Programme
Writing high quality, understandable PPIs within a pharmaceutical company is 
a formidable task, especially when the marketing director, the medical director, 
and the company lawyer are looking over one’s shoulder. The pressure to 
launch the product onto the market quickly and if possible ahead of schedule 
is tremendous. Few companies are prepared to stall the introduction of a 
product for a lengthy discussion with the regulatory authorities over the 
wording of a few sentences in the PPI. PPI authors within companies were on 
unfamiliar territory when the Belgian authorities decided that Belgium would 
have PPIs a few years ahead of the other European countries. Writing style 
guides and vocabularies were published to assist authors of PPIs. However, to 
control and enforce compliance to good readability standards, a computerised 
readability test specific for PPIs was developed. 
4.1.1 Writing style guide for patient package inserts
The objective of the Belgian Health Authorities was to make a contribution to 
alleviate the task of PPI authors, avoiding confusion and ensuring consistency 
in the structure of the PPI, the wording of the section headers of the PPI, and 
the use of popular terminology. A concise writing style guide in the Dutch and 
French language for written drug information was developed, in cooperation 
with experienced linguists.[138][139]
4.1.2 Trilingual (Dutch, French and German) vocabularies of 
technical and popular medical terms
A trilingual (Dutch, French, German) vocabulary of technical and popular 
medical terms was published.[140][141] This was a trilingual list of 1,400 
technical medical terms frequently used in written drug information messages. 
Each term was then “translated” (vulgarised) in each language to a more 49
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This was considered an important issue, because group terms are needed for 
cross-referencing with the item “interaction with other drugs”. In addition, the 
list was indexed according to the International Classification of Primary Care. 
In retrospect, we found that this list was extensively used, although the quality 
of the “translation” was sometimes questioned. A Babel-like multiplication of 
divergent “popular terms” has probably been avoided.
note This exercise was repeated in 1993, after the European Union also 
adopted the principle of PPIs. A revision and extension of the 
trilingual vocabulary was commissioned. The Heymans Institute of 
Pharmacology and the Ghent Mercator School of Translators 
embarked on a low budget mission to extend the list of terms to 1830 
entries (now based on a computerised frequency ranking of terms in 
a compendium of Summary of Product Characteristics). Each term 
was given a concise definition to avoid problems of homonymity (a 
term having more than one possible meaning, but with a different 
translation in another language). All terms were translated on the 
technical level into the then 9 official languages of the European 
Union. Each technical term was then vulgarised to a more popular 
term in each language, if appropriate. 
This complex work was put on the World Wide Web as early as 1995, 
under the name “Multilingual Glossary of Technical and Popular 
Medical Terms”, in nine European languages. Greek is not included in 
the web site: at that time it was too cumbersome to include the Greek 
alphabet on the web site. The site is still operational, and attracts 
some 1,500 visitors per day from all over the world. A number of 
major medical sites provide a link to this application. Its functionality 
stems from the programmed creation of thousands of internal links. 
This technical approach was quite suitable for the initial creation of 
the site in 1995. However, this now hampers the updating and 
maintenance process. A major revision of the site with a web-based, 
interactive group-authoring tool is planned. For a full discussion of 
the linguistic approach and translation difficulties, we refer to the 
web.
4.1.3 The development of the readability test
The Belgian Health Authorities realised that it was not enough to make a legal 
statement that inserts should be understood by the general public. Some 
mechanism had to be developed to check author’s drafts and the chances that a 
draft would be understood by a sufficient number of people in the general 
public audience. Civil servants did not have the expertise to perform 
readability control. Disputes about the level of readability of a text would 
always remain in the realm of subjectivity. Application of general readability 
tests, aimed at a wide range of topics, were unlikely to be suitable for a highly 
structured patient package insert, focusing on a very specific subject. 
Development of a context-specific, computerised readability test would 50
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pretest. 
Before a computer programme could be created, the scientific basis of such 
a programme, viz. a suitable readability formula had to be created. This 
research was commissioned to the Department of Experimental Psychology of 
the Ghent University.[177]
In a field study with 432 Dutch speaking patients, the impact of 
terminological and grammatical text characteristics (assessable by computer 
analysis) on the readability of medication information was explored. The idea 
was to create a readability formula, composed of the selected variables, which 
would be able to predict the percentage of persons from a randomly selected 
group, who would understand a given patient package insert. This readability 
formula could then be integrated in a computerised text analysis tool for 
checking whether Belgian patient package inserts were understandable. 
This research was only conducted for the Dutch language. (For the French 
language, an existing readability formula was adapted).[178] The full reports of 
these analyses were presented to a wider audience in 1994.[179] 
The following 11 characteristics were selected for the study: 
1. proportion of words longer than 8 characters 
2. proportion of frequent terms
3. diversity index
4. the proportion of forbidden words 
5. the sentence length in words
6. the average number of punctuation marks per sentence
7. the average number of finite verbs per sentence
8. the average number of finite verbs per hundred words
9. the proportion of auxiliary verbs
10. the proportion of prepositions
11. the proportion of gerund-like terms (verbs turned into nouns)
The first four variables assess the lexical complexity of the text. Long 
words and words not part of a basic general vocabulary make a text difficult 
to understand. When many different words are used in a text and few words 
are repeated, comprehension will be more difficult. Forbidden words were 
technical terms, present in the Trilingual Medical Vocabulary (see above), with 
a credible popular alternative. It was assumed that not using this alternative 
would not enhance readability. Flagging the forbidden words (from a list 
explicitly pertaining to written drug information) makes this readability test 
context-specific. This means it cannot be used for texts dealing with other 
subjects, but it may also ensure the power of the test in the appropriate 
context. The last 7 variables assess syntactical complexity, and try to flag long 
and complex sentences, which make comprehension of the text less likely. 
Complex sentences will contain more punctuation marks (such as commas), 
more auxiliary verbs, more prepositions (a fixed list in the Dutch language), 
more gerund-like terms (verbs or adjectives turned into nouns). Texts with 51
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subject or imperatives). 
Each of the 432 participants was given two inserts to read and then asked 
to answer 40 simple yes-or no questions. A rotation scheme for 18 different 
text in three levels of difficulty was made for distribution of the insert among 
the participants. In a multiple regression analysis the correlation between the 
text characteristics and the percentage of correct answers was analysed. The 
multiple correlation coefficient was .71 (95% confidence limits .65 to .86), 
with 50% of the variance explained. 
An explained variance of 50% for variables, only pertaining to lexical and 
syntactical text characteristics, was considered to be a strong result. Also the 
fact that these variables needed to be present together to produce an optimal 
result was special. All the texts pertained to the field of written drug 
information (a homogeneous domain). As they were legally subjected to a 
particular structure, the texts were also standardised for semantic 
characteristics (the structure and the order of the information).
The validity of this readability test would be subject to change over time, if 
the general public was continuously and systematically exposed to high quality 
PPIs. Theoretically, the average medical knowledge and familiarity with 
medication information could improve and a new validation test would 
become necessary. 
Further discussion in the context of this thesis
The computer routines to analyse text variables and the formula described 
above were implemented in a programme. Texts of patient package inserts 
could be entered in a computer by scanning with optical character recognition 
or by electronic transmission. The headings of the different sections of the 
inserts were excluded by adding mark up to the titles. The computerised 
readability test was able to analyse patient package inserts, compute the 
readability prediction, apply a cut-off criterion and then flag patient package 
inserts of poor quality. Together with the verdict, a number of general 
suggestions for improvement were given, based on linguistic characteristics 
(e.g. a list of replaceable forbidden terms).
This procedure was administratively enforced as a part of the control cycle 
of draft PPIs in the early phases of the implementation programme.[180] In the 
first year, I was in charge of checking readability as a human reader, with a 
concomitant check of the conformity of the PPIs to the scientific data sheet. 
The computerised readability test was used a few times, to confirm the 
detection of flagrant cases of low quality. It worked as an early warning signal 
in the beginning of the programme, but its cumbersome application was not 
sustained in later years. Transforming the programme into a web application 
would make the analysis more feasible and accessible on a wider scale. 
The development of this readability test was an exercise in linguistics, 
helpful in the proofreading of over 2,000 drafts of PPIs during 1986 and 1987, 
and in writing experimental drafts of PPIs (see Chapters 2 and 4 of Part III). 52
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constituencies: regulatory affairs managers
Motives for this study
In Belgium, the responsability for authorship of the patient package insert lies 
with pharmaceutical companies. Within the company it is the regulatory 
affairs manager who supervises the drafting of the Summary of Product 
Characteristics and the patient package inserts. He/she is also responsible for 
getting the draft through the approval process. In 1993, there was a 
symposium at the Heymans Institute, co-organised by the Belgian Consumer 
Association and the Belgian regulatory affairs managers, to discuss the 
transition from Belgian Patient Package Inserts to European User Package 
Leaflets (the term used in the 1992 EEC regulation). The present study was 
conducted in the months prior to the symposium. The results were presented 
at the symposium, but have not been published elsewhere. 
Objective of the study
Our primary aim in conducting this study was to explore the attitude and 
experiences of Belgian regulatory affairs managers with regard to the impact 
of patient package inserts and the quality of the approval process. 
Setting: Belgium, a country where technical inserts and patient 
package inserts of approximately 5,000 marketed branded 
packages need to be drafted, approved and updated every five 
years in three different languages. 
Time frame: 1993, at the end of a 5-year cycle of the validation of 
old Summaries of Product Characteristics and the introduction of 
the Belgian Patient Package Insert, and at the start of new 
European legislation on written drug information. 
Design: An exploratory, descriptive mail survey.
Participants: Information officers and regulatory affairs 
managers of the 120 small and big pharmaceutical companies in 
Belgium.
Method:  A mail questionnaire with 25 items (14 statements with 
4 point agree/disagree Likert scales) and a section for open-ended 
remarks. The questionnaire was introduced by an official letter 
from the Heymans Institute of Pharmacology and the president of 
the Regulatory Affairs Managers Association. It was to be mailed 
back anonymously to the seat of the association. No reminders 
were sent. 53
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Questionnaires were returned by 33 regulatory affairs managers. Eight were 
affiliated to a Belgian company, 8 US, 8 other European, 3 Swiss, 2 
Scandinavian, 2 others and 2 independent consultants working for various 
companies. One in 3 respondents was male. Age was equally distributed over 
the decades (range 23 to 63). The majority of the respondents were Dutch 
speaking and 60% were pharmacists. The average number of fully processed 
PPIs per person was 37 (most of them not unconditionally accepted), with on 
average still 25 in the approval process at the time of the survey. 
The vast majority (94%) were convinced that less than 50% of the patients 
understood the technical insert. Sixty-four % were convinced that less than 
50% of the patients read the patient package insert. Opinions about the ability 
of the patients to understand the PPI varied. Half were convinced that the 
majority of patients understood it, half were convinced that the majority did 
not. The regulatory affairs managers tended to agree (strongly or moderately) 
with the following statements: 
• it is good that the PPI is always available for the patient (100%) 
• the PPI helps the patient to react more adequately to side-effects (97%)
• the PPI is useful to help them remember (81%)
• the PPI generates side-effects (66%) .
They had different opinions about the statements: 
• the PPI stimulates compliance
• the text is legible 
• the PPI is too long
• the PPI has a role to play in the information transfer to the patient. 
And they tended to (strongly or moderately) disagree with the last statements: 
• there is too much risk information in the PPI (64%)
• the PPI reassures the patient (73%)
• simplifying scientific information renders it incorrect (94%)
• the PPI stimulates automedication (97% )
• the health professional gives information, so the PPI is superfluous 
(97%)
• the PPI is useless (100%).
The writing style guides were generally well accepted by the regulatory 
affairs managers, but there was some criticism of the completeness and the 
validity of the vocabularies (see above). Lack of direct contact with insert 
assessors was deplored. Feedback from health authorities was often 
considered too little, too late, and sometimes inconsistent. Some respondents 
expressed the feeling that too much legalism was an obstacle for good 
communication with the patient. Poor legibility of inserts (set in small type size 
due to long texts in three languages) was considered a major impediment to 
communication. 54
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Just like the physicians, the regulatory affairs managers underestimate the 
percentage of patients reading PPIs (see Chapter 2 of Part II). This 
misconception is probably detrimental to their job satisfaction. However, 
regulatory affair managers have a diversified perception of the impact of the 
PPI. Their attitude toward this communication medium is ambivalent, but on 
the whole positive, in spite of serious practical problems and extensive 
bureaucratic effort. 
4.3 Follow-up studies of the implementation 
of the Belgian PPI Programme
During the years of transition from the technical insert (TI) to the patient 
package insert (PPI) in Belgium (1988 to 1993), a number of follow-up studies 
were planned, to confirm the gradual penetration of the PPI in the drug 
distribution system, to pick up possible unexpected phenomena, and to deepen 
our knowledge of the impact of written medication information. Here, we will 
present a population survey, mentioned in Chapter 1 of Part II, and a pre/post 
(during) clinical registration study among hypertensive patients in a general 
practice. 
The transition from 100% technical inserts (TIs) to 100% patient package 
inserts (PPIs) in the medication boxes took place on the Belgian market 
between 1988 and 1992. The first population study was conducted in 1988 
and repeated in 1991. The baseline clinical registration study was done in the 
spring of 1989, just before the start of the transition and repeated one year 
later in 1990, when the transition was in full swing.
4.3.1 Population study
note This study was only presented as an abstract.[181]
Motives for this study
The first population study in 1988 yielded the counter-intuitive finding that a 
vast majority of the general population reads inserts when using medicines. 
The finding merited scientific confirmation, as it was met with scepticism by 
the parties involved (see Chapter 2 of Part II). 
Objective of the study
Our primary aim was to make stronger (corroborate and confirm) an 
ascertainment of the 1988 survey, i.e. a high level of readership of inserts in the 
general population. In addition, we wanted to measure the current penetration 55
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change. 
Time frame: January 1991 
Design: A confirmatory, descriptive survey
Participants: A representative sample of 400 Belgian adults, 
stratified for Dutch and French speaking inhabitants 
Method: The method of quota sampling from the first survey was 
replicated in the same two Belgian cities (Ghent and Liège) and 
the surrounding country site. The investigators interviewed the 
respondents with a similar questionnaire, with some questions 
omitted and others added. Respondents were asked to show the 
packages of their current medication and the investigators 
determined whether the insert was a technical insert (TI) or a 
patient package insert (PPI). A difference of 10% or more in 
readership would be considered a relevant difference.
Results 
Data were collected from 403 respondents (200 Dutch speaking and 203 
French-speaking), after ringing 775 doorbells (174 absent, 128 refusals, 55 
outside the selection criteria and stratification quota, 15 interruptions during 
the interview). Fifty-two % were female, and the mean age was 42.7 years (SD 
17.8: range 16-89), with a somewhat better representation of the elderly 
(60+), but again a slight overrepresentation of the higher educated. At the time 
of the interview, 35% of respondents was taking medicines, 22% had taken 
medicines during the last year, 43% had not been taken medicines for at least 
one year.
The vast majority of the respondents (95%) was familiar with the concept 
of a patient package insert and was able to give a definition or an enumeration 
of sections of the insert. In the following table, readership results of both the 
first and second surveys are compared. 
Table 1: Level of readership of package inserts 
in two consecutive population surveys
Only 16% knew of the existence of patient package insert at the time of 
the interview (in the previous study, 20% knew that patient package inserts 
were coming), and only 4% had stated to have read one. 
DO YOU READ THE INSERT?
1988 
(N=198)
1991 
(N=203)
Yes, I do 89% 85%
No, but a relative does 7% 8%
No, neither does someone else 4% 7%56
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taking medicines, were collected and the type of insert was determined. Thirty-
nine % of the packages actually contained a patient package insert. 
Discussion and conclusions
Resulting from bias, inherent to the method of quota sampling in door-to-door 
interviews, the characteristics of this sample differ slightly from the first survey 
population sample characteristics, viz. with regard to education level. 
However, percentages of insert readership do not differ significantly 
between the two samples, which can be interpreted as a confirmation of the 
high readership, regardless of the type of insert. 
The shift from TI to PPI was well under way in early 1991 (39% 
penetration), but had gone virtually unnoticed. The awareness of the PPI 
among 20% of the public in 1988 had certainly not risen in 1991, coinciding 
with diminished media attention to the subject in that period. People hardly 
knew what a patient package insert was, were not aware of having seen one, 
and did not recognise the PPIs in their medication boxes. One of the reasons 
was certainly that the nature of the change was predominantly linguistic, not 
typographical. 
Further discussion in the context of this thesis
This study, presented as an abstract[181], illustrates the decline of the Belgian 
PPI implementation programme. Public attention to the subject was not 
sustained, because there was no public information campaign on the subject. 
The change was not visually obvious. However, one cannot conclude that the 
effect was nihil. A patient does not need to be conscious of change to undergo 
the impact of that change. However, it is possible that greater public 
awareness might have enhanced the impact of the change.
4.3.2 Two consecutive GP registration studies
note The full report of the joint analysis was part of the doctoral thesis by 
Van haecht,[1] and separate reports of the two studies were 
published.[182][183] 
Motives for these studies
Belgian research on the impact of written medication information was carried 
out in the realm of the clinical setting by Chris Van haecht, who worked at the 
Heymans Institute during the PPI Evaluation Programme. He focused on the 
use of inserts by patients in a specific clinical setting, namely the treatment of 
hypertension in general practice. Two consecutive registration studies were set 
up, with identical design, and separated by 13 months, in a crucial phase of 
the shift from technical insert (TI) to patient package insert (PPI). The 57
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the insert, the type of insert, and the occurrence of side-effects. Special 
attention was also given to the influence of the educational status of the 
patient. 
Objective of the study
The descriptive aim was to determine the intensity with which patients read 
the insert of a medicine for a chronic asymptomatic disease (hypertension), 
and whether or not PPIs were read more carefully than TIs. The explanatory 
aim was to explore the link between reading the insert and reporting side-
effects, and whether or not this link changed with the type of insert.
Setting:  Antihypertensive patients in Flanders, Belgium, recruited 
by general practitioners, experienced volunteer participants in an 
epidemiologic network of sentinel practices, who engage in short 
term registration projects on varying topics (three to four projects 
per year). 
Time frame: First study in April 1989; second study in May 1990
Design: Two episodes in a consecutive, cross-sectional, 
observational, clinical registration study
Participants: a consecutive sample of patients, seen for a repeat 
prescription of antihypertensives during the registration period 
(one month). The estimated average of patients to be recruited 
was 20 in one month. One hundred GPs were invited to 
participate, in the hope that 25 would volunteer.
Method: Physicians were asked to recruit antihypertensive 
patients in surgery and during house calls. Socio-demographic 
data, systolic and diastolic pressure, the date of first 
antihypertensive treatment and the list of antihypertensive 
medication currently used were recorded per patient. For each 
antihypertensive on the list, patients were asked whether they had 
read the insert (thoroughly or superficially) (recently or in the 
past). GPs also identified the type of insert for each 
antihypertensive, by requesting the insert from the current 
package and clipping it to the registration form. Finally, GPs 
recorded first spontaneous reports of general health problems 
(during the consultation) and then confronted patients with a 
checklist of 22 symptoms, described in popular medical terms 
(taken from published lists of side-effects of antihypertensives). 
Patients were asked whether they had experienced these 
symptoms (occasionally, often, daily) in the past month, and 
whether or not they thought there was a connection between the 
symptom and the use of antihypertensives (attribution). At the 
end, there was a short debriefing by the GP, to explain the 58
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side-effects. 
Results
In episode 1, 28 GPs recruited 702 patients. In episode 2, 19 GPs recruited 407 
patients (12 GPs participated twice, but there was very little overlap in 
patients). Characteristics of GPs and of patients were similar in both episodes, 
and similar to other samples of hypertensive patients in general practice. The 
percentage of higher educated patients was 9%, higher then in the first episode 
(p=.0.007). The average age in the first and second episode was respectively 64 
and 65 years (SD 12) and the percentages of women were 67% and 70%; the 
percentages of lower educated patients were 74% and 67% (higher in women 
and in 65+ patients). Patients had been treated for hypertension on average for 
9 years (SD 7). Sixty %, respectively 61%, were on monotherapy. The 
percentage of patients on beta-blockers and/or diuretics dropped from 63% to 
55%, compensated by a rise in ACE-inhibitors and calcium antagonists from 
20% to 30%. Penetration of the PPI had risen from 16% to 38%. 
Intensity of readership was first assessed with the insert as unit of analysis. 
Table 2: Intensity of readership of package inserts 
in two consecutive registration studies
There was no time trend in these data, neither did the intensity of 
readership differ significantly according to the type of insert, present in the 
packages (TI or PPI).
The data on intensity of readership was then regrouped to permit an 
analysis at the level of the patient. Patients were classified as “never readers”, 
“superficial readers” (when none of their inserts were read thoroughly, but at 
least one superficially, recently or in the past), or “thorough readers” (when at 
least one of their inserts were read thoroughly, recently or in the past). 
Among the patients younger than 65 years of age (in the first episode), 
29% never read the insert, versus 42% in the group of 65+; while 40% of the 
younger patients read the insert thoroughly versus 29% in the older group, a 
statistically significant difference. Results were again nearly identical in the 
second episode. 
An even stronger association was found with educational level. In the first 
episode 1, 41% of the patients with lower educational level never read the 
insert and 7% read it thoroughly. Among patients with a higher educational 
WAS THE INSERT READ? 
April 1989 
(N=702)
May 1990 
(N=407)
Never 33% 35%
Superficially in the past 31% 31%
Thoroughly in the past 36% 34%59
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were nearly identical in the second episode. It is well known that the elderly 
are less well educated for historical reasons. Logistic regression analysis 
revealed that the age effect was merely based on confounding by educational 
level, which was by far the strongest determinant of readership. There was no 
association between readership of the insert, on the one hand, and sex or type 
of insert, on the other hand. 
There was a small, but significant time trend in the tendency of patients to 
report health problems to the physician, either spontaneously (after a general 
probing question), or systematically (by checking a list of health problems). 
Table 3: Reporting of health problems by hypertensive patients. 
Comparison of two episodes
Reporting health problems was significantly associated with the 
demographical characteristic of “educational level” (not with sex and age). 
The higher the educational level, the more patients reported health problems, 
and attributed them to the medication. The overall percentages in the second 
episode were higher (see above), but the associations with educational level 
were comparable. 
In the first episode there was no association between reading an insert and 
reporting and attributing health problems. In the second episode, there was a 
tendency toward a higher frequency of reporting spontaneously and 
attribution in the group of thorough readers, but this failed to reach 
significance. 
A final subanalysis was made among the patients who read at least one 
insert superficially or thoroughly (N=449 in episode 1 and N=271 in episode 
2). Here the association was investigated between the type of insert and 
reporting and attributing health problems. 
In the first episode, spontaneous reporting and attribution was higher 
when a PPI was read. This association was not significant in the higher 
education stratum. 
In the second episode, the overall frequency of reporting and attribution 
was higher and the penetration of the PPI had climbed from 18 to 36%. In this 
episode, the association with type of insert was significant for all three types of 
reporting. This association remained after stratifying for educational level, and 
LABEL 
April 1989 
(N=702)
May 1990 
(N=407)
Chi2 test
% of patients reporting 
spontaneously (without prompting)
30% 36% p=.02
Total % patients reporting health 
problems (after checking a list)
68% 75% p=.04
% of patients attributing health 
problems to medication
24% 30% p=.0460
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confirmed that the type of insert and the educational level of the patient were 
two independent predictors. 
In comparing the two episodes, it might be observed that the time trend of 
higher reporting was restricted to the group of PPI readers. In the first episode, 
the percentage of patients reporting was 72% versus 83% in the second 
episode, and for attribution it was 35% versus 41% respectively (both 
differences statistically significant).
Discussion and conclusions
The samples in the two episodes were comparable for demographic 
characteristics, except for a slightly higher number of higher educated patients 
in the second episode. As the two episodes were twelve months apart, the time 
frame had of course changed. 
With these two consecutive studies, we showed the general trend of 
increasing penetration of patient package inserts (confirmed from other 
observational studies) in this particular clinical setting, which can be 
considered as an argument of face validity for these studies. 
When turning to clinical practice, to experienced patients, and older 
patients, the picture of readership is different from the results in the 
population study presented in study 1, where 9 in 10 predominantly healthy 
and better educated adults stated to read the insert. There are still two thirds 
who read the insert one way or another, but the figures had decreased. Forty-
one % with lower education state that they never read inserts. 
Again we observed no difference in readership between the TI and PPI, 
neither in episode 1, neither in episode 2, despite the ongoing shift. Our 
interpretation was that the shift from TI to PPI is not consciously noticed by 
the patients, because of the lack of visual clues in design change. Another 
explanation might be the diminished media attention to this subject. 
This study clearly indicates that educational level is a demographic 
characteristic of paramount importance. Higher educated patients read inserts 
more frequently and more thoroughly and report more health problems. The 
results do not warrant conclusions on whether higher educated patients 
actually experience more health problems. 
The results on the frequency of health problems reporting in this study 
must be considered carefully. The health problems reported here are not 
related to hypertension, neither necessarily related to the antihypertensive 
drugs. These problems also tend to occur frequently in the general population. 
We used an unusual method of recording the reporting of health problems, 
first with a general prompt and then by repeating the inquiry with a checklist 
(this method is seldom used in clinical trials, because they may lead to 
misinterpretation of safety assessments of important new drugs). Hence, we 
found percentages of 68% and 65% of the patients reporting health problems. 
This is in contrast with the normally reported frequency of mild side-effects 
with beta-blockers of 10%. 61
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on the subjective perception of patients, which might be affected by suggestion 
(experiencing the side-effects mentioned in the insert just by reading them) or 
by incorrect attribution (linking to the drug bodily symptoms which are not 
related to the intake to the drug). This observational study is not able to 
distinguish between the different underlying mechanisms of health problem 
reporting (see further in Part III). 
There were no obvious differences in reporting between patients who read 
the insert and those who did not. Interpretating this finding is difficult. 
Possible explanations are averaging to zero of opposing effects in TI and PPI 
readers or lack of power in the study (relatively few PPI readers, especially in 
the first episode). 
Our interest in this study was in the relative difference between frequencies 
of subjectively perceived health problems between the PPI and the TI groups, 
not in the absolute frequencies. To determine whether a reported health 
problem is in fact an adverse drug reaction, a complex causality assessment is 
needed (which was not performed in this study). 
We did pick up effects of the type of PPI (which can only be mediated 
through reading). We found effects both on the total reported (only in the 
second episode) and on attribution. 
We did find higher attribution in the second episode. It could be caused by 
higher penetration, or by different education levels among patients, chance 
variation, or another time-related variable outside the scope of the study. 
As often in science, this study provided a few answers, but raised more 
new questions, to be addressed with new and more sophisticated 
interventional studies. 
In conclusion, the percentage of patients who read the insert is extensive, 
even in a group of elderly, chronic, and experienced users. The advent of the 
PPI has not changed this, either upwards of downwards. The higher educated 
patients tend to read inserts more often, and more thoroughly. Reading the 
PPI is associated with higher reporting and attribution, also in the group of 
the lower educated (the biggest group). This was found in both episodes, but 
overall reporting was higher in the second episode, coinciding with a higher 
implementation of the PPI. We formulated the hypothesis that the 
introduction of the PPI has an impact on the reporting of health problems 
(and hence potential side-effects). Experimental research is needed to test that 
hypothesis. 
Further discussion in the context of this thesis
This study was pivotal in the evolution of the research in this project towards 
interventional studies. The results confirmed once again the high level of 
readership of inserts (regardless of their style), this time in a specific clinical 
setting. For the first time we discovered something that may have been an 
overall effect of the generalised introduction of the PPIs in Belgium. We 
observed a puzzling association between readability of the insert and higher 62
OTHER DESCRIPTIVE RESEARCHlevels of communication between physicians and patients about adverse events 
(not necessarily adverse reactions). Finally, there was a hint that the 
educational level of the patient is an important variable that needs to be taken 
into account in further studies.
4.4 Descriptive studies in focused groups of patients
In addition to the study of the elderly in nursing homes (see Chapter 3), several 
other studies were performed to explore the way the elderly deal with 
medicines and information about medicines. In the past decade, medication 
utilisation by the elderly has been the subject of many studies of growing 
sophistication.[184] Nevertheless, we will briefly present three studies here, 
performed in connection with the Belgian PPI Evaluation programme, because 
they focus on the informational aspects of drug use by specific subgroups 
among the elderly. A fourth study will deal with healthy adolescents. These 
studies were performed by Master students, in collaboration with our 
department.[185][186][187][188] In fact, some of these data were collected well after 
the closing of the formal evaluation programme, but as their subject is little 
affected by the time frame, we want to present them, as their results offer 
additional perspectives. An overview of the studies focusing on the aspect of 
polypharmacy among the elderly has been published in Dutch.[189] 
4.4.1 Socially active elderly, living at home
note This work was carried out in the context of a Master thesis 
by Marleen Bekaert and Alain Van Den Dungen.[186]
Objective of the study
Our primary aim in conducting this study was to explore the information 
channels and knowledge about drugs among the elderly, living at home, but 
mobile, and regularly leaving home to engage in social contacts. 
Setting: Community centres for the elderly, run by city councils, 
(providing meals, coffee and refreshments, sports facilities, body 
care, educational training, entertainment, creative expression and 
meeting facilities), in two Dutch speaking cities (Ghent and 
Bruges) in Belgium. 
Time frame: February to April 1993. 
Design: An exploratory, descriptive cross-sectional survey by 
interview 63
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the visitors of 60 years and older to the 17 centres in the two 
cities. 
Method:  Two trained interviewers asked 34 closed questions in a 
15 minute interview. Respondents were asked whether they were 
currently taking medicines and if no, to name these medicines. In 
case the name was not know, the function or the colour and the 
shape of the individual medicines was asked. Knowledge of 
dosage regimen and side-effects was assessed. Respondents were 
recruited till a quota sample of 400 respondents was reached. 
Results
Interviews were taken from 400 older patients (4 refusals). The mean age was 
72.3 years old (SD 6.7y, range 60-91 y). There were 49% men (38% married, 
9% widowers, 2% single men) and 51% women (24% widows, 22% married, 
5% single women). The percentage of respondents with a schooling age of 
more then 14 years was 7% among the 80+year old, 19% among the 75-79, 
27% among the 70-74, 31% among the 65-69, and 31% among the 60-64 
year old (the group of elderly who were 13 to 17 year old at the beginning of 
World War II in 1940). Women were less educated (21% with a school-leaving 
age higher than 14 years, versus 30% in men). One third lived alone. Of the 
other two thirds, 4% had a partner in need of constant care, 5% lived with 
their children or had their children still living with them, 1% lived with a 
brother or sister. One third had no outside help (or did not need it), one third 
only had cleaning help, and one third had various combinations of nursing 
help, help from family or neighbours, or cleaning help. Contact with the centre 
was on a daily basis for 45%, at least once a week for 50% and occasional for 
5%.
Of the respondents, 83% stated that they were currently on medication 
(10% on 5 or more medications). Men listed a mean of 1.7 medications, 
women 2.6. Most illnesses were chronic (83%), most medicines were 
registered, allopathic medicines and given on prescription (96%). The 
majority of the medication was once taken daily (60%), 17% twice daily, 8% 
three times daily, 5% two to three times per week, 4% sporadically, and 6% 
when needed. The 860 medications listed by the elderly were communicated 
by name, colour, shape or function. Twenty-three % was not able to name any 
of their medications. Only 10% of the elderly were able to list at least one 
possible side-effect of at least one of their medications. Among the respondents 
currently taking medicines (N=333), 87% fetched the medication themselves 
at the pharmacy, 12% had someone else to fetch the medication, and 2% had 
a pharmacist who delivered at home. Eighty-four % were fully autonomous 
with regard to medication management (keeping and ordering stock, 
preparing for intake), 5% left it to the partner and 1% to others (children, 
neighbours, nurse). A medication chart was used by 3%, 10% used a day box 
and 2% a week box. 64
OTHER DESCRIPTIVE RESEARCHTwenty-two % had been hospitalised in the past year (3% twice and 1% 
three times). Three % were on a waiting list for the nursing home. 
Respondents were asked whether their physician or pharmacists gave them 
medication information on what the medicine was for, how to take the 
medicine and what the side-effects were. Respondents mentioned that their 
physician mainly gave procedural information (how to take) (28% a little, 
69% extensively), and explanation about the purpose of the drug (28% a 
little, 64% extensively). The perception of information activities by 
pharmacists were limited to procedural information (36% a little, 16% 
extensively) and even less about the function of the drug (15% a little and 
13% extensively). Seventy-five % stated that they have not received any 
information about the risk of medications from either the pharmacist or the 
physician. 
The package insert of their medications was read by 69% of the 
respondents, 2% had someone else read the insert to them, and 29% did not 
read the insert, neither was anyone asked to read the insert. Among the 
readers of the insert (N=282), the motive to read the TI was to be able to 
comply to therapy (89%), to be reassured (72%), to know more about the 
medicine (73%) or to decide whether or not to take the medicine (45%). The 
information contained in the insert was perceived by readers as useful (97%) 
and complete (89%); 85% found it reassuring that a TI could always be 
consulted. Dissatisfaction was reported as difficulties understanding (70%), 
reading (69%) and remembering (39%). The insert was considered graphically 
dull by 51%. Induction of fear to take the medicine by reading the insert was 
reported by 15%, and 11% thought that confidence in the physician might be 
reduced by reading the TI. 
Important information sources are the prescribing physician (97%), 
personal experience (93%), the pharmacist (59%), the insert (59%), the media 
(21%). Family, friends and neighbours were hardly mentioned (1%). 
The respondents were satisfied with their medication knowledge: 84% 
stated they know enough about their medicines (ranging from 69% in the 60-
64 years group to 100% in the 85+ group). Thirty-one % would like to know 
more about their medication (9 in 10 through a more readable insert, 5 in 10 
through the physician, 5 in 10 through the pharmacist and 2 in 10 through an 
educational meeting). 
Discussion and conclusion
This was a study of information and knowledge about medication, not an 
attempt to measure drug utilisation objectively. Patient self-reporting may lead 
to underestimation. 
Most of the socially active elderly take a substantial number of 
medications and know little about their risks, but do not seem to mind. The 
prescribing physician, and, to a lesser extent, the pharmacist, are considered to 
be important information sources. However, one cannot rely on these channels 
with regard to the transfer of risk information. The elderly consider the 65
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medication seems to fade with growing age and disability, and to be mainly 
limited to procedural aspects. This situation cannot be solved solely by 
providing better inserts. If a more profound knowledge of the medication is 
considered desirable (from a general point of view or in specific cases of 
disease management) personalised and tailored educational interventions will 
be needed. Such interventions can only benefit from cooperation with 
preferred information sources, such as the prescribing physician and the 
pharmacist. 
4.4.2 Frail elderly living at home
note This work was carried out in the context of a Master thesis 
by Anniek De Roep.[186]
Motives for this study
We had previously looked at two extremes in geriatric health care setting: 
elderly in nursing homes and socially active elderly living at home. Somewhere 
in between are elderly who still are at home, but only rarely leave their 
residence, and who require a lot of attention and health care resources. We 
wanted to find out whether the information needs of these patients differ. 
Objective of the study
Our primary aim in conducting this study was to explore the information 
channels and knowledge about drugs among frail elderly living at home. 
Setting: A community care organisation (Familiezorg Oost-
Vlaanderen, of Christian denomination, but pluralistic) for 
intensive family and elderly assistance in the Dutch-speaking 
region of Belgium.
Time frame: January to March 1994. 
Design: An exploratory, descriptive cross-sectional survey by 
interview 
Participants: One hundred patients in one community (Lokeren, 
17,000 inhabitants) of one community care organisation were 
invited to participate. Inclusion criteria were age (65+) and being 
under the care of the organisation. 
Method:  Fifteen professional family helpers were trained to 
interview 4 to 8 patients under their care in the region, with a 
question list similar to the one used in the study among socially 
active patients. In addition, permission was asked to collect 
information on monthly revenue (available from the 
administrative dossier in the community care organisation) and 
private medication expenses (available from the pharmacist). 66
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Ninety-two patients were recruited (5 could not be interviewed because of 
hospitalization, 3 refused to participate). The mean age was 78 years (SD 7y, 
range 66-93 y). Seventy % were women (51% widows, 14% married, 5% 
single women) and 30% men (half of them married and half widowers). The 
percentage of respondents with a schooling age of more then 14 was 15%. 
Sixty % lived alone, 28% lived with their partner, 7% lived with their children 
or had their children still living with them, 1 had a spouse in the nursing 
home).
The care delivered by the community care organisation was the only 
family help (cooking and help with shopping) in 75%, only cleaning help in 
15%, and both services in 5%. Thirty-eight % had, in addition to these 
services, a nurse, paying home visits.
The monthly income was less than 500 EUR (recalculated in current prices 
from Belgian francs in 1993) in 8%, between 501 and 1000 EUR in 64%, and 
more then 1000 EUR in 28%. There was a strong relation between the level of 
income and the educational level.
Of the respondents, 90% stated that they were currently on medication 
(43% on 5 or more medications), with a mean of 4.4 different medications per 
patient. Almost all medicines were chronic, on prescription (96%) and 
allopathic.
Monthly private spending on medication (in surplus of reimbursement) 
was 30 EUR or less in 49%, between 31 and 60 EUR in 24%, between 61 and 
90 EUR in 20% and more then 90 EUR in 7%. The median number of drugs 
per patient was 4 in the income group below 1000 EUR/month and 6 in the 
group above 1000 EUR/month (p=0.02). Medication consumption was lower 
in the lower educated group, but this was confounded by income. 
Among the respondents currently taking medicines (N=83), 62% had 
someone else to fetch the medication, 36% fetched the medication at the 
pharmacy themselves, and 2% had a pharmacist who delivered to their home. 
Seventy-four % was fully autonomous with regard to medication management 
(keeping and ordering stock, preparing for intake), 14% left it to the partner, 
9% to the children, 2% to the nurse and 1% to the family helper. A 
medication chart was used by 2%, 3% used a day box and 5% a week box. 
Thirty-three % had been hospitalised in the past year (21% twice). 
Eight % were on a waiting list for the nursing home. The remaining 92% 
firmly denied being on a waiting list. 
Respondents mentioned that their physician gave procedural information 
(how to take medicines) (76% a little, 21% extensively) and explanation 
about the purpose of the drug (61% a little, 19% extensively). The perception 
of information activities by the pharmacists was limited; it mainly contained 
procedural information (58% a little, 11% extensively) and very little about 
the function of the drug (33% a little and 5% extensively). Seventy-three % 
state that they have not received any information about the risk of medications 
from either the pharmacist or the physician. 67
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that they knew enough about their medicines. 
Discussion and conclusion
With regard to drug utilization, the frail elderly living at home more closely 
resemble the elderly in the nursing homes than the socially active elderly living 
at home. Nevertheless, few are anticipating transfer to the nursing home.
Two-thirds no longer had direct contact with the pharmacist, and, hence, 
were alienated from an important information source. Written drug 
information, often read by someone else, may play an important backup role 
in this situation. The expressed need for more medication information is 
rather limited. 
There is a complex relation in polymedicated frail elderly between income, 
educational level, private drug spending, and medication utilization. Some 
elderly with a low income and a high drug bill apparently have to make tough 
choices (alone) between buying food and other essentials or buying medicines, 
probably resulting sometimes in non-compliance with crucial medication. 
4.4.3 Elderly hospitalised in subacute geriatric wards 
note This work was carried out in the context of a Master thesis 
by Bart Coingiez.[187]
Objective of the study
We wanted to explore the transfer of information about medication between 
the former residence and the hospital among elderly in subacute geriatric 
wards, assess the shifts in medication lists during hospitalisation, and assess 
the efforts to inform the patient about the current medication list during the 
hospital stay and at discharge. 
Setting: Subacute geriatric wards in the hospitals of the city of 
Ghent, Belgium (a catchment area of 250.000 persons). 
Time frame: January 16 to February 16, 1995. 
Design: An exploratory, descriptive cross-sectional survey by 
chart review. 
Participants: All discharges in the participating wards during the 
index period. 
Method:  One trained nurse reviewed the medical and nursing 
charts of discharged elderly, transferring data on medication and 
medication information to a portable computer. Entry of 
medication lists was facilitated by brand index, ensuring quick 
and accurate recognition of active ingredients, galenic form and 
strength and automatic conversion to the ATC/DDD  drug 68
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cognitive status was not assessed.
Results
Six of the seven geriatric wards in Ghent participated. From the 202 
available subacute geriatric beds, 224 elderly were discharged during the 
index period. The mean age was 82.1 years (SD 7.8y, range 59-101y), with 
35% men. 
Half of the patients were transferred from acute hospital wards, 43% from 
home and 7% arrived from a nursing home. The mean length of stay was 27.0 
days (SD 25.7), with 72% of the patients staying less than 30 days (the limit of 
length of stay for full budgeting). Of the discharged elderly, 42% returned 
home, 17% were newly transferred to a nursing home, 16% died, 12% 
returned to the nursing home, 7% were hospitalised to acute wards and the 
remaining 6% were transferred to revalidation centres.
The mean number of different oral medications per patient was 5.3 at 
discharge (no medication 3%; 5 or more medications 56%). 
In all patients admitted from nursing homes, it was possible to reconstitute 
from the medical or nursing charts the medication list prior to admission, 
either from a transcript of the medication list in the nursing home chart, or 
from a referral letter from the nursing home general practitioner (present in 
94% and containing explicit information on medication in 75% of the cases). 
In patients admitted directly from home, information about medication prior 
to admission was present in 89% of the charts, either from questioning the 
patients or their next of kin, or from a general practitioners’ referral letter 
(present in the ward chart in 81% and containing medication information in 
64% of the cases). In patients transferred from other acute hospital wards, 
information about the medication list prior to admission to the acute ward 
was present in only 66% of the cases, with the GP referral letter absent or lost 
in 73% of the cases. 
Among patients where it was possible to reconstitute the medication list 
prior to hospital admission, the mean number of different oral medications 
was 4.8 (no medication 8%, 5 or more medications 48%). 
All discharged patients received a copy of the discharge medication list or a 
preliminary referral letter to the general practitioner, including discharge 
medication information. Patients received a limited supply (for a few days) of 
the discharge medication, without patient package inserts. We did not find 
evidence in the ward charts of formal discharge training for new chronic 
medication or for continuation of new (sub)acute medication, nor evidence of 
explanations given for discontinuation of former medication. 
For some drug classes there was no difference before and after 
hospitalisation in the percentage of patients taking medicines pertaining to this 
class. This was the case for cardiovascular drugs in general (C) (58% post and 
57% prior), for anxiolytics, hypnotics and sedatives (N05B+N05C)(43% 
prior and post), for digitalis (C01A) (19% prior and 20% post) and for 69
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percentage rose from 18% before admission to 29% at discharge. For drugs 
for peripheral vascular disease (C04A), the percentage dropped from 19% 
prior to admission to 14% at discharge. Antibiotics (J01) were given to 26% 
of the patients, mostly initiated during admission, to be continued after 
discharge in almost half of them. 
Discussion and conclusion
The shift towards polypharmacy observed here during hospital admission may 
be caused by acute new illness or exacerbation of chronic illness, which 
triggered hospitalization. Opportunities for reduction of inappropriate 
therapy seem to be missed during hospitalisation (except perhaps for 
peripheral vasodilators). Use of laxatives rises, maybe because of 
immobilisation. When patients are transferred from other acute hospital 
wards, communication about prior medication between the treating general 
practitioner and the geriatrician does not seem optimal. Despite changes to the 
medication list, which are sometimes substantial, little information is given to 
the hospitalised patient at discharge, and the rescue supply at discharge is not 
accompanied with written drug information. 
4.4.4 Healthy adolescents 
note This work was carried out in the context of a Master thesis 
by Katrien Santy.[188]
Objective of the study
We wanted to explore occasional medication taking behaviour and the 
medication information behaviour of healthy adolescents, in the third grade of 
secondary education (normally 17-18 years of age). 
Setting: Adolescents of the 2 last years (third grade) of secondary 
education in schools in West-Flanders, Belgium. 
Timeframe: Winter 2001-2002. 
Design: An exploratory, descriptive cross-sectional survey by self 
administered questionnaire. 
Participants: A sample of 616 adolescents from 7 schools, 
stratified for age, sex, type of school (general, technical, crafts-
oriented) and type of school network (community or Catholic). 
Method: A questionnaire was developed based on “Health 
behaviour in School-Aged Children”, an instrument used for 
international and longitudinal research.[190] Questionnaires were 
distributed during class (after approval of school management), 
with an informed consent document, to be signed by at least one 
parent, if the respondent was younger than 18 years old. The 70
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return it, after a few days, to the class teacher in a sealed 
envelope. Entry of medication lists was facilitated by brand index, 
ensuring quick and accurate recognition of active ingredients, 
galenic form and strength and automatic conversion to the ATC/
DDD  drug classification. 
Results
We received 460 usable questionnaires, duly signed by at least one parent 
(a response rate of 75.7%), without significant differences between the study 
population and the respondents for the characteristics of stratification. 
Twenty-two of the 460 respondents (4.8%) stated that they suffered from 
a chronic disease or serious health problem, and 3.9% reported taking 
medicines for this illness. Results are further given for the group of 438 
“healthy” adolescents in the last two years of secondary school. Only 15.3% 
were older than 18 years. Male students represented 54.1%. Only 7.4% 
valued their health status as poor or very poor. Daily smokers represented 
22%, occasional smokers 7%. More girls reported health complaints 
perceived almost every month to almost daily (as opposed to seldom or never). 
Medication for headache had been taken at least once in the past month by 
44%, the common cold 27%, abdominal pain 15%, nervousness 3%, sleep 
disorders 2%, and weight loss 1%. The percentages were somewhat higher 
among females, but only substantially (more than 20% difference) for 
headaches. Use of vitamins in the last month was reported by 29% and use of 
homeopathic medicines by 13%. The step towards intake of medication is 
taken within a few hours for headache and abdominal pain, within a day or 
two for cough and common cold, and only after one week for nervousness or 
sleep disturbances. Anticipating use of medicines is reported by 14%, and use 
without complaints (except for general unwellness) by 8%, mostly 
antipyretics, and to a lesser extent vitamins or homeopathic medicines. There 
was no question concerning the use of the contraceptive pill among girls. Of 
the respondents 46% felt no need to get additional information about the 
medication used, 30% turned to the patient package insert, 15% to the 
physician, 11% to the pharmacist, less than one percent to books or Internet. 
Only 3% of those students who turned to the insert stated that they did not 
really understand the insert. 
Discussion and conclusion
The use of medication, and especially problematic use, might be underreported 
by the obligation to have the questionnaire signed by at least one parent. 
However, adolescents seem to be confronted with serious health problems 
relatively rarely. Their use of legal medication is generally not problematic. 
Over-the-counter (OTC) medications for minor complaints are occasssionally 
taken, often on their own initiative, and without much perceived need for 71
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important information source in this age group, with little complaints about 
comprehensibility among the readers, its role is limited. 
4.5 Studies on medication distribution 
in health institutions
Research into drug information is intricately linked with the study of the 
distribution process of medications, especially in institutional care. Again with 
the help of two Master students,[191][192] we were able to explore the setting of 
the nursing homes and the setting of hospital care. 
4.5.1 Medication distribution in the nursing homes
note This work was carried out in the context of a Master thesis 
by Jean-Marie Clarebout.[191]
Objective of the study
We wanted to explore medication distribution practices for oral medication in 
Flemish nursing homes, Belgium. 
Setting: Nursing homes in West-Flanders, Belgium, where 5% of 
65+ inhabitants reside in nursing homes, mostly close to the 
former residence. 
Time frame: Winter 1994-1995. 
Design: An exploratory, descriptive study by direct observation 
and assisted questionnaire. 
Participants: A heterogeneous sample of 7 nursing homes. 
Method: Consent to participate in the study was asked from 
nursing homes management. A trained geriatric nurse visited the 
nursing home for direct observation with a structured observation 
list and questioned the head nurse responsible for medication 
management. 
Results
Two of the selected nursing homes refused to participate and were replaced by 
two other homes. 
The size of the nursing homes ranged from 31 to 116 residents (mean 85). 
Small nursing homes had all their residents in one medication distribution 
unit. Larger homes were split into two or more distribution units. The smallest 72
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by 6 nurses. 
Responsibility for the organisation of the medication distribution was 
assumed by one head nurse (or specially assigned medication nurse) in all 
homes, but daily distribution of medication was shared by several nurses and 
sometimes also with non-paramedical caregivers (evening, night, weekend, 
replacement of absence). Residents were supervised by their former general 
practitioners, hence nurses had to deal with 4 to 12 different physicians. 
Formal rules about nurse attendance during the physician’s visit only existed in 
3 homes. 
In 4 homes, medications were delivered by several local community 
pharmacists on alternating role. 
Medication is kept in a pharmacy cupboard at the nursing post in two 
parts: the collection of boxes, with packs belonging to one individual, on the 
one hand, and a non-individualised backup collection for occasional first aid 
or emergency medication, on the other hand. Access to medication is not 
strictly reserved for nurses in all homes and the medication cupboard is not 
always locked. 
In all homes, one nurse per distribution unit (mostly the head nurse) is 
authorised to write an individual medication scheme for each resident, to be 
updated every month, based on oral or written instructions from the 
physician. This individual medication scheme is kept in the nursing chart. In 
some nursing homes, the information is copied manually several times (to 
make pharmacy orders or to give instructions).
Preparation for actual dispensing covered one week in three homes and 
one day in the other homes. This preparation was always performed by a 
nurse, but not always the head nurse or a specially designated nurse. For 
weekly preparation, week boxes (with 4 divisions per day) of 7 trays with cups 
(one tray for each day) were used. For daily preparation, a tray with cups was 
used in most cases. Pills were removed from their blisters during this 
preparation phase. 
Actual dispensing was in four rounds (08.00 a.m.- 11.00 a.m. - 5.00 p.m. - 
08.00 p.m.). The evening dispensing was almost exclusively for sleeping pills. 
Medication is either given personally to the patient, or set next to the patient 
with visual control of intake. Written information is not dispensed to the 
patients. Very few patients preserve any autonomy over their medication.
No formal systems for the control or reporting of medication errors were 
in place. Communication between physicians and nurses about side-effects 
and special intake procedures was limited. A (mostly outdated) drug 
compendium was kept in the unit, and package inserts were occasionally read 
but not collected systematically by the nurses. 
Discussion and conclusion
In the 1995 Flemish nursing home, nurses were responsible for the correct 
distribution of medication to a relatively small and stable population, on 73
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was limited, communication with the treating physicians not optimal, and 
formal systems to reduce medication errors were not available. Intervals 
between dispensing rounds are pharmacologically inadequate for medications 
to be given three times a day. The patient package insert is still present in the 
distribution process, but only available for the nurses, who do not use them 
systematically.
4.5.2 Medication distribution in hospitals
note This work was carried out in the context of a Master thesis 
by Kathleen De Sutter, and published (in Dutch).[192]
Objective of the study
We wanted to explore medication distribution systems and medication error 
management systems in Flemish hospitals 
Setting: Secondary and tertiary care in Flanders, Belgium. 
Timeframe: February – March 1997. 
Design: An exploratory, descriptive study by interview with 
hospital pharmacists and head nurses 
Participants:  We selected a convenience sample of 6 hospitals (2 
tertiary university hospitals, 2 community and 2 private 
secondary hospitals). 
Method: A two-hour interview was carried out with the hospital 
pharmacist and a one-hour interview with two head nurses (one 
from a surgical department, one from a medical department). 
Direct observations were made of the medication distribution 
documents and depots in the departments of the nurses 
interviewed. 
Results
Five hospitals agreed to participate. One refused and was replaced by another 
volunteering hospital within the same stratum. 
All hospitals worked with a distribution system from the central pharmacy 
to departmental depots. Hence, none of the hospitals worked with the 
internationally proposed standard of direct distribution from the central 
pharmacy of individual unit doses to the patient. 
In three hospitals these depots were predominantly collections of 
individualised boxes with a small supply of maximum 4 to 5 days (and in 
addition a limited depot of non-individualised rescue medication). In the 3 
other hospitals, there were predominantly general non-individualised depots 
(with individualised boxes for some special medication only).74
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nurse supervising the departmental depot and to the central pharmacy, mainly 
for billing purposes and a posteriori renewal of supplies. 
Nurses kept a medication list in the nursing chart, often to be changed on 
the basis of oral orders from the physicians, and to be transcribed manually 
(sometimes several times) for actual dispensing orders on the ward. 
Actual dispensing to patients was prepared on a daily basis (with removal 
of identifying blisters), and given to patients in individual doses, often by other 
nurses on different shifts. 
In none of the six hospitals did any formal quality control programme for 
the prevention of dispensing errors exist. 
Medication arrived at the ward from the central pharmacy in bulk, blisters 
or in units, with no written patient package insert available. 
Discussion and conclusion
The sample in this study is too small to make generalisations. In the past years, 
new quality regulations have been issued and information technology has been 
applied to the medication distribution process. However, unit dose 
distribution (distribution of doses for individual patients per intake, directly 
from the central pharmacy to the patient on the ward) has not been introduced 
widely. 
From findings in international literature, estimates of the prevalence of 
medication errors and their clinical outcomes have been made. Non-optimal 
distribution techniques could be associated with medication errors leading to 
an excess length of stay of 4.6 days in 4.35% of all hospital 
admissions.[193][194][195][196][197] It is estimated that this prevalence could be 
reduced by 2/3 by introducing unit dose distribution systems. An estimate of 
mortality of “drug misadventures” (the sum of mortality by adverse reactions 
to correctly taken medicines + mortality by medication errors) ranged from 
0.09 to 0.24 per 100 admissions.[198]
In the hospital setting, groups of nurses are responsible for dispensing 
incisive medication to rapidly changing patient populations, with unstable 
medication regimens, in a complex and stressful environment, while using 
suboptimal distribution techniques. Medication information support for 
nurses and patients (e.g. by the provision of patient package inserts) is 
virtually non-existent. 75
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in Belgium revisited
note This work was carried out in the context of a Master thesis 
by Pieter Paul Clompen.[199]
Objective of this study 
To conclude the series of descriptive studies, we wanted to perform a small 
assessment of the quality of Belgian patient package inserts in 2000, 16 years 
after Belgian legislation was first published and 8 years after the European 
legislation. 
Setting: Belgium, the European country that pioneered the legal 
enforcement of readability in drug information. 
Time frame: 2000
Design: A descriptive study by linguistic computer analysis and 
direct observation. 
Material: A quota sample of 18 inserts (in Dutch) from 5 
therapeutic classes. 
Method: The inserts were evaluated as to readability by computer 
analysis and by direct observation for legibility, design, 
comprehensiveness and consistency.
Results
There was considerable variability in length. Half of the inserts (N=80) were 
between 500 and 699 words long (one third shorter: between 300 and 499; 
one quarter longer: between 700 and 1299 words per insert). The number of 
sentences was 40 and 49 in half of the inserts (in one third shorter between 20 
to 39; in one quarter longer between 50 and 79 sentences per insert). 
In half of the inserts the average sentence was 14 to 15 words long (12 to 
13 words in one third; 16 to 19 words in one quarter). One half of inserts had 
less than 2 punctuation marks per sentence and the other half 2 or more. 
The proportion of medical jargon words of total words was less then 3% 
in one half of the inserts and 3% or more (up to 5%) in the other half. Only 
two inserts had less than 1% medical jargon words. 
Six inserts (one third) failed the readability test (described above) and 12 
(two thirds) succeeded. 
Legibility was assessed by measuring the height of the letters (the x-height) 
and the space between lines (line space). Only 8 of the 18 inserts had sufficient 
x-height (minimum 1.4 mm, according to the European Guideline on the 
Readability of the label and the package leaflet of medicinal products for 
human use[95] and none had sufficient line space (minimum 3 mm). Line space 
was even less than 2.5 mm in 8 inserts. 76
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inserts (with contrast problems in one). There was disturbing use of capital 
letters in one insert. Eight inserts did not use structured lists for enumerations 
(e.g. of side- effects). In only one insert, punctuation for structured lists was 
used as recommended by the guideline (introduction by colon, line end by 
semicolon and group end by full stop). Inserts for products with the same 
active ingredients had different lists of side-effects and indications. 
Discussion and conclusion
During the nineties, there was little improvement in the quality of patient 
package inserts. Many companies continue to produce unattractive 
documents, barely complying with the minimum requirements. Other 
companies make an effort to produce an acceptable insert within the 
boundaries of regulatory constraints. None of the inserts testified to 
innovative, creative design. Regulatory authorities failed to enforce legislation, 
to ensure quality of communication and consistency in information across 
different brands of the same medicine. 77

Part III
Intervention studies on the impact 
of written drug information
Tu vivras de projets qui ne feront qu’attendre.
Jacques Brel
In Part II we have focused on the evaluation of a particular drug information 
programme, namely the introduction of patient package inserts (PPIs) in 
Belgium between 1988 and 1992. We conducted a number of descriptive 
studies in different settings and with different constituencies. We tried to 
monitor a few changes in patient behaviour at the level of the general (Belgian) 
population by means of uncontrolled pre-post studies. 
In Part III we will focus on interventional studies, aimed to generate a 
better understanding of the impact of written drug information. 
In Chapter 1 of Part III, we will start with a conceptual reflection on the 
relationship between written drug information and patient compliance, 
triggered by recent improvement in the measurement of patient compliance 
with electronic monitoring, a new and much more precise method. 
In Chapter 2, we will describe the results of a comparative randomised 
clinical trial of atenolol versus lisinopril in the treatment of essential 
hypertension, with a nested design for additional testing of two different 
information strategies (PPI versus no information). This will provide a 
preliminary exploration of how the impact of drug information on patient 
compliance could be examined. 
In Chapter 3, the results of an experimental psychological study with 
human volunteers is described, exploring the effect of the addition to the PPI 
of a small section on the benefits of the medicine. 
In Chapter 4, we report on an additional randomised clinical study by Van 
haecht on the impact of a patient package insert (PPI) versus a technical insert 
(TI) on the risk perception of patients using Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDS)  for small accidents with joints (wrist, shoulder, ankle or 
knee). It is presented extensively here, because it was a key study in our 
research programme. In addition, we will briefly report on the design of a 
placebo controlled randomised trial, which was not completed. This trial 
compared the impact of atenolol versus placebo in essential hypertension, on 
patient compliance and reported side-effects, with a secondary nested 
randomization of PPI versus TI. The findings of the experimental studies 
presented in Part III will be discussed in Part IV. 79

Chapter 1
Written drug information and 
patient compliance
Originally published as: Vander Stichele RH. Promises of a measurement breakthrough. 
In: Metry JM, Meyer UA (Eds). Drug Regimen Compliance. Issues in clinical trials and 
patient management. New York: John Wiley and Sons, 1999. (see facsimile 4 in Annex 1)
Nothing is so firmly believed as that which we least know.
Michel de Montaigne
1.1 Motives for this review
In 1996, I was invited by the editors of the book mentioned above to write a 
chapter in the field of drug information and report on my experiences with 
electronic monitoring of patient compliance. During the 1988 conference on 
patient package insert in Ghent, Belgium, I had the privilege to meet Prof. 
John Urquhart, invited to the conference to speak about models of risk 
communication. Prof. Urquhart introduced me to the developments on the 
scene of compliance measurement. He showed me a new device to measure 
daily drug intake by electronic monitoring, the Medication Event Monitoring 
System (MEMS). After seeing the first results of observations of real life 
patient behaviour, the importance of this new instrument was clear to me. I 
had been following the compliance literature for years and had taught on the 
subject to medical students and general practitioners. I grasped the importance 
of this development for the issue of written drug information and embarked 
on writing a review of the methods to measure compliance in clinical trials.[200] 
In 1990, I had the opportunity to participate in a trial where the MEMS 
technology was used (see chapter 2 of Part III), and later I was involved in the 
design and analysis of the results of a number of other trials with electronic 
monitoring. 
Below is an overview of relevant concepts. 
1.2 Relevant concepts developed in this review
We will only present a short description of the concepts developed in this 
qualitative review. 81
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measurement
In this review of 1999, the field of patient compliance is described as a 
stagnating research field, with few original contributions, hampered by the 
lack of precise measurement techniques. In the eighties and nineties, the 
number of qualitative reviews far exceeded that of original publications (by 
one to ten; see fig.1 in facsimile), indicating slowing progress, repetition and 
stagnation. 
1.2.2 A breakthrough in measurement technique
The advent of electronic monitoring has thoroughly changed the research field 
of patient compliance. The MEMS device resembles an ordinary cylindrical 
pill container with a somewhat oversized cap. In the cap, microelectronic 
circuit was concealed, able to record the date and time of the opening and 
closing of the box. This circuitry consisted of a clock, a micro switch, a 
memory and an output device. Each time the cap was removed to open the pill 
box, the micro switch was triggered. A time and date reading is then fed into 
the memory. Later, these readings can be retrieved by placing the cap over an 
output reader and transferring it to computers for further analysis by special 
software. 
Figure 1: Principal elements of electronic monitoring devices.
The arrival of electronic monitoring was considered a breakthrough in 
measurement. What was fundamental in this innovation was the ability to 
identify and time stamp the occurrences of dose omissions. 
Prof. Urquhart, inventor, developer and advocate of this novel 
measurement technique, has also proposed a taxonomy for the interpretation 
of the data stemming from MEMS.[201] For the initial decision to start the 
prescribed treatment, he suggested the term “adherence” (here meaning 
acceptance of treatment). It is a yes-or-no decision. 82
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consultation and before going to the pharmacist[201], before picking 
up the ordered medication at the pharmacist’s,[202] or at home, after 
the purchase of the medication.
The term “execution” for the middle part of patient compliance. Here, we 
look at the congruence between two time series: the time series as prescribed 
by the physician and the time series as taken by the patient. Finally, after some 
time, patient compliance can come to a final stop. The proposal here was to 
use the label “(dis)continuation”. Again, this is a yes-or-no decision. The term 
“persistence” applied to the time which elapsed between the start of the 
treatment and its final discontinuation. 
note Patient compliance, adherence or concordance?
Confusion patient compliance is well reflected in the sometimes 
harsh discussions on the terminology. “Patient compliance” is the 
oldest term. Haynes defined it as “the extent to which a person’s 
behaviour (in terms of taking medicines, following diets, and or 
making life style changes) coincides with medical or health 
advice”.[203] 
In reaction to judgemental use of the term, a new label, i.e. 
“adherence”, was proposed: it implies “a more active, voluntary 
collaborative involvement ... in a mutually acceptable course of 
behaviour to produce a desired preventative or therapeutic result”.[204] 
More recently, yet another term, “concordance”, has been adopted by 
some researchers in the field,[205] to underline the move to patient 
empowerment in the physician-patient relationship. Although the 
latter trend may have its advantages, the more pragmatic viewpoint 
on this labelling issueis to stick to the MESH keyword “patient 
compliance”, which was introduced in 1975 and is still used today. 
Search strategies in MEDLINE using the terms “compliance” (without 
the prefix “patient”), “adherence”, and “concordance” yield smaller 
recall and much less precision, because irrelevant articles on lung 
diseases, blood diseases and statistical issues turn up in publication 
listings. One could not agree more with Myers and Midence when 
they state: “If clinicians and researchers cannot agree on suitable 
terminology on the topic they are investigating, how are they going 
to agree on anything else?”.[167] 
With the new and precise method of electronic monitoring, the stages of 
patient compliance can be unravelled and researchers can look at the details of 
the actual regimen and its deviation from the regimen prescribed (see Fig. 1. in 
facsimile 5) with sometimes frightening precision. In the other chapters of the 
book in which this review was published, ample testimony was given of the 
promises of this new technique, with the fascinating results of more then 50 
peer-reviewed publications of studies with MEMS in the previous decade.
In our chapter, we examine which impact more precise measurement of 
compliance could have on the development of new insights with regard to risk 
assessment and to risk communication by means of patient package inserts. 83
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In observational studies of compliance, the distribution of compliance (the 
percentage of patients taking x% of prescribed dosages) is similar across 
different clinical settings.[206] 
However, results of intervention studies on modifying compliance obtained 
in a particular clinical setting should not be generalised too easily to other 
clinical settings. 
Indeed, the clinical setting is determined both by the characteristics of the 
disease and by the characteristics of the medicinal treatment. By proposing the 
term “disease-drug dyad”, we want to stress that there is an unbreakable bond 
between the two elements in the patient’s perception which determines the 
specificity of the clinical situation. Important characteristics of the disease are:
• whether the disease is acute or chronic
• whether the disease is symptomatic or asymptomatic (not perceivable 
by the patient)
Important characteristics of the medicinal treatment are:
• whether the treatment is complicated by frequent minor but 
perceivable side-effects
• whether the treatment is associated with serious risk
• whether the treatment prevents, cures or only alleviates the disease
• whether the treatment is vulnerable to (short) interruptions in the 
regimen.
We will first enumerate some examples of these disease-drug dyads and 
then look at their characteristics. 
Table 4: Disease-drug dyads
Let us explain in more detail some of these examples. 
A patient who has suffered from severe headache for 2 months may be 
confronted with the bad news that she/he has cancer. The good news is that it 
is a curable form of cancer, but again there is bad news: to get cured, she/he 
will have to take a drug that will cause hair loss (be it temporary). 
DISEASE DRUG
Curable cancer Hair-loss-inducing oncology treatment
Hypertension Beta-blockers
Acute bronchitis Antibiotics
AIDS Experimental treatment
Tuberculosis Streptomycine
Depression Amitryptilline
Asthma Inhaled steroids84
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that he/she suffers from severe hypertension, and starts taking beta-blockers, 
which make him/her feel “old and cold”.
A patient with acute bronchitis is given antibiotics, which he/she stops 
after three days because of heartburn and because he/she is feeling somewhat 
better. He/she is in good shape again, six days after the onset of the illness. 
A patient with severe depression finally gives up resistance to getting 
proper treatment, feels even worse after one week of taking amitryptilline, 
because of dryness of the mouth, dizziness and constipation. He/she was not 
told that these embarrassing but mild side-effects would probably subside after 
two weeks, nor that it would take at least two weeks before he/she would feel 
less depressed. 
A patient who has lived a merry life until now is confronted with the 
diagnosis of AIDS and presented with a complex experimental treatment, 
which entails unknown efficacy, is potentially riddled with dangerous serious 
side-effects, and has a high probability of less dangerous, but inconvenient 
minor side-effects. The treatment must be followed meticulously; otherwise, 
the theoretical chance of getting better is lost. 
In the fifties, a patient with severe tuberculosis, a disease without 
efficacious treatment at that time, was given the opportunity to start a 
treatment with streptomycine; at the same time, he was informed that this 
might cause permanent deafness. 
The mother of a young adolescent child with asthma, characterised by 
frequent severe attacks of wheezing, is told that she should administer a high 
dose of inhaled steroids to her child every day, in the midst of his/her growth 
spurt. 
These are just a few examples to illustrate the difficult choices people have 
to make, often in difficult conditions, with very little precise information or 
too much or conflicting information. And yet, they have to make judgements 
and decisions to act (or not to act). 
With these examples, we also want to illustrate that the characteristics of 
disease and treatment are intricately related and mould together in the 
patient’s mental perception of the risks and benefits of a treatment for a 
disease in a specific clinical situation. 
1.2.4 Non-compliance and benefit/risk perception of treatment
We can distinguish different types of (non-)compliance: 
• the (perfect) complier
• the partial complier
• the overuser
• the erratic user
• the partial dropout
• the dropout.85
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told him/her to do so, or because he/she really wants it that way. The partial 
complier intends to follow the treatment as directed, but occasionally forgets a 
dose (a dose omission) or takes a drug holiday (a period of 3 consecutive days 
where no dose is taken); he/she regularly presents at control visits and may not 
mention non-compliance, unless prompted to do so in a non-obtrusive way. 
The overuser abuses the drug and systematically takes more than directed. The 
erratic user may alternate drug holidays and periods of frantic overuse. The 
partial dropout alternates short periods of use with prolonged drug holidays. 
The dropout has stopped taking the drug altogether. 
The complier may benefit fully from the treatment and minimise its risks. 
The partial complier will not benefit fully from the drug; in some cases even 
minor deviations of the treatment schedule will jeopardize efficacy; in 
addition, interruption of the treatment may cause additional risks to which 
regular drug takers are not subjected; ending a series of regular intake may 
cause withdrawal effects. Starting a new series of intake after a drug holiday 
may cause strong first dose effects, which is not without danger for the 
patient. The overuser will be exposed to the risks of overdose and addiction. 
The erratic user will combine the worst of two worlds: more risk and less 
benefit. The partial dropout will have little gain from his treatment, but will 
still be exposed to its risks. The dropout will no longer be subjected to any risk 
from the treatment but not benefit from its action anymore either.
For each of the six types of non-compliance, we have indicated the risk of 
the treatment with a grading scale (absent risk, acceptable risk, moderately 
augmented risk, strongly augmented risk). We did the same for the benefit of 
the treatment (optimal, suboptimal, doubtful, absent). By combining the two 
approaches, a categorical classification into six types of non-compliance is 
constructed, based on alterations in the risk/benefit ratio of the treatment.
Not all of these types of non-compliance may be prevalent in all clinical 
situations. Erratic users are seldom found among users of antihypertensives, 
but can be found among users of inhaled bronchodilators for asthma or 
benzodiazepine users for chronic fear syndromes. 
Another important point to make is that the distinction between compliers 
and partial compliers cannot be defined by a simple rule that is valid for all 
clinical situations (e.g. less than 80% of the doses taken). Whether a particular 
number of dose omissions causes deterioration of treatment efficacy or side-
effects, depends on the pharmacodynamic and pharmacokinetic properties of 
the drug itself. Patients with a transplanted heart or kidney must scrupulously 
take their immunosuppressive medication, since even a short interruption of 
therapy is a risk factor for acute rejection, organ loss or even death. Patients 
on long acting antihypertensives (reserpine, amlodipine, perendopril) may skip 
their treatment for more than one day without having their blood pressure run 
up again. The moment when the coverage of a drug subsides, depends on the 
drug. When a dose is omitted, the normal prescribed dosing interval is 
prolonged. When the actual dosing interval between the last dose in a regular 86
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the duration of the action of the drug, a period of absence of therapeutic 
coverage starts (from the moment of the waning drug action to (and some time 
after) the moment of the first dose of the new series of doses). 
Figure 2: Duration of drug action, dosing interval, 
therapeutic coverage
In every clinical situation, where clinicians and researchers try to improve 
compliance, the distinction between punctual and partial compliance must be 
set a priori, by taking into account the pharmacokinetic and 
pharmacodynamic properties of the drug itself. Only electronic monitoring 
provides enough detailed information about dosing intervals and other aspects 
of non-compliance, to allocate patients to these classes of non-compliance htat 
have been defined a priori. 
1.2.5 Model for studying the impact of written drug information 
on compliance
To study how written drug information may influence compliance, we needed 
to establish a pathway, and an array of possible intermediate and confounding 
variables. In this exercise, we will make abstraction of procedural information 
(information on how and when to take the medicine) and compliance 
problems caused by patients not knowing how to execute the treatment 
schedule correctly. We will focus on the impact of written drug information on 
patients’ perception of the risks and the benefits of the treatment on patients’ 
decision to start or continue a treatment. 
We started by making a graph of what was well-known from the 
compliance literature (see fig. 2 in facsimile 4 of Annex 1). 
For a drug to have an effect, it must be taken. So, in between the drug and 
its effects stands patient compliance as one important intermediate variable, 87
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in drug effect.[207] 
The effect of the drug may influence patient compliance in a variety of 
ways. A good effect can motivate the patient to continue treatment, but if 
symptoms of the disease disappear, the patient may lose the motivation to 
continue treatment (as often happens in treatment with antibiotics). The effect 
of diuretic agents (forcing the patient to urinate frequently and abundantly in 
the hours after the morning intake) may hinder activities of daily life and may 
be a cause for postponing intake on special days. Patients may also engage in 
stop-and-start experiments “to check from time to time whether the treatment 
still works”. 
Drugs not only have effects but also side-effects. The occurrence of side-
effects may cause a change in the subjective benefit/risk perception of the 
patient, which may lead to non-compliance, as patients may immediately 
withdraw from therapy or engage in stop-and-start experiments “to check 
whether the side-effect is related to the drug”. 
Dose omissions (whether intentional or caused by forgetfulness) can 
reduce the beneficial effect of the drug treatment on the disease for which the 
drug is indicated. Dose omissions may cause withdrawal phenomena which 
will be interpreted by patients as side-effects. In addition, upon resumption of 
dosing, first-dose effects may occur. Hence, because a number of patients 
regularly engage in drug holidays, the objective balance between the benefit 
and the risk of drug, susceptible to withdrawal phenomena and first-dose 
effects, may alter. If these phenomena are perceived by the patient, the 
(subjective) perception of the risk of the treatment might be acutely distorted, 
leading to further deterioration of patient compliance. 
The question is now how drug information (either verbal or written) can 
impact on these phenomena. Here, the assumption is that the decision to 
comply with therapy (start or continue) will be influenced by the benefit/risk 
perception of a particular patient in a specific clinical condition.
This benefit/risk perception may be shaped by prior experiences and 
general knowledge about drugs through education, and it will be changed by 
specific information provided prior to the first intake. It will also be changed 
(and possibly dramatically so) by personal experience of effects or side-effects 
during intake, at which time information can again be consulted to interpret 
bodily symptoms.
1.2.6 Designs for testing the impact of written drug information 
on compliance
In the following chapters we will present trial designs to test active groups and 
controlled groups in a randomised way for the differential impact of written 
drug information in various shapes. One can test written drug information 
versus no information. This design may be ethically difficult in clinical 88
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(or more) different types of written drug information will be tested. One can 
test the impact of linguistic differences, graphical differences, differences in 
communication style, differences in the extent of risk information and 
differences in the extent of benefit information. It is hazardous to mix more 
than one of these aspects in one trial. 
In clinical psychology studies, one can work with human volunteers who 
are not exposed to the drug (but to a clinical scenario) and are then exposed to 
different forms of written drug information. In the clinical situation, the 
intervention is composed of two elements, namely the drug under study and 
the written drug information that goes with it. 
The design can be made more complicated, by testing different types of 
written drug information and by testing the intake of an active drug versus 
placebo or versus an active comparator. 
In the nested design of the comparator being aplacebo, the content of the 
information provided to the placebo group can be identical to that in the 
active group (although twice nested into different styles of information, but 
with identical content). 
If the clinical trial tests an active product versus another active product, 
then we are confronted with a problem of differential exposure and a difficulty 
of unblinding of allocation. Different drugs may have different side-effect 
profiles when applied to the same indication. Suppose we limit the content of 
the written drug information for patients exposed to drug A to the side-effects 
of drug A (albeit in two different styles) and also limit the content of the 
written drug information for the comparator drug to the side-effects of the 
comparator drug. By doing so, our intervention would not only introduce two 
different drugs and two different styles of written drug information, but also 
two different contents of written drug information. This would certainly 
confound our appreciation of the impact of the difference in style in written 
drug information. For the clever physicians and patients participating in the 
trial it would, furthermore, introduce a technique to escape the blinding of 
allocation of the two drugs. By studying the informed consent messages and 
the written drug information provided (regardless of its style) it would be 
possible to discover to which drug the patient was allocated. This would of 
course invalidate the results of the trial. 
In the study presented in the next chapter, we provide a solution to this 
problem. We decided to merge all information elements with regard to side-
effects of drug A and of drug B into one text. This hybrid text was then 
rewritten in the two different styles to be tested, while maintaining the content 
common to both drugs. 
An example of such a hybrid insert, combining content information on 
atenolol and on lisinopril (in the patient package insert version) is given in 
Fig. 1 of Facsimile 5. A similar, but more sophisticated, version is given in 
Fig. 3 of Facsimile 4. The exposure to two different medicines remains 
blinded, as the content of the information is completely identical for all 89
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dilemma between blinding and correct information. 
1.3 Further discussion in the context of this thesis
Since the advent of electronic monitoring, theoretical insights into the problem 
of patient compliance have deepened. The importance of staging patient 
compliance in phases (adherence, execution, discontinuation) becomes more 
and more underpinned with empirical data. We have used this staging 
approach to make decisions on where to focus our research. 
Scholars in clinical psychology had effectively warned us not to expect too 
much from this piece of Bible-type paper, in terms of motivational support in 
the action and maintenance stages of medication taking behaviour. In these 
stages, social support and control, cueing, and human motivational efforts are 
needed to support the patient in his/her initial steps and in developing 
routines.
In the later stages, however, the concept of benefit/risk perception remains 
of some importance, and might be more dynamic than static. Experiences of 
effect and side-effect during the initial try-out or during routine drug intake 
might affect and change benefit/risk perception and induce changes in 
compliance and ultimately less or more discontinuation. We simply do not 
know whether this latter mechanism or rather a gradual motivational slip of 
routine procedures by a lack of cueing is the most common cause of partial 
compliance and dropout. 
The study presented in Chapter 2 of Part III was an attempt to explore the 
magnitude of potential differences in execution of treatment between different 
drug classes for chronic therapy of hypertension, with and without patient 
information.
In the study presented in Chapter 3 of Part III, we decided to focus on the 
initial phase (adherence) as the most important target for our research, and 
more specifically on the processes of benefit/risk perception as perceived by 
the patient in that phase. 90
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Measuring patient compliance with electronic 
monitoring: lisinopril versus atenolol 
in essential hypertension
Originally published as: Vander Stichele RH. Thomson M, Verkoelen K, Droussin AM. 
Measuring patient compliance with electronic monitoring: lisinopril versus atenolol in 
essential hypertension. Post Marketing Surveillance 1992;6:77-90. (see facsimile 5 in 
Annex 1)
Motives for this study
As early as 1990, the Belgian branch of the pharmaceutical company Merck, 
Sharp and Dohme invited me to participate in the early phases of preparation 
for a phase IV trial of a new product against hypertension from a new 
pharmaceutical class (an ACE-inhibitor, named lisinopril). The product had 
just been registered by the Belgian authorities. Hence, the basic evaluation of 
the available data from sophisticated pre-registration studies on efficacy and 
safety were evaluated with a positive initial result, as the product was allowed 
to be launched into the market. 
At that moment, companies like to conduct additional post marketing 
studies for various reasons. One reason may be to familiarise opinion leaders 
with the new product or “to get the product into the pen” of prescribers. 
Getting more information on safety under natural conditions is another 
possible motive. The company might also want to compare the new product 
with the main competitor drug. 
When I was called on board to consult the company, the decision had 
already been taken to conduct a relatively small comparative trial, to test 
lisinopril versus atenolol, a beta-blocker agent, a classic product for use in 
hypertension. I was interested in this comparison, because beta-blockers are 
first-line agents for the prevention of the clinical consequences of hypertension 
(in principle a condition without symptoms). Many patients experience no 
side-effects under atenolol, but a substantial number of patients report 
experiencing a feeling of cold hands and tiredness. Beta-blockers also cause a 
drop of the heart rate (which physicians may notice). These medications also 
restrain the normal quickening of the heart beats when a patient performs 
physical exercise, hence reducing the ability of patients to exercise. Atenolol 
might be considered as a drug with noticeable effects. This means that the 
patient and/or the physician is capable of observing the effects of the drug on 
the body in some cases. Lisinopril was not known at that time to have this 
peculiarity (although it was soon to be discovered, that ACE-inhibitors may 
cause an annoying cough in 1 in 20 patients). 
I agreed to participate in the conduct of this study (as affiliated to the 
General Practitioners Research Institute and not to the Heymans Institute of 91
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MEMS-device) in this study. To me and to the company, it was first hand 
experience with this new instrument to measure patient compliance, at that 
time a new, expensive and somewhat fragile device, considered a gadget by 
some. Furthermore, the company accepted my proposals to change the 
research protocol and raise the sample size, to add a dimension of testing the 
impact of patient package inserts to the study. 
Setting
Post Marketing Surveillance General practice in Belgium, a western European 
country.
Objective of the study
To compare two antihypertensive medications (lisinopril, an ACE-inhibitor 
and atenolol, a beta-blocker) for side-effects and patient compliance and to 
investigate the impact of a patient package insert (PPI) on patient compliance. 
Timeframe
Autumn 1990. 
Design
This study was a randomised, open, comparative trial with one week of 
washout and 8 weeks of active treatment in two trial groups (without and 
with PPI), while each group was randomised further to either lisinopril or 
atenolol. The splitting into two trial groups was performed by group 
randomization: fate allocated each participating general practitioner to either 
a group where all GPs gave all their patients the study medication with a 
patient package insert, or a group where no participants got a PPI. This 
procedure was chosen to reduce confusion among GPs. Each participating GP, 
however, had to agree in advance to participate, regardless of the outcome of 
this allocation. The allocation within each of these trial groups to either 
lisinopril or atenolol was performed as follows: each physician received 6 
medication packages, 3 with 60 tablets of atenolol 100 mg and 3 with 60 
tablets of lisinopril 20 mg. GPs were not blinded to this allocation (they could 
see the difference between tablets), but were given a block randomization 
scheme (a random sequence of even and odd numbers in a envelope) to let fate 
decide which patient would get what, together with a firm request to follow 
the scheme.92
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R = randomisation
Hybrid info: a patient package insert with information about typical side-effects 
of the two drugs
Visits for blood pressure measurement and adverse events report writing were 
planned on the first day, after one week of washout, 4 weeks later and again 4 
weeks later for final evaluation. 
The tablets were distributed, prepacked in the MEMS device (a plastic pill 
container with a screwable cap, containing electronic circuits to record 
opening and closing times of the cap). The MEMS devise was itself placed 
within an outer carton package (containing either a PPI or not), according to 
the allocation. MEMS devices were supposed to be operational during the 8 
weeks of the trial, to be retrieved for further analysis at the end of the trial. 
The PPI was a hybrid of the official insert of both atenolol and lisinopril, 
blended into one text, and then transformed into an understandable text, 
without loss of information (see Facsimile 5 in Annex 1). 
We wanted to have a least 32 patients in each of the four subgroups, a 
minimum to have some power in the analysis. 
Participants
We invited 26 GPs to recruit 6 patients each, for a target total of 156 patients. 
Patients had to be older than 21 and younger then 65 years and to have mild 
to moderate hypertension not treated yet or treated with a drug that did not 
control the blood pressure or was not well tolerated. Patients should not have 
been treated before or have contraindications for beta-blockers or ACE-
inhibitors, and should not have additional severe health problems. So, this was 
to be a selection of uncomplicated hypertension patients, mainly on diuretics, 
with one or other reason to switch to a new antihypertensive agent. 93
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We asked the GPs to record pulse rate and blood pressure at each visit, with a 
standardised procedure, more stringent than in every day practice, as is the 
custom in research projects. 
At each visit, the physician inquired about all adverse events in the past 
period with an open question (not a questionnaire), and recorded whether or 
not he/she considered the event to be a side-effect of the medication. 
The use of the MEMS device to measure patient compliance (see Chapter 1 
of Part II for illustration) was not concealed from the patients and was part of 
the informed consent procedure. Patients were asked to return the MEMS at 
the end of the study. A description of what kind of information can be 
extracted from this device is given in Fig. 1 of Facsimile 5 in Annex 1). The 
MEMS data were used to classify patients in three categories, relevant for 
hypertension treatment: 
• punctual complier
• partial complier
• dropout.
According to the nature of the data (percentages or averages), the 
appropriate statistical tests were used to test relevant differences in a 
conservative way for significance. 
Ethical issues
The protocol of the trial was submitted to the Ethical Commission of the 
Flemish Research Institute, a certified board to supervise clinical medical 
research. Informed consent was given orally on the nature, aim and conduct of 
the study and on the use of the compliance monitoring device. 
Results
Eight of the 26 physicians did not recruit a single patient (6 in the PPI trial 
group, 2 in the non PPI group). The remaining 18 GPs provided data for 74 
patients (a median of 4 patients recruited per participating physician). Three 
patients (each from a different physician) were excluded because the GPs did 
not comply with the stipulations of the protocol for letting in or keeping out 
patients. Retrospectively, the data from another 3 patients, all from the same 
physician, were excluded from the analysis, because we discovered that the 
data was fake (see below for explanation). 
Hence, we retained 68 patients for analysis. All were white Caucasians, 
between 23 and 65 years old, 53 years on average, with two more female than 
male patients. Six patients (one on lisinopril and 5 on atenolol) were recruited 
for intolerance to previous treatment, 15 were not previously on treatment (5 
on lisinopril, 10 on atenolol) 44 were recruited because of low control of 
blood pressure, and 3 for a combination of reasons. 94
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to atenolol (18 with a PPI). There was no significant difference between the 
patients allocated to atenolol or lisinopril with regard to sex, height, and 
weight. There was a significant difference in age, as in the 60+ group only 6 of 
the 25 patients were on atenolol. Analysis revealed that 3 physicians had not 
respected the allocation procedure and had only put younger patients on 
atenolol. 
Of these 68 patients, 18 did not complete the trial. Fifteen of them 
discontinued the trial and notified their physicians. Three others were 
identified as dropouts only later, after the analysis of the compliance date in 
the MEMS device. One of these patients experienced an abnormal slowing of 
the heart rate (bradycardia) and heart pounding (arrhythmia), notified his 
physician (who did not withdraw the patient), stopped taking the drug 
without notifying the investigator, but attended the visits till the end of the 
trial; two other patients did not take any medications in the first 28 days of the 
trial but started intake after the second visit. 
Among the 18 dropouts, 13 experienced an adverse event; among the 50 
patients who completed the trial, 7 experienced adverse events (a statistically 
significant difference).
Among the 38 patients on atenolol, 11 patients experienced 16 adverse 
events (11 of which were side-effects to the drug, according to the physician), 
and 8 dropped out. Among the 32 patients on lisinopril, 9 experienced 11 
adverse events (4 probable side-effects) and 5 patients dropped out. 
Among the 20 patients experiencing adverse effects, 10 had received a PPI 
and 10 not. Seven of these 10 patients with adverse effects and with a PPI 
dropped out, one was a punctual complier, 2 were partial compliers. Six of the 
10 patients with adverse effects, but without a PPI dropped out, and 4 
remained punctual compliers. 
During the trial, the mean heart rate in the lisinopril group remained 80 
beats per minute, while in the atenolol group the mean rate dropped to 68 
beats per minute, again a statistically significant and clinically relevant 
difference. 
The drop in blood pressure was equal in both groups, with one in six 
patients not responding. 
Of the 50 patients who completed the trial, 4 patients failed to return the 
MEMS device. Hence, we had compliance data from 46 patients, of whom 36 
did not miss one day of dosing, and hence were punctual compliers. In the 
lisinopril group, 91% of the patients were punctual compliers, in the atenolol 
group 65% were punctual (a significant difference).
In Table 2 of Facsimile 5 in Annex 1, a detailed breakdown is given of the 
number of adverse events occurring in punctual compliers, partial compliers 
and dropouts, depending on their allocation to lisinopril or atenolol or to the 
PPI group or to the group without PPI. The highest number of dropouts (n=5) 
was found in the group of patients receiving a PPI, but the numbers were too 
small even to attempt statistical analysis.95
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once daily intake (see Fig. 2 of Facsimile 5 in Annex 1). On weekdays the 
average hour of intake was 07.30 a.m., on Saturday 09.00 a.m., and on 
Sunday 09.30 a.m. Drug holidays started slightly more often in the weekend. 
Short overview of the discussion and conclusions in the original publication
The first objective of this study was to compare two antihypertensive 
medications in a general practice setting. We did not need to perform this 
study to know that both medications lower the blood pressure and that 
atenolol lowers the heart rate. Because this study was performed in general 
practice, we experienced a number of problems: failure to reach recruitment 
targets, a few protocol violations, one case of physician fraud, a relatively high 
rate of adverse reactions and dropout, some missing data in the case report 
forms, a few recording devices not returned. This all contributed to a loss in 
empirical power, beyond the level where a clear answer to the second objective 
(is there an impact of the PPI on compliance?) was possible. In addition, the 
procedure for random allocation was not followed by 3 physicians, choosing 
younger patients for atenolol, introducing selection bias. Finally, in studies 
involving beta-blockers, there is always the element of observer bias, as 
physicians who are supposed to be blinded to the allocation can observe the 
lower heart rate in patients.
This was a company-driven trial in post marketing and maybe not 
conducted with all the rigour one could expect in a premarketing trial. In 
addition, we could have chosen a stronger randomization procedure in the 
design. Nevertheless, the continuing logistic support of the company (also 
when things were not running exactly as planned) helped much to finalise this 
project. In retrospect, not enough precautions were taken to assure blinding. 
The main drive for occasional breaking of the blinding by a limited number of 
physicians was probably the reluctance of physicians to prescribe beta-
blockers to elderly (also documented in other studies), while those physicians 
may not have grasped the negative consequences for the analysis of the data.
The problems we encountered prevented us to reach firm conclusions with 
regard to the objectives. Even the significant findings must be looked at 
critically, because of the possibility of bias and confounding by age. However, 
there are interesting lessons to be learned from the problems observed, 
interesting descriptive results, and interesting experiences in the light of 
subsequent research. 
This study tells us something about the reality of research in general 
practice. Eight GPs agreed to participate, but did not recruit. Maybe it was too 
difficult to say “no” to a pressing demand to participate. Maybe, the 
allocation to the PPI group led to investigator dropout despite prior agreement 
on this issue. The reluctance of GPs to prescribe beta-blockers in the elderly is 
well known, although the rationale may be questioned. Many GPs only 
occasionally participate in trials, are not trained in the rigour of procedures, 96
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here to thank the investigators of this study for their efforts. 
In this study, electronic monitoring played a crucial role in the detection of 
one of the first documented cases of investigators’ fraud. The fraud was 
discovered because the recordings of the time of dosing in all the patients of 
this particular physician consistently showed unusual opening times between 
10.00h and 11.00h in the morning and no recordings on Saturday and Sunday 
(the weekend). We soon realised that these were fake patients, that the 
physician had filled in the case report forms himself and manipulated the 
medication vials (without fully understanding the concept of timing).
This potential for audit and quality control in clinical trial of this 
technique, designed to measure patient compliance, was unexpected. Equally 
unexpected was the finding that a detection procedure for fraud is necessary, 
even among physicians who participate on a voluntary basis.
This study was one of the earliest clinical trials with the MEMS device, 
and it illustrated its power for describing the different aspects of compliance, 
some of them unattainable by other methods. It was possible to study in detail 
the variation in the length of the time interval between the all the doses one 
patient has taken during the study (the mean dosing interval). It was possible 
to look for intervals that exceeded 24 hours by more than 6 hours. This was 
then used to explore the consequences of different ways to separate punctual 
from partial compliers (see Table 3 of Facsimile 5 in Annex 1). 
Unfortunately, we did not get far in the analysis of the impact of PPIs in 
this study. There was a small trend towards more adverse events and dropout 
and more compliance problems in the atenolol group with PPIs. After taking a 
critical look at the available data, it was clear that the numbers were too small, 
the power was too low, and the potential of bias too big to make any 
conclusion. 
Further discussion in the context of this thesis
We realised that in new trials on this subject, a design testing the impact of PPI 
would no longer be feasible. From the early nineties on, medical ethics 
committees, supervising the conduct and protocols of clinical trials, rightly 
started to stress the importance of written informed consent and would no 
longer accept a trial where some of the patients were withheld information in 
one way or another. 
It was frustrating to realize that our thorough analysis of the compliance 
data could not lead to firm conclusions. “Looking at the data” was, however, 
a tremendous experience, which shaped our thinking about future trial design 
and typology of different classes of patient compliance. We could not refrain 
from proposing a hypothesis for a future study: In clinical trials, involving 
drugs with noticeable signs and symptoms of drug action or with noticeable 
signs of fading drug action or a high frequency of minor side-effects, it can be 
hypothesised that patient compliance and the perception and attribution of 
adverse reactions will probably be influenced by written drug information, 97
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dropout.
The next logical step was to test the hypothesis formulated in the previous 
study in a bigger trial, which was better designed and more rigorously 
conducted. Our interest was sharpened to design a decisive new trial. In 
Chapter 4 of Part II, we will describe a study by our colleague Van haecht 
from 1990, focusing on an intermediate step, and one other attempt in 1992 
to come up with more definitive answers. Before that, and somewhat against 
the chronology, we will discuss a study from 1998, published in 2002. That 
study focuses on the benefit side of the benefit/risk perception of medication 
by the patient. 98
Chapter 3
Impact of benefit messages in patient package 
inserts on subjective drug perception
Originally published as: Vander Stichele RH, Vandierendonck A, De Vooght G, Reynvoet 
B, Lammertyn J. Impact of benefit messages in patient package inserts on subjective drug 
perception. Drug Information Journal 2002;36:201-208 (see Facsimile 6 in Annex 1).
Shannon’s Observation:
Nothing is so frustrating as a bad situation
that is beginning to improve.
note Because precedence is given to first author publications, this study 
from 1998 is presented here prior to the studies from the first half of 
the nineties, described in chapter 4 of Part II. Readers who prefer to 
read the studies chronologically are advised to read that chapter first.
Motives for this study
In 1996, after an interruption of a few years, we resumed our interest for 
patients package inserts, triggered by two students in experimental psychology 
from our university. The proposal was to conduct a study now focusing on 
benefit perception, rather than on risk perception. There were several motives 
for this.
First, we realised that our previous research was predominantly focused on 
risk perception, and that it was time to look at the insert from the opposite, 
more positive side.
Secondly, we realised that the content of the patient package insert is of 
course predominantly risk information. The section of the side-effects is the 
largest section, and there are sections on contraindications, special warnings 
and what to do in case of overdose. The amount of space allotted to explain 
what the drug is for is limited, in fact, to the name of the drug, the list of its 
indications and the pharmaceutical class to which the drug belongs. That can 
hardly be considered a coherent, ample and convincing description of the 
benefits of the drug. 
In the literature on the impact of doctor-patient interaction, there is some 
evidence that a doctor who explains the nature of the disease to the patient, 
how the drug works and how it will affect the illness will obtain patient 
satisfaction and compliance to a large extent.[208][209][210][211] This led to the 
hypothesis that a similar message in the patient package insert will lead to a 
similar result.
In the late eighties I had reviewed several thousands of drafts of patient 
package inserts for the Belgian Registration Commission. It was my experience 
that the registration authorities were reluctant to permit paragraphs on the 
positive side of the medication. The PPI was considered an authoritative 99
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into the texts. Furthermore, it would require too many resources from the 
regulatory authorities to check these passages, discuss them with the company 
and enforce compliance to the ban on promotional messages in the package 
insert. This attitude was confirmed in 1996 in a series of in-depth interviews 
with regulators in the Belgian Pharmaceutical Inspectorate and medical 
managers and regulatory affairs managers from the industry. 
Yet, during our proofreading, we noticed that most of the drafts of the 
PPIs were not of good quality. Our review was limited to flagging jargon 
words and overly complex sentences. It was not for us to edit the 
communication style of these texts, which was, in our opinion, mediocre most 
of the time. 
In chapter 1 of Part I, we mentioned the paradox that before the transition 
of technical inserts to patients package inserts in 1988, the majority of a 
representative sample of the Belgian population read and appreciated the 
technical inserts, despite the fact that they were basically unintelligible. Maybe 
lay people read technical inserts in the way that one listens to a Gregorian 
chant or a Latin Mass. Enveloped and enchanted but hardly grasping the 
meaning of things. 
We realised that taking away jargon and long sentences, without changing 
the communication style and the content, may lead to a more direct and 
unbalanced confrontation with risk information, which can be frightening, 
even when (or especially when) partly understood.
After long debate with the Department of Experimental Psychology of 
Ghent University, we decided to go for a “what if” approach, and to test the 
impact of a well-written, easy to understand patient package insert, which 
included a small paragraph on benefit hidden in the text. We discussed the 
protocol of the study and drew up a budget for adequate logistic support to 
permit the department of clinical psychology to conduct the study. Once there 
was an agreement, I contacted Willem Amery, Vice-president 
Pharmacovigilance at the Janssens Research Foundation, with a request for an 
unconditional grant. A contract was signed and the study was launched. 
Setting
The study was conducted in Flanders, the Dutch speaking part of Belgium, 
among members of community associations for women, among female 
relatives of psychology students, and among caregivers (partners or family 
members) of psychotic patients, recruited through a self-help group. 
Objective of the study
To evaluate the effect of the insertion of benefit information into a patient 
package insert on patients’ knowledge and subjective benefit/risk perception. 100
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Data were collected from the autumn of 1997 to the spring of 1998.
Design
A randomised controlled clinical psychology experiment with human 
volunteers.
Methods
We decided on the following basic approach:
1. to work with human volunteers to whom a scenario would be read 
and not with patients actually experiencing the disease (for 
pragmatic reasons)
2. to conduct an experiment where the participants would be 
randomised into three groups: 
– a group without an insert (the control group) (CON-group)
– a group with a normal patient package insert (PPI-group)
– a group with a benefit paragraph added to the normal patient 
package insert (BEN-group)
3. to carry out the same experiment three times, each time placing the 
patient into a different clinical condition. 
In each of the three experiments an identical procedure was followed. We 
set out to recruit 90 volunteers (called subjects hereafter). Subjects were given 
a briefing on the nature of the study before being asked for informed consent. 
Subjects were read an introductory script to familiarise themselves with the 
clinical context of the experiment. This means they were told a story of 
someone experiencing an illness. Subjects were then asked to imagine that this 
story was their own story, that they went to see a doctor, and that a 
prescription was issued, and that they were now back home with the 
prescribed medicine. Subjects were then randomised (with a machine 
producing numbers by chance) to one of three conditions:
• the CON-group was given another reading task, for a similar length of 
time
• the PPI-group had time (5 to 15 minutes) to read the normal insert
• the BEN-group got equal time to read the insert with the benefit 
paragraph.101
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R = randomisation
CON = control group
PPI = Normal patient package insert group
BEN = patient package insert with a benefit message
Subjects could not speak to each other or have group discussions during the 
experiment. We used the text of the commercially available inserts, in 12 point 
type (big enough to be readable). For the products used in this study, these 
texts were of good quality, written for comprehension by readers with a low 
educational level (people who went to school till the age of 16). The scenario 
and the text of the benefit paragraph (60 to 80 words long) for each of the 
three experiments can be seen in Fig. 1. of facsimile 6 in Annex 1).
When reading time was over, the inserts and the control reading text were 
collected, and the volunteers were given a data collection booklet with 
measurement tests:
1. A knowledge test was taken. The test consisted of 20 simple 
questions, edited for readers with a low educational level, to be 
answered with YES or NO or DON’T KNOW, with one point for 
each correct answer. The minimum possible score was zero and the 
maximum possible score 20 points. Of the 20 questions, 16 related 
to the correct usage of the medicine and the risk messages, and 4 to 
the experimental benefit messages. 
2. A test of how subjects perceived the risk and the benefit of the drug 
was taken. Subjects were presented with a statement: “The benefits 
of this medicine are greater than its risks” and then asked to indicate 
whether they strongly disagreed, moderately disagreed, took a 
neutral stand, moderately agreed or strongly disagreed.
Figure 5: 5-point Likert scale to measure benefit/risk perception102
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The same experiment was repeated three times, each time with different 
subjects and placing them into a different clinical condition. 
• In Experiment 1, the clinical condition was the use of the drug 
cisapride (CIS) for benign disturbances of the stomach and the bowels. 
The benefit paragraph focused on explaining drug action. Tests were 
taken in small groups of 10 to 30 subjects. The subjects were adult 
women from community organisations. 
• In Experiment 2, volunteers were asked to imagine the use itraconazol 
(ITR) for infection by molds (fungus) of the toe nail. The subjects were 
relatives (mostly mothers) of psychology students. The benefit action 
focused on monitoring signs of healing. Tests were taken individually.
• In Experiment 3, the clinical condition was the use of risperidone (RIS) 
in chronic psychotic patients. The subjects were caregivers (partners or 
family members) of psychotic patients, recruited through a self-help 
group (SIMILES). The benefit paragraph focused on the relation 
between the disease and drug action. Tests were taken individually or 
in small groups of 10 to 30 patients.
We aimed at a sample size of 3 times 30 subjects per experiment. We used the 
appropriate tests for results in points (knowledge) and in percentages (% 
agreeing with the statement). We estimated in advance that differences of 20% 
points between subgroups could be considered a relevant difference, big 
enough to matter in clinical conditions. We chose the statistical power in such 
a way that we were reasonably sure (95% sure) that if the result was positive, 
this result could be trusted. In case the result was negative, we would be less 
sure (80%) that we had not missed a true difference. 
Ethical issues
The participating organisations agreed to the study and all subjects gave 
informed consent orally after an oral briefing. The design was discussed with a 
member of a medical ethical committee, but not formally submitted for 
approval, as no test medications were given nor incisive tests performed. All 
subjects were debriefed after the test. 
Results
In the 3 experiments, we recruited respectively 89, 102, and 83 subjects. All 
were female in experiments 1 and 2, and in experiment 3, 60% were female. In 
the second experiment, two-thirds of the subjects were highly educated 
(relatives of psychology students), while only one-third was highly educated in 
the other experiments. In the third experiment, 35% of volunteers (caregivers 
of psychotic patients) were familiar with the drug under study (risperdon) and 
they were older than the subjects in the other groups. There were no dropouts 
after randomization.103
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drug information, performed pretty badly on the knowledge test (the control 
caregivers in experiment 3 did somewhat better). The two experimental 
groups that did receive an insert did equally well in all three experiments 
(although both under 10 points out of 20 in experiment 1). 
Table 5: Median of correct answers on 20 simple questions 
on the medication
In Fig. 3 of facsimile 6 in Annex 1, more detailed information is given about 
the range of these results in each subgroup. 
In the next table, the results are given for the appraisal of benefit and risk 
by the patients. 
Table 6: Percentage of subjects agreeing with the statement: 
“the benefits of this medicine are greater than its risks” 
In the group confronted with benign stomach and bowel problems (Exp. 1), 
the appraisal of both control (CON) and PPI subgroups was significantly 
lower than the score of the subgroup with the benefit message (BEN). 
In the group confronted with the toe nail infection situation (Exp. 2), and 
among the caregivers of psychotic patients (Exp. 23), the PPI subgroup scored 
significantly lower than the control subgroup (CON) and the subgroup with 
the benefit message (BEN). In Fig. 4 of Facsimile 6 a more detailed and 
graphical representation of these results is given. 
In summary, the results were fairly consistent in the three experimental 
groups: 
• The 3 control subgroups had consistently worryingly bad results on the 
knowledge test, consistently worse than in the two intervention 
subgroups
• Benefit perception in the control subgroups was high (except in 
experiment 1, and very high in experiment 3)
EXPERIMENTAL GROUP CON PPI BEN
EXP 1 (CIS) 2 8 9
EXP 2 (ITR) 5 15 16
EXP 3 (RIS) 8 15 14
EXPERIMENTAL GROUP CON PPI BEN
EXP 1 (CIS) 36 31 62
EXP 2 (ITR) 62 41 64
EXP 3 (RIS) 84 54 70104
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experiments, and always significantly lower than CON and BEN 
(except CON in experiment 1)
• Benefit perception in the BEN subgroups (with a benefit paragraph in 
their insert) was high again and significantly higher than in the PPI 
subgroups, consistently in the three scenarios.
The significant differences were higher than 20 percent points (16% for CON/
BEN in experiment 3), and hence clinically relevant. 
Short overview of the discussion and conclusions in the original publication
This was an experimental study in clinical psychology, not a clinical study with 
patients. One must be careful not to make generalizations for the entire 
population or even for patients suffering from the conditions studied here. 
Our selection of volunteers was not intended to represent the general 
population. We deliberately sought female subjects, because we wanted 
subjects with a keen interest in drug information. We knew women play the 
role of gatekeeper for the other members of their families (see Chapter 1 of 
Part II). Furthermore, it was convenient for us to address and get access to 
these groups of volunteers through community social organisations (that is 
why this is called a convenience sample). This selection procedure may affect 
our possibilities to generalise the results, but it did not affect the internal 
validity of the study. Indeed, once the group was selected, the division into 
three subgroups was left to chance (randomization). Each subject in the 
convenience sample had an equal chance of ending up in any of the three 
subgroups. Therefore, conclusions from these results are valid, but must be 
limited at least to persons (women) with a keen interest in medication.
We have chosen three clinical conditions to conduct our experiments, 
rather pragmatically by taking medications from one single company. First of 
all, this company had a reputation for producing good quality patient package 
inserts. Secondly, in doing so, we were able to choose an interesting mix of 
clinical situations. In experiment 1, we had a benign, acute, self-limiting 
disease, causing clear and not very frightening symptoms, to be treated by 
medication without frightening side-effects; in experiment 2, it was a chronic 
disease of a more cosmetic nature, to be treated with a drug, with the potential 
to cause severe liver problems (although these seldom occur); in the third 
experiment, we were dealing with serious, chronic mental illness, for which a 
drug with troublesome side-effects has to be taken. 
It is possible that subjects in experiment 1 with cisapride considered the 
situation as not serious enough to be treated with medicines. Subjects in 
experiment 3 might have had a positive bias toward the unavoidable need for 
the medication, given their familiarity with the situation (caregivers) and, to 
some extent, with risperdon. 
We were surprised by the strong and consistent results:
• The effects on knowledge were obvious, expected and interpreted as a 
confirmation of the design and the quality of conduct of the study. We 105
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medication and that written drug information has an impact on 
knowledge (see the general discussion for a review)
• It came as a surprise that the (rather uninformed) subjects from the 
control subgroup apparently had a positive bias toward the benefits 
and risks of medicines in general, given their high scores (at least for 
experiments 2 and 3)
• In the subgroups confronted with the PPI, the benefit/risk balance was 
clearly typed to the negative side, as at least half of the subjects did not 
consider the benefits greater than the risk
• In the BEN subgroups (confronted with the benefit message in the 
insert), however, more than 60% of subjects perceived greater benefit 
for the medicine. This means a positive ratio between benefit and risk 
was maintained.
In both the subgroups confronted with the inserts, a real information 
transfer had occurred, including information about risk items. In the BEN 
subgroups, this transfer of knowledge seemed not have been detrimental to the 
benefit/risk perception. In the PPI group, the benefit/risk balance was less 
favourable. 
The consistency of the results in the 3 experiments with diverse clinical 
situations strengthens the credibility of the findings. 
Based on the findings, we formulated a hypothesis for further research: 
adding a section of benefit information within the patient package insert helps 
to integrate increased knowledge about medication into a more balanced 
benefit/risk perception. More research is needed to confirm (or reject) this 
hypothesis, and to explore its clinical relevance, for example with regard to the 
impact on patient compliance.
Further discussion in the context of this thesis
With this study completed, it was possible to end the research project on a 
positive note. The manuscript was submitted in 2001 and published early in 
2002. By that time, there was accumulating evidence that cisapride 
occasionally caused serious trouble with the rhythm of the heart (QT-
prolongation and torsades de pointes) when taken in combination with a host 
of other drugs. This illustrates that it is necessary to survey the safety profile of 
drugs constantly, even when they are already on the market. Reports on 
adverse events are collected and evaluated. They may lead to retraction or 
restriction of drugs, to changes in labelling, to different drug choices by the 
physician and, ultimately, to a change in the perception of the risk and the 
benefit of the drug by the patient.[212][213]106
Chapter 4
Other interventional research 
4.1 Impact of patient package inserts for pain killers 
in uncomplicated strains of joints and muscles
Originally published as: Van haecht CHM, Vander Stichele RH, De Backer G, Bogaert 
MG. Impact of Patient Package Inserts on Patients' satisfaction, adverse drug reactions 
and risk perception: the case of NSAIDs for post-traumatic pain relief. Patient Educ 
Couns 1991;17:205:215.
Motives for this study
This study was the central study of the doctoral thesis by Dr. Chris 
Van haecht. We report the study here, because it was conducted during the PPI 
Evaluation Programme, because of the experimental nature of the study, and 
because of its focus on risk perception and report of adverse drug reactions. 
The study focused on the use of Non Steroidal Anti-Inflammatory Drugs 
(NSAIDs). These are medicines which relieve pain and reduce swelling in 
strained joints or muscles. Patients in discomfort (pain, difficulty using the 
affected joints or muscles) can use these medicines for temporary relief of 
symptoms, which will usually subside with or without medicines in a 
maximum of 5 days. Patients are not obliged to take such medicines. If they 
do, they can stop taking the medicines at the first sign of side-effects. However, 
the use of these medications causes serious complications in a small percentage 
of patients, such as bleeding ulcers in the stomach. 
Hence the clinical situation chosen here was better suited to the study of 
risk perception than to the study of patient compliance.
Objective of the study
To measure the impact of a patient package insert (PPI) versus a technical 
insert (TI) with a non steroidal anti-inflammatory drug (NSAID) on:
• patient satisfaction with medication information
• reporting of side-effects
• benefit/risk perception.
Setting
Patients consulting in general practice in the Dutch-speaking part of Belgium. 
Time-frame 
March 1989 to February 1990.107
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A randomised, controlled, clinical trial testing a patient package insert (PPI) 
versus a technical insert (TI).
Figure 6: Research design of the NSAID study
R = randomisation
TI = technical insert
PPI = patient package insert
Participants
Patients with minor injuries (strains of joints or muscles) to whom the general 
practitioner (GP) would routinely prescribe NSAIDs were included. The 
following were excluded: children (less than 14 years of age), pregnant 
women, patients with contraindications for NSAIDs, and patients who had 
taken NSAIDS in the past 6 months. Forty-two GPs were asked to select 10 
patients each in a period of maximum 6 months. 
Method
The GPs were instructed to inform the patients about the symptomatic nature 
of the treatment, and to ask the patients to stop treatment when complaints 
disappeared or in case of adverse drug reactions. Patients were instructed to 
return for a control visit one week later. Patients were not informed about the 
existence of two types of package inserts. 
The study medication was the NSAID pirprofen (Rengasil) from Ciba-
Geigy. It was distributed by the physician during the first consultation, in 
packages of 30 capsules of 300 mg, normally to be taken three times a day. 
The study medication was distributed to the GPs in blocks of 10 numbered 
packages. Each set contained 5 packages with a patient package insert (PPI) 
inside, and 5 with a technical insert (Ti) inside, in an order determined by 
chance. The GP was not aware of the type of insert inside the packages. 
The inserts used were those approved by the Belgian health authorities (the 
PPI was approved in January 1989) without any linguistic or graphical 
change.108
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size (point 9). The main differences between PPI and TI were: 
• shorter sentences
• replacement of medical jargon by lay terminology (e.g. loss of appetite, 
tendency to vomit, stomach ache and stomach ulcer replaced anorexia, 
nausea, epigastric pain and ulcus ventriculi)
• lay terminology in the subheadings, turned into questions.
At the second control visit, leftover medication was returned to the 
physician for a pill count and the patients were asked to fill in a self-
administered questionnaire, immediately after the visit and return it directly to 
the researchers in a closed, prestamped envelope. Inserts were not retrieved by 
the doctor.
In the questionnaire, patient satisfaction was assessed by confronting the 
patient with nine statements, to be scored on 5 point Likert scales (from 
“strongly disagree” to “strongly agree”). Benefit/risk perception was evaluated 
by two separate scales (unlabelled semantic differential scale with seven 
grades). Each individual score on the benefit scale was to be subtracted from 
each individual score on the risk scale, to attempt to construct a composite 
measurement of benefit/risk perception. 
Figure 7: Unlabelled 7-point scales to measure benefit 
perception and risk perception
Patients were also asked to scale (with another seven grade scale) the 
influence of their physician, their family, their own opinion and the insert on 
the decision to take the medicine. 
Percentages were compared with the Chi-square test. The results of the 
scores on the seven grade scales were considered to be ordinal variables. This 109
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assume that the difference between 1, 2, 3, 4, 5, 6 and 7 is equal). When the 
comparisons were between two groups (e.g. PPI versus TI), the Wilcoxon-
Mann-Whitney test was used to make the distinction between significant and 
insignificant differences. In case the comparisons were between three groups 
(e.g. patients not reading the insert, patients reading the insert superficially, 
patients reading the insert thoroughly), the Kruskal-Wallis test was used. 
Differences between medians of groups of 1 point or more on the seven grade 
scale were considered relevant.
At the return visit all spontaneously mentioned reports of presumed side-
effects were recorded. In addition the patients were asked whether or not this 
side-effect made them stop taking the drug. In the questionnaire, 10 common 
health problems were listed. Patients ware asked to tick the health problems 
which they experienced any day during the last week, and to indicate whether 
they felt the occurrence of these health problems was related to the taking of 
the drug. 
Figure 8: Gradation in 4 methods to assess the frequency 
of health problems 
Ethical issues
The study protocol was approved by the Ethics Committee of the Ghent 
University Medical School. All patients were asked for oral consent to 
participate in the study. 
Results
A total of 366 patients was included in the study. Thirteen% did not show up 
at the control visit or did not return the questionnaire. Between the 
respondents and the drop-outs there were no significant differences in sex and 
age, type of injury or type of insert. Further analysis is based on a sample of 110
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group).
The average age of patients was 36 years (SD 15 years, range 14 to 82y). 
Fifty-five % were male. Fifty % had a schooling age of 14 years, 32% of 18 
years, and 18% a higher educational level. Patients suffered from an injury to 
the foot or ankle, hand or wrist, knee, in the back, mostly from a direct hit 
(contusion) or from a bad movement (distortion). Forty-three % were also 
prescribed a topical treatment and 3% another oral drug. 
Only 29% of the patients stated that they had not read the insert; 43% 
read the insert superficially and 28% thoroughly (no difference between PPI 
and TI group). The insert was read by 61% of the lower educated and 84% of 
the higher educated patients(P>.001). 
Overall satisfaction with the insert among the 225 readers (108 allocated 
to the TI group and 117 allocated to the PPI group) was quite high (median 6 
on a scale from 1 to 7) and independent of the type of insert. The PPI was 
judged more understandable than the TI (6 versus 4) and less vague (2 versus 
4).
The median benefit perception was 5, whether the insert was (superficially) 
read or not. TI readers scored a median of 6 and PPI readers of 5 (Wilcoxon P 
= 0.0451).
Median risk perception was 1 for non readers, 2 for superficially reading 
patients, and 3 for thoroughly reading patients (Kruskal-Wallis P = 0.0072). It 
was 2 for TI readers and 3 for PPI readers (NS). 
The median span between the median benefit score and the median risk 
score was 3 scale points in the TI group and 2 scale points in the PPI group 
(Wilcoxon P = 0.0163).
Readers of the insert scored the influence of the physician at 6, with non-
readers at 7 (Kruskal-Wallis P = 0.0494). Patients who had read the insert 
thoroughly scored their own opinion at 4 and the influence of the package 
insert at 3, while non-readers and superficially reading patients scored resp. 2 
and 1 (Wilcoxon P resp. 0.0162 and 0.0001). The score for the influence of 
family was 1 in all reading groups. 
In total, 53% of patients checked one of the health problems on the 
questionnaire, and 42% attributed such a problem to the drug. Thirty-
three % spontaneously reported a problem to the physician and 13% 
mentioned that the problem had been a reason to stop taking the drug. The 
problems mentioned were predominantly problems with the bowels and the 
stomach. 
Nearly all patients reported discontinuation of treatment after 5 days.
Women reported 1.5 problems on the checklist and attributed 0.9 
problems to the medication, while men reported 0.9 problems (P < 0.01), and 
attributed 0.6 problems (P < 0.05). There were no associations with age or 
educational level. 
The data were split according to package insert readership.111
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an injury of joints or muscles, according to insert readership
In addition a breakdown was made according to the type of insert. 
Table 8: Reporting of health problems and side-effects by patients 
with an injury of joints or muscles, according to the type of 
insert (TI versus PPI)
Discussion and conclusion
In the clinical context of this study (non-serious injuries of joints and muscles), 
slightly fewer patients read the insert (thoroughly) , as compared to the level of 
readership in previous studies reported in Part I. There were no differences in 
readership according to the type of insert. 
This study is one of the few which tests two types of inserts randomly. As 
the differences between the two types of insert in this study were small and 
limited to linguistic change, it was remarkable that relevant and significant 
differences were found in benefit/risk perception and in the perception of 
health problems and side-effects. 
LABEL Non-readers (N=92)
Superficial 
readers 
(N=136)
Thorough 
readers 
(N=89)
Chi-square 
P
% of patients experiencing 
a health problem 41% 55% 61% P=0.025
% attributing the health 
problem to the drug 28% 48% 48% p=0.005
% of patients 
spontaneously reporting 
to the physician 16% 37% 42% P=0.001
% reporting that they 
have stopped the drug 5% 17% 14% P=0.035
LABEL 
Patient 
package insert 
readers(PPI) 
(N=117)
Technical 
insert readers 
(TI)(N=108)
Chi-square P
% of patients experiencing a 
health problem 61% 53% NS
% attributing the health 
problem to the drug 53% 43% NS
% of patients spontaneously 
reporting to the physician 46% 31% P=0.034
% of patients reporting that 
they have stopped the drug 21% 11% NS112
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understandable and less vague, the overall satisfaction was high, with no 
difference between types of insert; both PPI and TI scored 6 on a scale from 1 
to 7. This paradox might be explained by the hypothesis that with regard to 
satisfaction, the very fact of giving information is more important than the 
content of that information. 
Readers of the PPI scored the benefits of the drug lower and the risks 
higher than readers of the TI. The question is whether this effect is 
troublesome or not. Especially with NSAIDs, one might say that the patients 
obtained a more reasonable perception of the drugs’ benefit and risk by 
reading an understandable insert. 
In this study, a clear link was established between reading of an insert and 
perceiving health problems. It would be wrong to interpret this as proof for 
the popular belief that reading the side-effect section of a package insert 
suggests side-effects to patients, who will then promptly experience these side-
effects. One could say that reading the insert makes patients more aware of 
signals given by the body, whether these are related to taking the medication 
or not. 
In addition, the health problems experienced were more often associated 
with the medication. In this attribution process, the patient makes a mental 
link between the health problem experienced and the medication. In this study, 
we had no possibility to check whether this attribution process was correct or 
not. 
It was also clear that patients reported health problems more often, when 
they have read the insert, especially if they had read it thoroughly and if the 
insert was a PPI. Again, one can look at this phenomenon in two ways. On the 
one hand, it can be considered a waste of resources and needless harassment of 
physicians, if this increased reporting is interpreted as exaggerated sensibility, 
incorrect attribution or sheer suggestion of side-effects. On the other hand, 
one can welcome more dialogue between the patient and the physician about 
the safety profile of the medicine. Anyway, this study does not permit 
evaluation of the correctness of the attribution process by patients.
The percentage of patients naming side-effects as a reason to stop 
treatment was clearly higher among readers of inserts. There was a trend 
toward more cessation under PPIs, but this was not significant (the study may 
be underpowered). Again, this can be interpreted in different ways. One might 
say that written drug information has a detrimental effect on patient 
compliance. However, one may also welcome all interventions that make 
people stop taking a potentially dangerous comfort medicine such as NSAIDs 
earlier (at the first sign of a potential problem, or as soon as one feels better). 
The method for recording the duration of drug intake in this study was patient 
self-reporting. The validity of this method was considered too doubtful to 
engage in an analysis. 
This study concluded that in the setting of an optional, symptomatic 
treatment of a self-limiting disease (injury to joint and muscles), reading 113
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benefit and more risk perception; more health problems experienced and 
attributed) and on patients’ behaviour (more spontaneous reporting of health 
problems and more cessation of therapy because of perceived side-effects). 
Reading a patient package insert (as opposed to reading a technical insert) was 
associated with a higher percentage of patients reporting health problems to 
the physician. 
Further discussion in the context of this thesis
The results of this study were both thrilling and frustrating. Thrilling because 
a clear effect of reading understandable written drug information was shown 
on patients’ perception and behaviour. The results were frustrating because 
they did not allow to evaluate correctness of attribution process and the 
(non)existence of suggestion effects. 
Ciba-Geigy participated in this study by providing the packages and inserts 
of the product pirprofen (trade name Rengasil). One might say the company 
took some risk by involving its product in a trial focusing on risk perception 
and using self-administered questionnaires with a list of possible health 
problems. Such a technique yields high rates of presumed side-effects, which 
can be easily misinterpreted. Anyway, a few months after the end of the study, 
pirprofen was withdrawn from the market. The reason was probably that the 
product did not fit the companies’ portfolio well, with other more successful 
NSAIDs on the forefront. 
The study by Van haecht was also an incentive for us to look for ways to 
go beyond the improvement of only the linguistic quality of inserts. Making 
inserts more understandable by shortening the sentences and getting rid of 
medical jargon reveals more clearly that the content of the insert is unbalanced 
with an excess of risk information. If improving readability does not coincide 
with improvement in communication of risk and benefit information, then 
potentially detrimental effects of written drug information could be enhanced. 
This insight was the main trigger for setting up the study on benefit messages, 
reported in Chapter 3 in Part III. 
4.2 A tale of a halted study
I can live with despair, but it is the hope I cannot stand.
John Cleese, in “Clockwise”
Motives for this study
In 1992, we were given the opportunity to write a protocol for a trial that 
would take this research field one step further, incorporating new methods and 
answering some key questions. We received a research grant from a charity 
fund, after our proposal was selected by the Federal Fund for Scientific 114
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sufficient to set up a clinical trial in General Practice. In the following 
paragraphs, we will describe the protocol of the study, in order to explain the 
aims and the ambitions of the study. Results will not be presented, because the 
study was aborted, as we failed to recruit enough valid cases. We report on 
this unfortunate outcome to illustrate that failure is not uncommon in 
scientific work, to explain the design of this study, and to reflect on the 
experience gained.
Description of the study
The aim of the study was to explore the effect of complete, understandable 
written drug information about a beta-blocking agent, used in the treatment of 
essential hypertension on:
• patient compliance
• the attribution of health problems to the medication
• spontaneous reporting of side-effects 
• benefit/risk perception.
The study was a randomised placebo controlled clinical trial comparing 
atenolol 100 mg once daily (and a lay language patient package insert) with 
placebo once daily (with the same patient package insert) to be conducted in 
general practice.
Figure 9: Research design of the halted atenolol 
versus placebo study 
R = randomisation
PPI = patient package insert115
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120 patients, to be randomised into two groups of 60 patients, and to be 
followed for 3 months in 4 visits at D0 (start), D14 (two weeks), D42 (six 
weeks) and D83 (twelve weeks). Patients needed to be between 20 and 70 
years of age, presenting mild to moderate, uncomplicated essential 
hypertension, either newly detected, or switched from previous therapy 
because of non-response or intolerance. Patients should be able to answer a 
simple self-administered questionnaire and to self-administer their medication.
We excluded patients with: 
• serious problems of the hearth, liver, gut or kidney
• dementia
• treatment with beta-blocking agents in the preceding year
• shortage of the mineral potassium in the blood (hypokalemia)
• pregnant women, lactating women, women wishing to become 
pregnant and women taking oral contraceptives
• contraindications for beta-blocking agents
• co-medication that could interact with beta-blockers.
Patient compliance in this study was to be measured by electronic 
monitoring, using the Medication Event Monitoring System (MEMS, Aprex, 
USA). 
Spontaneously mentioned side-effects were to be recorded. Side-effects 
mentioned as a reason for stopping the therapy were also recorded. 
At the third visit, on day 42 (six weeks after the start of the study) a 
questionnaire was given to the patient, to be filled in and collected at the last 
visit. Patients were asked to tick a list of potential health problems experienced 
during the last month, and to note whether, in their opinion, the health 
problems were related to taking the medication. There were 10 potential 
health problems on this list. Five of them were symptoms possibly attributable 
to atenolol (because in other trials it was documented that these symptoms 
occurred more frequently than placebo).
For the measurement of benefit/risk perception in this study, we again used 
the technique of the two unlabelled semantic differential scales, one for benefit 
perception, one for risk perception (see above). 
Blood pressure was to be measured with the stricter procedure for clinical 
trials. The pulse rate was to be determined at each visit. 
We designed the study to test the hypothesis that the rate of punctual 
compliance was equal in the atenolol group and the placebo group (the null 
hypothesis). 
The study protocol was approved by the Ethics Committee of the Ghent 
University Academic Hospital. Patients were given full information on the 
aims of the study, and were informed of the use of placebo and electronic 
compliance monitoring. Investigators were to give written confirmation that 
oral informed consent was obtained from each patient. Patients were informed 116
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reason, without repercussions for their further treatment.
Start and halt of the study
We originally planned a study duration of 9 months to give time to each 
participating general practitioner to recruit 8 patients. After 4 months, it 
became clear that most participating GPs would not reach their recruitment 
targets and that the study would fail.
Discussion of the reasons for failure
There was a clear discrepancy between the demands of the protocol and the 
severe inclusion and exclusion criteria, on the one hand, and the capability and 
motivation of participating GPs to recruit patients, on the other hand. 
The exclusion criteria were harsh, logistic support and rewards for GPs for 
the extra work limited. 
Last, but not least, there was the placebo-controlled nature of the study, 
which might have made it more difficult for patients to agree to participate, 
for GPs to accept to participate in the trial, and for GPs to be motivated to try 
to convince patients to enlist in the trial. 
Looking back, a design with an active comparator instead of placebo 
would have been more suitable. We chose not to go for an active comparator, 
because possible differences might in effect have been more subtle and more 
difficult to detect with relatively small sample sizes. 
One could put it bluntly and say: we gambled and lost. It is more 
appropriate to say that designing scientific studies involving patients is 
difficult. Trade-offs have to be made between rigour, concern for the safety of 
the patients and willingness to achieve trustworthy results. 
Further discussion in the context of this thesis
This study was originally planned as the closing study of this research 
programme. It would have enabled us to continue the work of Van haecht, 
reported in Chapter IV of Part III, with regard to the experience, attribution 
and reporting of health problems during chronic drug intake. It was a 
disappointment when the study failed, and for some years there was little 
impetus to continue research on this subject. Luckily, in the late nineties, we 
were able to conduct a less ambitious and more modest experimental 
psychology trial, reported in Chapter 3 of Part III, as a worthy closure of the 
programme.117

Part IV
General discussion 
and conclusions
Science must be explained as simply as possible but not simpler.
Albert Einstein
In the final part of this thesis, we will first provide a round-up of the 
descriptive studies in Part II regarding the Belgian Patient Package Insert 
Evaluation Programme. We will list the main findings of the intervention 
studies from Part III and briefly discuss the results in connection to other 
findings in the literature. We will then group the hypotheses for further 
research resulting from this work. In addition, we will list a number of 
recommendations for future developments with regard to patient package 
inserts. In the final conclusions we will focus on the two main themes of this 
thesis, namely the acceptance by the public of patient package inserts (PPIs) 
and their impact on benefit/risk perception by the patient. 
1 Discussion of Part II
1.1 Round-up of the descriptive studies in the Belgian Patient 
Package Insert Evaluation Programme
These studies can be grouped into:
• descriptive studies describing the attitude of relevant parties: 
– patients
– physicians
– regulatory affairs managers.
• consecutive pre-post studies, providing time series information on the 
progression and the impact of the introduction of patient package 
inserts on a national scale: 
– Two repeated population surveys
– Two repeated registration studies in general practice.
In addition, a number of descriptive studies were conducted describing the 
provision of drug information to specific patient groups (socially active elderly 
living at home, frail elderly at home, elderly in subacute geriatric wards, 
elderly in homes for the aged, and adolescents). Finally, we described the 119
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Belgium. 
From a methodological point of view, the studies presented here have their 
limitations. Most studies are exploratory and descriptive, primarily on quota 
samples, often making abstraction of the time line of the implementation of 
PPIs in Belgium. Choices have been made between covering a broad range of 
specific populations on the one hand, and precision by large sample sizes,  
intense recruitment and non-response management, on the other hand, 
sometimes at the expense of generalizability of the conclusions. The pre-post 
studies (or more accurately pre-during studies) are merely two consecutive 
cross-sectional unpaired measurements, and not (quasi)-experimental studies 
or even controlled studies. The interest of this research resides perhaps more in 
the diversified approach of different settings and actors. The results provide a 
broad perspective on the background of giving drug information in health 
care, and some hints about the possible impact of a shift from Technical 
Inserts to Patient Package Inserts on a national scale. Our aim was to exploit 
this natural experiment as much as possible, to evaluate the introduction of 
PPIs in Belgium, and, more generally, to provide more insight in the way 
patients deal with medication and medication information. 
It was our ambition to measure the impact of the implementation of a 
health policy programme, namely the introduction of patient package inserts 
on a national scale in Belgium between 1988 and 1992. We will comment on 
the quality of the implementation of the programme, on the quality of the 
Belgian inserts and on the impact of the programme in Belgium. 
1.2 Evaluation of the impact of the Belgian PPI Programme 
We demonstrated by a non-paired, pre-post population survey that there was 
no significant difference between the proportion of patients (9 in 10) stating 
they read the insert, before the change and half way through the change. The 
percentage of people stating they read the insert was somewhat smaller in 
lower versus higher educated patients, but still high. We consider this as proof 
that there was no decrease of the readership of inserts in Belgium. We also 
demonstrated that patients in Belgium were not aware of the transition. We 
established that acceptance by the public of technical inserts was high before 
the introduction of PPIs, and high beyond the possibility of improvement. The 
measurement of satisfaction was not repeated, hence the possibility of a 
reduction in the general level of satisfaction was not excluded. 
The transition from technical inserts to patient package inserts was limited 
in scope (only linguistic simplification) but complete in implementation. By the 
end of 1992, all inserts were replaced. This transition has gone by unnoticed, 
without protest from the health care providers or complaints from the general 
public, as monitored by our surveys of the physicians and the population. 
Consumer associations, however, expressed their disappointment in the 
quality of the inserts. 120
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practice registration studies (one in spring 1989 and one in spring 1990) are of 
interest. We observed a limited but relevant impact of the PPI on patients 
reporting possibly drug-related health problems. We observed a small increase 
in the percentage of patients spontaneously reporting health problems to their 
GPs in a follow-up visit for hypertension (from 29% to 43%), no change in 
percentage of patients reporting a health problem after prompting (around 
70%), and a slight increase in percentage of patients attributing these 
prompted health problems to the medication currently taken (from 21% to 
35%). This increase was observed in higher educated patients as well as in 
lower educated patients. There was also a hint that the increase might be 
associated with the introduction of the PPIs. 
This may have been a temporary effect, an artifact caused by the increasing 
percentage of higher educated people in the population. It may also be an 
indication that PPIs do have small impact but on a massive scale in reporting 
minor ailments from medication usage. If among the population the reporting 
of health problems possibly related to drugs increases, this may be a blessing 
or a curse. It may mean more unnecessary work for health care workers. But it 
may also lead to greater awareness and prompter detection of adverse effects, 
and a swifter reaction. A key issue is whether a patient experiencing a relevant 
health problem, while taking medication, will attribute this health care 
problem correctly to the drug taken. This aspect has not been studied in this 
work. 
When the introduction of PPIs in Belgium was well under way, our 
research focus and the remaining funds available for evaluation research were 
diverted to more fundamental and experimental research on the impact of 
written drug information on patient behaviour, described in Part III. It was 
clear by then that the political drive to implement high quality patient package 
inserts had waned. Readability control was again taken up by 
pharmacological experts. As the Belgian Pharmaceutical Inspectorate did not 
have a document management system, it was not able to control the 
consistency of the different drafts, even for products with the same active 
ingredient. 
A public information campaign, drawing attention to the existence of PPIs, 
was not conducted. In 1995, the European Medicines Evaluation Agency 
(EMEA) became operational, and many new products were evaluated centrally 
(including the evaluation of the user leaflet). Interest in the subject further 
subsided.
Because of the requirement to have an insert in the three official languages 
(Dutch, French, German), companies continued to be confronted by too much 
text to be printed on sheets that were too small, a problem often resolved at 
the expense of type size, making the inserts barely legible. By 1992, it was 
clear that the transition to patient package inserts in Belgium was going to be a 
minor operation, limited to making the texts of the inserts more readable by 
using shorter sentences and by reducing medical jargon. However, graphical 121
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emphasis. The disparity among inserts for similar drugs has not decreased. 
Belgian inserts are of variable length and quality. Moreover, the content of 
inserts for similar drugs is not always consistent. Some companies, for 
example, managed to slip a small benefit section in the approved text of their 
inserts. 
1.3 Integration with the literature about acceptance of written 
drug information by patients
To review the literature on acceptance of written drug information we will 
address the following topics:
• do patients read PPIs when it is provided?
• do patients emotionally accept PPIs in the drug distribution system?
1.3.1 Do patients read patient package inserts?
There are a number of studies from European countries where inserts are 
routinely provided in the distribution process. These studies date from before 
the era of the introduction of patient package inserts. So the readership data 
provided here pertain to readership of technical inserts. In Italy, in a 1990 
survey of almost 7000 respondents, recruited through community 
pharmacists, 80% stated they usually read the insert of their medicines.[214] In 
Germany also, readership was high in a study of 315 patients, where 96% said 
they regularly read the insert (of which three quarters in full, and one quarter 
only certain sections).[215] A Swiss survey (German and French speaking parts) 
showed that 67% of respondents stated that they always read the insert, 20% 
sometimes, and 13% never.[216] In another Swiss observational study (N=102), 
56% of the patients had read the package leaflets of antihypertensive and anti-
infective drugs in full, 26% in part and 18% not at all.[217] 
Rupf in Switzerland also took advantage of the gradual change from TI to 
PPI in the drug distribution system in the late eighties, to set up an 
observational study, with focus on readership.[218] He found that 79% of the 
47 patients who received a PPI read it in full, versus 35% of the 55 patients 
who received a TI (P less than 0.001, stratified by age). 
For Belgium, a number of studies were presented in this thesis, confirming 
the high levels of readership for technical inserts and patient package inserts. 
This level remained steady during and after the introduction of patient 
package inserts. 
In our studies, readership levels were a bit lower in the elderly, the poorly 
educated, and the chronically ill (with strong intercorrelation between these 
demographic variables). Readership levels were somewhat lower in clinical 122
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observational and interventional research (see Chapter 4 of Part III).
It is clear that changing from a drug distribution system with technical 
inserts to a drug distribution system with patient package inserts does not 
affect the high levels of readership of this document.
In systems where PPIs are not part of the drug distribution system, one 
needs to address the question whether a PPI was distributed before one can 
ask whether the insert was read. 
In the US, an exceptional twelve year series rate of 4 cross-sectional 
telephone surveys was conducted to assess the reception of voluntary provided 
drug information on a nation-wide scale with subjects who retained a new 
prescription at the retail pharmacy during the past 4 weeks (for themselves or 
for a family member), in 1982, 1984, 1992, and 1994.[219] The percentage of 
patients reporting to have received any written information from physicians 
increased only slightly (from 5% to 15%). However, there was a gradual 
increase of penetration of written drug information dispensed by pharmacists, 
from 16% in 1982 to 59% in 1994. High reading levels of written drug 
information were noted, similar to the levels in Europe. A slight increase was 
noted in the frequency of spontaneous verbal counselling, both by physicians 
(focused more on side-effects and precautionary information) and by 
pharmacists (more on instructions and precautionary information). The 
number of patients asking questions remained very low (less than 10%).
This can be seen as a remarkable result of the efforts of pharmacists 
associations, legislation (OBRA 1990) and voluntarism from private 
initiatives.[220][221][222][223] 
In a recent assessment of the implementation and quality of written 
information with new prescriptions in community pharmacies in the US, based 
on trained actors, the percentage of patients receiving written drug 
information was 87%. However, the length and quality of the leaflets varied 
greatly and the majority of leaflets did not include adequate information about 
contraindications, precautions, and how to avoid harm.[224] 
The controversy about the voluntary or mandatory approach[58][225][113] is 
not over. It remains unlikely that the goals of full distribution of information, 
fulfilling minimum requirements will be reached by voluntary efforts only. 
From the UK, where the introduction of PPIs was slow, there are two 
studies with contrasting results. In a 1999 study, when mandatory leaflets 
were still a novelty, one fifth of patients failed to notice the leaflet. Of those 
who recalled receiving a leaflet, only two fifths read some of it and one fifth all 
of it.[226] The other study is a qualitative study with ethnographic interviews 
and focus groups, where patients indicated that they rarely use information 
leaflets (of OTC products), only when the medication was new or when a side-
effect was experienced.[227] We have no direct explanation for these diverging 
results, except to see them as an artifact of the turmoil in a changing 
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There are numerous anecdotal reports, showing dissatisfaction with technical 
inserts (TI) and even with PPIs, because the information presented was too 
complex, too extensive, not extensive enough, difficult to read, difficult to 
understand, difficult to remember, causing fear, causing confusion. 
Surprisingly, this does not seem to affect the overall appreciation of the 
provision of written information. 
Most of the studies on readership described above also investigated 
satisfaction with communication. Van haecht reviewed an impressive array of 
studies showing that the introduction of a PPI contributes to a feeling of 
satisfaction among patients, efforts to produce a more understandable insert 
are appreciated, and the patient package insert (PPI) is considered to be 
useful.[38]
In Italy, a large scale prospective study was conducted studying the 
acceptability of TIs and experimental PPIs of 3 OTC products and 2 
prescription drugs, in the wake of the upcoming European regulations.[214] The 
study found higher satisfaction for the PPI than for the TI with regard to 
accessibility of content and ease of understanding the contraindications of 
drug use.
There are indications that too much zeal in trying to lower readability 
levels of PPIs may lead to dissatisfaction among readers, judging the text as 
uninteresting and childish.[228]
Emotional reactions to risk information may hinder information transfer 
and reduce acceptance of the PPI. Our studies indicate that fear arousal by 
reading inserts, even with ill-designed inserts, was limited to less than one 
third of the patients. 
Confusion (a state of cognitive disarray with a strong emotional 
undertone) may arise from conflicting information between messages from 
physicians, pharmacists and inserts, or from information overload. Confusion 
may be more prevalent when the text is incomprehensible. In Rupf’s study, 
93% of the patients reading a TI felt somewhat confused, compared to 27% 
reading a PPI.
In the randomised control trial on NSAIDs, reported in Chapter 4 of Part 
III, there was no difference in overall (high) levels of satisfaction between the 
TI group and the PPI group. 
It is, however, unlikely that PPIs will relieve dissatisfaction caused by the 
absence of agendas or insufficient discussion of treatment options.[49] 
However, we found convincing arguments in our studies and in the literature 
that providing written drug information is perceived positively by the majority 
of patients, as the majority of patients desire drug information, but do not 
often get it from health care providers or recall having received it. This 
satisfaction with written drug communication will probably reinforce pre-
existing satisfaction with physician-patient interaction during the 
consultation. PPIs may relieve frequently occurring dissatisfaction caused by 124
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and accepted. 
2 Discussion of Part III
Benefit and risk of treatment are concepts with vast connotations. The 
literature on the subject is extensive and it is easy to get lost. We will stick to 
the discussion of empirical data about the impact of an intervention (the 
patient package insert) on subjective cognition (benefit/risk perception of 
medication). 
2.1 Round-up of the interventional studies 
on benefit/risk perception
We worked on new designs to introduce written drug information in the 
context of clinical trials, without jeopardizing concealment of allocation. We 
acquired some experience with electronic monitoring of patient compliance 
and with finding new ways for expressing these data. We tested two different 
scales to evaluate benefit/risk perception by patients. We worked with self-
administered questionnaires to explore the process by which patients are 
experiencing, reporting, and attributing health problems possibly related to 
their medication.
This work on measurement instruments was exploratory, as it was 
considered premature to engage in formal validation procedures. 
The publications of Part III can be grouped as:
• a qualitative review of the impact of written drug information on 
patient compliance from a conceptual point of view
• two ill-fated attempts to explore the impact of written drug 
information on antihypertensives:
– atenolol versus lisinopril, presented in Chapter 2 of Part III, where 
the blinding of allocation was biased, and hence the results could not 
be considered as conclusive
– the halted atenolol versus placebo study, briefly discussed in 
Chapter 4.2 of Part III, without results
• two intervention studies with conclusive results
– a clinical trial of two type of inserts for NSAIDS for pain in acute 
injury, presented in Chapter 4.1 of part III
– a clinical psychology study on benefit messages, presented in 
Chapter 3 of Part III.
We will limit ourselves in this discussion to the empirical results of the two 
conclusive interventional studies. 125
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We will first list the main findings of these studies separately, and then 
confront our findings with other studies on this subject. 
2.2.1 Results of the NSAID study by Van haecht
First, we would like to stress the clinical setting in which these results were 
obtained, namely the short treatment of joint or muscle injury. The main 
conclusions are as follows:
• insert readership is independent of the type of insert 
• highly educated patients are more likely to read inserts
• overall satisfaction with inserts is high, independent of the type of 
insert
• the PPI was judged to be more understandable and less vague than the 
TI
• benefit of medicines is rated high by patients, whether or not they read 
inserts
• reading the PPI reduced the positive benefit perception somewhat and 
sharpened the risk perception somewhat
• reading inserts resulted in a higher rate of experiencing health 
problems, a higher rate of attribution and a higher rate of stopping 
therapy because of presumed side-effects
• reading a PPI resulted in higher rates of spontaneous reporting of 
health problems. 
2.2.2 Results of the benefit study
As for the results of the benefit study, we would like to stress the fact that this 
is a study in human volunteers and not in patients. The study fount that:
• people who are not presented with written drug information have a 
positive prejudice toward the benefit of medicines, but know little 
about their risks
• reading an insert increases knowledge about the medicine
• among readers of a PPI without benefit information, the percentage of 
readers with a positive benefit/risk perception was lower than among 
controls
• among readers of a PPI with benefit information, the percentage of 
readers with a positive benefit/risk perception was not lower than 
among controls.126
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by patients
A number of reviews and conceptual articles have been devoted to the 
cognitive processes of medical decision-making by patients, general risk 
information,[229][230][231] information on the risk of treatment,[232] and drug 
information.[233][234][235][236][237][238][239][240]
In addition, researchers have pointed to the detrimental effects of 
information overload and fear arousal on the limited ability of most patient to 
process risk information.[236][241] 
The seminal paper on cognitive processes in response to written drug 
information is by Morris and Aikin. In this article an analogy is drawn 
between how the brain processes risk information and how the body processes 
drugs.[233] 
Direct measurement techniques of how people perceive the risk and benefit 
of drug treatment are scarce and riddled with methodological problems. 
Examples of such research can be found in studies focusing on public 
perception of pharmaceutical risk among other environmental and medical 
risks[242][243][123][124] and on differences in risk perception between different drug 
classes.[244]
In pharmacoeconomic research, “willingness to pay” techniques and 
standard gambling techniques are used to assess patients’ perceptions of drug 
value.[245] This can also be seen as an attempt to measure subjective benefit/risk 
assessment by the patient. 
In two studies presented in Part III of this thesis, scales were presented for 
direct assessment of either risk or benefit, or a composite measurement of 
benefit/risk weighing. It has been argued that it is impossible to dissect benefit 
and risk perception processes in the mind, and that one should only look for 
composite measurements of benefit/risk perception.[246] However, in most 
intervention studies, the effect of risk communication is most often measured 
by behavioural results, such as patient choices between two possible 
treatments or patient compliance, and not by a direct measure of benefit/risk 
perception.
In a recent systematic review of one-to-one risk communication 
interventions in health care, the focus was predominantly on oral 
communication and on behavioural change.[225] 
The study by Van haecht (presented in Chapter 4.1 of Part III) is a rare 
example of a clinical study with direct measurement of benefit/risk perception 
of drugs. 
In the field of benefit communication, research is even scarcer and limited 
to experimental psychology studies. Misselbrook and Armstrong reviewed 
patients’ perceptions of the benefit of treatment in reaction to different 
numerical expressions of reduction of the risk of illness.[247] In our 
experimental study, presented in Chapter 3 of Part III, we ascertained a 
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risk perception of human volunteers. 
For a thorough proposal for a research agenda to improve our 
understanding of the cognitive aspects of benefit/risk perception, we refer to 
Lilja.[248]
3 Suggestions for further research
A researcher may reflect on the results of other authors, on the relevant 
theoretical frameworks, on the experience with new measurement tools and 
on the interpretation of one’s own results. This leads to hypotheses for further 
research, to be tested in new studies, and consequently confirmed or refuted. 
From the work presented here, we have derived a number of hypotheses, 
which we will list below. 
• The characteristics of disease and treatment are intricately related and 
mould together, when patients create mental perceptions of risks and 
benefits of a treatment for a disease in a specific clinical situation.
• The results of intervention studies on modifying compliance, obtained 
in a particular clinical setting, should not be generalised too easily to 
other clinical settings.
• Deciding to start a medicinal treatment (after reading the insert), will 
result in new experiences, which will change the nature of the stimuli 
that lead to the coping action. Changes in disease representation and in 
the emotional status from before the coping action have also been 
observed, and these changes will form the basis of the appraisal of the 
coping action.
• In clinical trials involving drugs with noticeable signs and symptoms of 
drug action or with noticeable signs of fading drug action or a high 
frequency of minor side-effects, it can be hypothesised that patient 
compliance and the perception and attribution of adverse reactions 
will probably be influenced by written drug information, resulting in 
differential occurrence of dosing irregularity, drug holidays or dropout.
• Making inserts more understandable by shortening sentences and 
getting rid of medical jargon reveals more clearly that the content of 
the insert is unbalanced, with an excess of risk information. If 
improving readability does not coincide with improvement in 
communication of risk and benefit information, then potentially 
beneficial effects of written drug information will be reduced.
• Adding a section of benefit information within the patient package 
insert helps to integrate increased knowledge about medication into a 
more balanced benefit/risk perception.128
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addressed positive aspects of the impact of the PPI. For a full appraisal of the 
impact of the PPI, the behavioural effects of the PPI need to be addressed. The 
following topics merit further research into the effect of the PPI on:
• effect on attribution and reporting of health problems 
• patient compliance
• other behavioural aspects
– avoiding medication errors
– reacting adequately to side-effects
– observing precautions outcome.
4 Recommendations for future developments 
with regard to patient package inserts
Patient package inserts have become an established part of the drug 
distribution system in the European countries and in a host of other countries. 
Given the strong tendency to international harmonization in pharmaceutical 
regulations, it is more likely that PPIs will eventually also be generally 
introduced in the US and in Japan, rather than abolished in Europe. Continued 
interest in enhancing the quality of this traditional printed medium is 
warranted, even more so in the light of the general penetration of information 
technology.
4.1 Improving the quality of the scientific data sheet 
to produce better PPIs
Reducing information overload is an important endeavour in high quality risk 
communication. Hence, it is crucial to be able to discriminate between noise, 
signals, events and reactions in relation to a specific drug. Hopefully, advances 
in pharmacovigilance and scientific risk assessment will help to strike a better 
balance between information overload and relevant risk information in the 
future.
More systematic reporting of pharmacokinetic and pharmacodynamic 
data may make it easier to assess the clinically relevant items to be transposed 
to patient information. Proposals for a standardised assessment of the quality 
of the technical clinical pharmacology information in drug labelling for 
professionals have been made.[249] Two potentially important information 
items are often underreported in technical drug labelling.[249] Firstly, 
information on the mechanism of action of the active ingredient may be useful. 
Secondly, information on the clinical consequences of interrupting drug dosing 
may be important.[250] A good example of the latter can be found in the US 129
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do if you miss a pill?”.[251]
All claims of efficacy in drug labelling have to be accepted by the 
regulatory authorities. However, lists of possible indications may be 
accompanied by a grading of the level of evidence in support of such claims. 
Such grading scales have been developed for professional guidelines, and may 
also be used in drug labelling. Moreover, where available, references can be 
made to meta-analytic synthesis of effect sizes.
More controversial is the addition of information about the decrease in 
effects size in various patterns of non-compliance. A historical example of this 
can be found in the labelling of the lipid lowering drug colestyramine.[252] One 
may argue that more effort is needed to provide enough numerical data about 
effectiveness of drugs in everyday practice (in contrast with efficacy data from 
clinical trials) to underpin benefit messages about the merits of full 
compliance. 
It is possible that with growing maturation of health outcome research, 
quality of life research and pharmaco-economics, these new forms of benefit 
information will find their way into drug labelling and ultimately into patient 
drug information.[253][254]
4.2 Solving liability issues as impediments 
to high quality communication
Fear of liability has been a strong incentive for full risk disclosure in drug 
labelling for professionals. 
European legislation on drug labelling in 1992 clearly stipulated that risk 
information should be conveyed in patient package inserts. It sets the stage for 
full but balanced risk disclosure, making overt legal prudence superfluous. In 
the European courts with the Napoleontic legal tradition and in the UK courts 
with a Common Law tradition, liability claims for adverse reactions to 
medicines have seldom been introduced or sustained.[255] In the absence of no-
fault compensation systems, this situation is only acceptable if high quality 
risk information is provided to the public.[256] 
In the USA, where liability claims are harsh reality for manufacturers, the 
line of defence has been the “learned intermediary” doctrine. In this line of 
reasoning, companies cannot be sued for harm caused by medicines to 
patients, as long as the company has fully informed the physician and the 
pharmacist (the learned intermediaries), who will then inform the patient. This 
situation had two consequences. Firstly, drug labelling for professionals tends 
to be excessively exhaustive. Secondly, the USA pharmaceutical industry has 
not embraced the concept of the patient package insert, as it would undermine 
their liability defence. However, there is ample evidence that health care 
providers (the learned intermediaries) do not routinely engage in elaborate 
activities of providing risk information about medicine. Hence, this legal 130
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inadequate system for informing patients about the medicines they use.[257] 
The approach will be difficult to sustain, with increasing switches from 
prescription to over-the-counter status,[258] increasing penetration of direct-to-
consumer advertising for prescription drugs,[259][260][261][262][263] the advent of 
other forms of manufacturer-affiliated communication in the information 
age,[264] and attempts at coalition forming between the industry, patient 
educators[265] and patient advocacy groups.[266] 
It is time for the legislators to make the necessary adaptations to legal 
doctrines, so that the liability impediments to the production of a high quality 
tool in drug information can be lifted.
4.3 Avoiding inconsistency between patient package inserts
A weak spot of patient package inserts is the lack of consistency in length, 
content or structure between the different patient package inserts of medicinal 
products with the same active ingredient. This is the inevitable consequence of 
the final authorship of this document by the manufacturer. In times of frequent 
shifts from original brand to generic and from generic to generic, this may be 
confusing for patients.[267]
Inconsistencies may be generated by diverging company policies, but also 
by inconsequent or incompetent regulatory control. Sometimes, economic 
policies of primary or secondary patent protection are involved.[268] 
Reviewers in the regulatory agencies should have the tools to compare PPIs 
from different medicines with the same active substances, and if possible with 
a generic template for frequently used active substances. 
Some guidance in the translation of technical terms into popular terms 
would be welcome, as diverging attempts to simplify medical jargon may 
result in a Babel-like confusion. This is especially true for the names of 
pharmaceutical groups, necessary for consistent cross-referencing, e.g. in the 
sections on drug-drug interaction. 
With regard to the risk of taking the drug during pregnancy and breast 
feeding, international bodies have proposed a range of specific formulations, 
reflecting the current state of knowledge about the risk of each active 
substance.[269] 
4.4 Investing more expertise in the production 
and testing of PPIs
4.4.1 A multidisciplinary approach to the production of PPIs
More and more pharmaceutical companies have realised the importance of a 
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can be left to the local regulatory affairs manager, assisted by a lawyer. 
Writing a good PPI involves the collaboration of the medical and 
marketing director, and the involvement of linguistic experts, communication 
specialists, psychologists, specialists of instructional manuals, and experts in 
graphical and functional design. Typographical expertise is critical for 
documents, where the pressure to use small print is high.[270] Use of pictograms 
is a tricky issue, that should be left to experts.[271]
The functionality of the text can be greatly enhanced by involving users 
(patients) from the early conceptual phases to the completion of the 
document.[272][273][274]
Multinational companies will need to elaborate document management 
systems to oversee different versions of one PPI, to ensure a house style in the 
PPIs of their drugs, and to coordinate translations and regulatory adaptations 
for the PPIs of their drugs in different countries.
4.4.2 Testing PPIs
Readability testing by means of computer programmes is an often forgotten 
means of quality control in the production process.[275] The popular general 
purpose word processors nowadays have this function built in, but adaptation 
to the specific domain of written drug information is necessary. This can be 
achieved by constructing controlled vocabularies.
However information technologies cannot be a substitute to user testing. 
There are simple ways and more sophisticated ways to put drafts to a panel of 
users.[128][276] The EMEA has recommended one particular method of user 
testing, putting perhaps too much emphasis on one of the possible 
approaches.[96] Nevertheless this is a breakthrough: it was accepted that results 
of user tests could be brought into the discussion between a company and the 
regulatory authorities.
In the previous decade, a number of formalised measurement techniques 
have been developed for user tests, focusing on user satisfaction,[277] the effect 
on self-efficacy,[278] and on the overall assessment of design quality.[279] Some 
techniques focus on the suitability of the text to sustain shared-decision 
making,[280][281] but as stated previously, this might be a little bit outside the 
scope of the PPI, which we regard as an instrument for informed compliance 
(or non-compliance), rather than an instrument for informed choice between 
different treatment options.
More attention should be given to an integration of testing and appraisal 
of the PPI in the regulatory approval process. No company wants to risk delay 
in registration due to a dispute over the wording of a paragraph in the PPI. 
The rush to registration may be so hectic that there is little time for 
multidisciplinary discussions and user testing in the production of a PPI. 
Hence, a proposal could be to acknowledge the preliminary character of the 
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submission of a final PPI, six to twelve months after registration. 
4.5 Linking up with new media for patient drug information 
Besides the patient package insert, there are many other forms of written drug 
information. Written drug information can be handed out by physicians or 
pharmacists, in preprinted forms or generated on the spot by printing 
machines, connected electronically to a collection of drug monographs. 
Numerous drug books with general information on drug taking and essential 
information on the popular medicines are published in many countries.[282][283] 
For numerous ailments, specific leaflets, pamphlets or brochures have been 
written, focusing on self-management, treatment options, shared decision 
making, or drug taking compliance. 
The attraction and impact of the content of printed media can be enhanced 
by taking it into the realm of multimedia. Television, video[284] and computers 
may display a richer and more appealing array of messages, but remain in 
their simple form examples of uni-directional mass communication, requiring 
more technical and educational skills and generally more money. Internet 
technology has provided cheaper production of programmes, cheaper 
distribution and almost global connectivity. Drug information can now be 
provided through the Internet on kiosk screens or PC terminals, in the 
physician’s surgery or in the pharmacy,[285] or in the privacy of the patient’s 
home. 
A striking feature of these electronic media is the ability to react to the 
consumer’s input (interactivity), so that the user can navigate through the 
information and decide to what extent he/she wants to be informed.[286] 
Moreover, the content and style of the information can be adapted to the 
users’ characteristics (individualization), such as sex, age, native language, 
educational level, and even coping style in risk information seeking.[287][288][289]
However, these fascinating developments will only supplement and not 
substitute the face-to-face dialogue with the health care professional, neither 
will they, in my opinion, obviate the need for the presence of a PPI in drug 
packages.
4.6 Integrating Evidence Based Medicine in PPIs
Traditionally, the source of information for the PPI is the pharmaceutical 
company, but the content is approved by the regulatory authority, in 
collaboration with the national centre for pharmacovigilance, in many 
countries united into one institution. This makes the PPI an authoritative 
source for the patients. The experts of regulatory authorities advise on 
whether or not a new product can be marketed and which indication, 133
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yes-or-no discussions on whether a specific item should be listed or not, with 
occasionally fierce fighting over the subtle wording.
In the final text, there is little room to refer to the original evidence for the 
decisions to list or not to list a particular indication or side-effect. The original 
studies are often not referenced, neither is there referral to the quantitative 
details of these studies. Statements in the PPI are seldomly accompanied by the 
level of evidence, in contrast to what is often the case in more elaborated 
practice guidelines.[290] 
One solution could be to build bridges of information between the PPI and 
national Drug Information Centres (DICS), closely linked to the registration 
authorities. Such centres exist in many countries, with the aim of providing 
independent drug information to health professionals, and increasingly to 
patients.[291] 
A number of these DICs have brought their drug bulletins and formularies 
to the Internet, and have gained experience in communicating with their 
audience through this new medium. By inserting a link to the Drug 
Information Centre in the Patient Package Insert, access to more elaborate and 
more generic evidence-based information on indications and side-effects of 
specific products can be provided. It will be a challenge to integrate the 
difficult notions of evidence-based medicine and the desire to provide 
understandable information on the complex issues of risk and benefit of 
medicines,[292] Examples,[293][294][295] recommendations[296] and quality 
criteria[297] are beginning to emerge. Moreover, gateways should be available to 
more general information sources supporting shared decision-making (e.g. the 
Cochrane Collaboration Consumer website),[298][299] with clear criteria to rate 
the quality of health related websites.[300][301][302][303]
4.7 Intensifying the interaction between “learned 
intermediaries” and the PPI
Health care providers in primary care (physicians and pharmacists) have 
traditionally taken a rather negative attitude to the provision of written drug 
information in the form of PPIs. The associations of pharmacists in the US and 
also in Europe, however, have increasingly been engaged in a number of health 
education projects, including written (or multimedia) drug information.
There is little communication between physicians and pharmacists,[304] and 
hence, there is poor coordination between information given by the physician, 
the pharmacist and the PPI. Very little research has been done on the effects of 
a positive reinforcement of the messages in PPIs by health professionals and 
about using the PPI as an instrument for communication between health care 
providers and patients.[305][306]
Hopefully, more physicians will realize that good communication with the 
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and professional health care professionals has been closing since the advent of 
the World Wide Web, as patients increasingly have access to the information 
sources for professionals.[308][309]
Health care professionals should adopt a more positive attitude towards 
PPIs, and accept that they have an important supportive role in the flow of 
drug information toward the patient. Physicians and pharmacists should adapt 
to better educated patients with better drug information sources, such as the 
PPI and the World Wide Web. On the one hand, persuading patients to 
continue chronic drug therapy with inconvenient side-effects will be 
increasingly difficult. On the other hand, it will be more difficult to persuade 
patients to start necessary treatment with inconvenient side-effects. In the 
former situation, physicians will be forced to reconsider their choice of 
therapeutic groups. The latter situation is an appeal to the art of convincing 
patients to do what is necessary, despite inconveniences. 
4.8 Embedding PPIs in health education 
and public health policy
Health education has become an established part of public health in many 
sectors of health care and prevention. With regard to pharmaceuticals, 
regulatory health authorities should realize that “educating prescribers as well 
as patients may be a critical ingredient to an evolving and still imperfect 
framework of drug policy”.[310]
In 1996 the World Health Organisation organised a global survey on the 
activities of nations in the area of public education in rational drug use.[311] 
The study concluded that there is a well evidenced and compelling need for 
public education in the appropriate use of drugs, with potential benefits for 
the individual, the community and the policy-makers. The study found that in 
most national drug policy documents, public education on drug use is included 
as a core element. Nevertheless, a lack of commitment to systematic and 
structured public education in rational drug use was observed in developed as 
well as in developing countries. 
Recommendations can be found in the literature for both epidemiological 
approaches to target drug information[312] and to design health education 
interventions,[313][314] which can be adapted to the subject of pharmaceuticals.
In Europe, there has been a clear policy on the role of written drug 
information in the distribution of medicinal packages with the introduction of 
mandatory patient package inserts in 1992. The implementation of this 
legislation, however, has been lagging. 
In many countries, the government has supported Drug Information 
Centres, producing independent drug information for professionals but 
increasingly also for patients135
PART IVSome countries have fully supported the Evidence-Based-Medicine (EBM) 
movement and provided logistic support for the production and dissemination 
of the EBM information products. In the near future, we could witness open 
access for health professionals as well as for patients to high quality 
independent drug information services through electronic libraries.[315] 
The continued physical provision of high quality written drug information 
in the form of PPIs (preferably with links to the independent sources of 
information) can only strengthen these new developments. This mix of 
interventions will put education about pharmaceuticals at the core of drug and 
health policy.
5 Final Conclusions
Patient package inserts are an essential part of modern drug distribution 
systems and a tool for patient education and health policy. Routinely provided 
inserts are read by the vast majority of patients and have a positive impact on 
patient satisfaction, regardless of their quality. 
A drug distribution system with patient package inserts has been accepted and 
welcomed by the population.
High quality patient package inserts have a proven positive impact on 
knowledge about drugs in those patients who read the insert. The effects on 
readership, satisfaction, and on knowledge alone may warrant their automatic 
provision, each time a medicinal product is dispensed, with or without 
prescription, in spite of the slightly higher distribution costs. These are strong 
arguments for the universal application of the European system of mandatory 
and comprehensible patient package inserts. Additional claims of positive 
behavioural effects of PPIs on patient compliance have barely been 
demonstrated. The evidence is limited for an impact of current PPIs on the 
reduction of medication errors and off-label use, on the observance of  
precautions, and on the stimulation of adequate reactions when side-effects 
occur.
Benefit/risk perception is an important cognitive concept for 
understanding patients’ mental processing of written drug information in 
patient package inserts. Direct measurement of benefit/risk perception with 
more validated tools is necessary for an improved comprehension of the 
relation between benefit/risk perception and behaviour. This may be crucial to 
our ability to design (and retest) better patient package inserts, to help patients 
make informed and shared decisions about adherence to drug treatment, and 
to assist them in the proper and safe continuation of treatment. One 
instrumental aspect of writing better PPIs may be the introduction of an 
elaborate benefit section. By combining benefit messages and risk messages in 
the patient package insert, improved transfer of information and a more 
balanced benefit/risk perception may be achieved.136
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